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Abstract 
 
Several studies have suggested that induced pluripotent stem cell-derived cardiomyocytes 
(iPSC-CM) and human embryonic stem cell-derived cardiomyocytes (hESC-CM) are 
sufficiently comparable to adult myocardium to facilitate application in a wide range of 
toxicology, drug development and disease modelling applications. Evidence from the 
literature is however, inconstant. We tested the hypothesis that iPSC-CM and hESC-CM have 
a predictable and consistent response to pharmacological manipulation, finding in many 
instances this was not true.  
 
We then focused on methods to improve the maturity of iPSC-CM, in particular, on the effect 
of cell alignment on intra-cellular Ca
2+
 cycling. For much of the exploratory work and 
validation of the techniques we used neonatal rat ventricular myocytes (NRVM). They are 
more readily available than iPSC-CM and have similar properties. We hypothesized that cell 
alignment of immature cardiomyocytes, in a fashion analogous to the adult myocardium, 
would improve the speed of intra-cellular Ca
2+
 cycling. We found that structured culture 
modulated  Ca
2+
 cycling in iPSC-CM, and that this was probably due to improvements in 
sarcoplasmic reticulum Ca
2+
 release mechanisms. In contrast to NRVM, structured culture 
did not appear to have a significant effect on Ca
2+
 extrusion mechanisms in iPSC-CM. 
Furthermore, we found that the physical properties of the constructs made it difficult to fully 
explore the mechanisms underlying these experimental findings. Consequently, we developed 
and validated novel constructs which would facilitate exploration of the mechanisms 
underlying the association between cell-alignment and the functional properties of immature 
cardiomyocytes.  
viii 
 
These findings suggest that tissue engineering approaches are likely to be relevant to in vitro 
modelling with iPSC-CM. An important next step will be to conclusively demonstrate that 
these techniques overcome the limitations of iPSC-CM highlighted in the first part of this 
thesis, and improve their efficacy for myocardial disease modelling. 
. 
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“The individuation field, then, is the agent which 
controls the growth of the different parts in a 
harmonious way so that a normal individual is formed. 
In later life, the individuation field splits up into smaller 
separate fields, such as leg fields, head fields, etc.” 
 
(Waddington, 1935) 
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1 Introduction 
  
2 
1.1 Introducing the heart, pluripotent stem cells and tissue engineering 
 
Existing therapies for end-stage heart failure are largely palliative. This is because the 
pathological adult myocardium has limited regenerative capacity. Cell therapies, using 
immature myocytes or undifferentiated stem cells, have been widely proposed as a means by 
which lost myocardial tissue could be replaced. It is also suggested that cell therapy can be 
used to improve the function of the endogenous myocardium (Nelson et al., 2009, Menasche 
et al., 2008, Abdel-Latif et al., 2007, Bolli et al., 2011, Makkar et al., 2012, van Laake et al., 
2009).  
 
In marked contrast to adult cardiomyocytes the immature cardiomyocytes proposed for cell 
therapy are readily accessible and easily maintained in culture without loss of phenotype. 
Many of these cell types have also demonstrated an impressive potential to proliferate, 
differentiate and form beating syncytia in vitro. As a consequence several authors advocate 
the use of immature cardiomyocytes as in vitro models of cardiac physiology and disease 
(Abdul Kadir et al., 2009, Carvajal-Vergara et al., 2010, Moretti et al., 2010, Tanaka et al., 
2009, Brand et al., 2010, Sun et al., 2012, Lan et al., 2013).  
 
The immature, heterogeneous phenotype of these cells, however, is arguably poorly 
representative of adult myocardium (Ma et al., 2011, Kehat et al., 2002, Itzhaki et al., 2011b, 
Matsa et al., 2011). It has been suggested that this may limit the utility of immature 
cardiomyocytes in cell therapy, disease modelling, drug development and toxicology 
screening (Liu et al., 2009, Oh et al., 2012). Interestingly, several strategies including tissue 
engineering approaches have been explored to modify the phenotype of immature 
cardiomyocytes in vitro (Liu et al., 2009, Shimazaki et al., 2008, Kraehenbuehl et al., 2008, 
3 
Tulloch et al., 2011, Fink et al., 2000, Chiu et al., 2011, Radisic et al., 2004, Yin et al., 2004, 
Bien et al., 2003).  
 
The following paragraphs discuss the characteristics of pluripotent stem cells (Section 1.2), 
how they are differentiated into cardiomyocytes (Section 1.3), and the functional and 
structural properties of cardiomyocytes derived from pluripotent stem cells (Section 1.4). The 
application of cardiomyocytes derived from pluripotent stem cells in myocardial cell therapy 
(Section 1.5) and disease modelling is discussed (Section 1.6). Tissue engineering technology 
currently available to manipulate the phenotype of immature cardiomyocytes is also briefly 
discussed (Section 1.7). Finally experimental plans are outlined to test the hypothesis that 
modification of the structural phenotype of immature cardiomyocytes using tissue 
engineering techniques can improve the degree to which immature cardiomyocytes could be 
considered to be representative of adult myocardium (Section 1.8). In particular, we focus on 
intra-cellular Ca
2+
 cycling, which is fundamental to excitation contraction coupling, a central 
component of cardiomyocyte physiology.    
 
1.2 Types of pluripotent stem cells  
 
Stem cells are undifferentiated cells (Thomson et al., 1998, Takahashi et al., 2007). They can 
renew themselves indefinitely through mitotic cell divisions and have the capacity to 
differentiate into specialized cell-types (Thomson et al., 1998, Takahashi et al., 2007). Stem 
cells can be classified according to how many distinct cell types they can be differentiated 
into, a property often called “potency” or “differentiation potential”. Pluripotent stem cells 
such as embryonic stem cells (ESC) and induced pluripotent stem cells (iPSC) are truly 
pluripotent and can be differentiated into any type of somatic cell. Multipotent stem cells 
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such as mesenchymal stem cells (MSC) can differentiate into cells from a number of related 
tissues. Oligopotent stem cells, often called progenitor cells, can differentiate into only a few 
cell types from a particular organ or organ system, such as cardiac stem cells (CSC). Finally, 
unipotent cells, whilst still maintaining the property of self-renewal, can only differentiate 
into one cell type, for example skeletal myoblasts (Figure 1.1) (Schöler, 2007, Hochedlinger 
and Plath, 2009).  Whilst all of these stem cell populations have been applied in cardiac stem-
cell therapy, the focus of this work will be on ESC and iPSC which have proven in vitro 
cardiogenic differentiation potential, and therefore the most relevance to myocardial disease 
modelling. 
 
 
 
Figure 1.1. The developmental potential and epigenetic states of cells at different stages of development. A 
modification of C. H. Waddington's epigenetic landscape model, showing cell populations with different 
developmental potentials (left) and their respective epigenetic states (right). Developmental restrictions can be 
illustrated as marbles rolling down a landscape into one of several valleys (cell fates). Coloured marbles correspond 
to different differentiation states (purple, totipotent; blue, pluripotent; red, multipotent; green, unipotent). Examples 
of reprogramming processes are shown by dashed arrows. Adapted, with permission, from Hochedlinger K, et al. 
Development 2009;136:509-523 (Hochedlinger and Plath, 2009) 
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1.2.1 Human embryonic stem cells 
 
ESC are extracted from the inner cell mass of pre-implantation blastocysts (Thomson et al., 
1998). Human ESC (hESC) have many properties that would make them amenable to cell 
therapy; they are pluripotent and can be propagated in vitro for many months without loss of 
normal karyotype (Ying et al., 2003). 
 
hESC have been applied to rodent myocardial infarction (MI) models. Graft survival has been 
demonstrated beyond 6 months after cell therapy, albeit without electrical integration into the 
host myocardium (van Laake et al., 2007). Encouraging data on global cardiac function has 
usually come from relatively short (4–8 week) studies (Caspi et al., 2007, Laflamme et al., 
2007). However, assessment of cardiac function beyond 12 weeks does not demonstrate any 
significant functional improvement (van Laake et al., 2007). It has been suggested that the 
improvement observed with hESC-derived cardiomyocytes (hESC-CM) is due to paracrine 
actions (See Section 1.5), and that the paracrine effect is diminished beyond 12 weeks, 
resulting in a reduction in benefit. It has also been suggested that hESC-derived grafts often 
remain encapsulated in a thin layer of extracellular matrix components, and that failure to 
fully integrate into the host myocardium may also explain the absence of long-term benefit 
(van Laake et al., 2007). The use of rodent models has also limited assessment of the safety 
of hESC cell therapy as the tumorigenic potential of hESC-derivatives may be impaired even 
in immunocompromised rodent models (Erdo et al., 2003). Significant heart rate differences 
between humans (70 beats per minute) and rodents (600 beats per minute in mice) may also 
impair survival and electro-mechanical integration of hESC-CM in rodent models (Xiong et 
al., 2011). Furthermore, as hESC are derived from embryonic tissue (Thomson et al., 1998) 
they are associated with both ethical (Lo and Parham, 2009, Passier et al., 2008) and 
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potentially technical problems such as host immune rejection of transplanted cells when used 
in cell therapy (Boheler et al., 2002, Saric et al., 2008).   
 
1.2.2 Induced pluripotent stem cells 
 
iPSC were first described by Takahashi and Yamanaka in 2006 and share many properties 
with ESC (Takahashi and Yamanaka, 2006). iPSC are reprogrammed pluripotent cells that 
are created by forced expression of embryonic transcription factors in non-pluripotent cells, 
such as adult somatic cells (Takahashi et al., 2007, Yu et al., 2007). In addition to being 
pluripotent, like hESC, they can be readily cultured and transfected. iPSC, however do not 
require the ethically problematic destruction of embryos (Lo and Parham, 2009, Passier et al., 
2008). Furthermore, as patient-specific iPSC-derived cardiomyocytes (iPSC-CM) can be 
generated, syngeneic transplantation is feasible, and host immune rejection can potentially be 
avoided (Boheler et al., 2002, Saric et al., 2008, Takahashi et al., 2007).  
 
iPSC-CM demonstrate similar properties to hESC-CM (Zhang et al., 2009, Zwi et al., 2009). 
Early studies suggest that injection of iPSC into ischemic and non-ischemic rodent models of 
cardiomyopathy results in integration of iPSC-CM into the host myocardium with promising 
improvements in contractile performance, pathological remodelling and electrophysiological 
properties (Nelson et al., 2009, Mauritz et al., 2011).  More recently, improvements in cardiac 
function and pathological remodelling have also been demonstrated using iPSC-CM cell 
sheets in a rodent model of ischemic cardiomyopathy (Miki et al., 2012). 
 
Despite promising early results concerns remain about the safety of iPSC cell-therapy. It has 
been suggested that undifferentiated iPSC may elicit a significant host immune response 
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(Zhao et al., 2011). There are also concerns about the tumorigenicity of undifferentiated 
iPSC, both because of their pluripotent nature and because of the activation of oncogenes 
during reprogramming (Lee et al., 2013, Okano et al., 2013). Novel reprogramming that 
avoids viral-genome integration may attenuate safety concerns associated with activation of 
oncogenes, and injection of differentiated cells reduces both their immunogenicity and 
tumorigenicity (Araki et al., 2013, Guha et al., 2013, Lee et al., 2013). This, however, may 
reduce the efficiency of therapy, as terminally differentiated myocytes do not have the 
proliferative potential of pluripotent stem cells. Consequently, there would be limited 
expansion of transplanted cells following introduction into the host myocardium. The use of 
differentiated cardiomyocytes necessitates optimization of reprogramming, expansion, and 
differentiation technology to improve the efficiency of this process. Finally, purification 
technology would also need to be optimized to ensure that only a pure differentiated 
myocytes population was used for cell therapy, free of contamination with potentially 
oncogenic iPSC (Okano et al., 2013). 
 
1.3 Differentiation of human embryonic stem cells and induced pluripotent 
stem cells into cardiomyocytes 
 
Fundamental to the application of hESC and iPSC as cardiac disease models, and arguably in 
cell therapy, is the differentiation of pluripotent stem cells into cardiomyocytes. This can be 
achieved using a number of different methods. 
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1.3.1 The embryoid body method 
 
The most commonly reported method of differentiating hESC and iPSC into cardiomyocytes 
remains the Embryoid Body (EB) System. First applied to hESC in 2001 by Kehat et al 
(Kehat et al., 2001), the EB method requires hESC or iPSC cultures to be dissociated into 
multi-cellular three-dimensional (3D) aggregates termed EB. EB are cultured in suspension 
and plated after 4–10 days. Within a few days the cells from the plated EB will differentiate 
into cells of all three germ-layer lineages, and cells will express cardiac markers (Kehat et al., 
2001). Spontaneously contracting areas subsequently appear in the cells which grow out form 
the EB (Kehat et al., 2001, Xu et al., 2002, Habib et al., 2008). Functional and gene 
expression analysis suggests that these areas have a number of cardiomyocyte characteristics 
(Ameen et al., 2008). 
 
The EB method for cardiac differentiation has several limitations. Its efficacy is highly 
variable due to the heterogeneous size and shape of aggregates which can differ significantly 
in size and morphology (Vidarsson et al., 2010). Forced-aggregation methods have been 
developed to standardize the size and shape of EB by centrifuging a defined number of hESC 
or iPSC in low-adherence 96-well plates (Burridge et al., 2007). The requirement for serum 
not only introduces further heterogeneity to the efficacy of the EB method but makes future 
therapeutic application of hESC and iPSC technology problematic (Habib et al., 2008, 
Vidarsson et al., 2010, Ludwig and J, 2007). Consequently, there is considerable interest in 
developing defined, animal-free differentiation protocols (Habib et al., 2008, Vidarsson et al., 
2010). 
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One of the most significant limitations of the EB method, however, remains the relatively low 
cardiomyocyte yield (Habib et al., 2008, Vidarsson et al., 2010). Consequently, several 
directed differentiation protocols have been developed to improve the efficiency of iPSC and 
hESC cardiomyocyte differentiation either with (Tran et al., 2009) or without EB formation 
(Laflamme et al., 2007) (Figure 1.2). 
 
1.3.2 Directed differentiation techniques 
 
 
 
Figure 1.2. Summary of methods for differentiating pluripotent stem cells into cardiomyocytes. Figure reproduced 
with permission of Rao et al. Phenotype and Developmental Potential of Cardiomyocytes from Induced Pluripotent 
Stem Cells and Human Embryonic Stem Cells. In: Ainscough J et al eds. Nuclear reprogramming and stem cells. 
Humana Press, 2011 (Rao et al., 2011).    
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As differentiation of hESC and iPSC into cardiomyocytes parallels many of the molecular 
and structural events seen during early in vivo cardiogenesis (Lev et al., 2005) lessons from 
developmental biology are readily applicable in stem cell research (Habib et al., 2008). For 
example, the endoderm that lies directly posterior to the embryonic cardiac crescent is 
considered essential to initiate cardiac differentiation (Olson, 2001, Graichen et al., 2008). In 
vitro experiments confirm that cardiac differentiation requires extracellular signals from the 
surrounding endoderm (Zaffran and Frasch, 2002, Olson, 2004). Co-culturing of 
undifferentiated hESC with a murine visceral endoderm cell line (END-2) has been shown to 
induce cardiac differentiation (Mummery et al., 2003). Even hESC lines, which ordinarily do 
not spontaneously differentiate into cardiomyocytes, have been shown to differentiate into 
cardiomyocytes when co-cultured with END-2 cells (Mummery et al., 2003). The co-culture 
differentiation system has since been further optimized by the removal of serum and insulin 
and the addition of prostaglandin I2 to the culture medium (Graichen et al., 2008, Xu et al., 
2008, Passier et al., 2005). Although the END-2 culture system improves efficiency of 
differentiation compared to the EB method, and results in more homogeneous cells, with up 
to 85% of the hESC-CM displaying ventricular phenotype (Mummery et al., 2003), reliance 
on murine feeder cells limits the therapeutic applications of the method and represents an 
additional source of heterogeneity. 
 
By focusing on factors expressed in the early endoderm known to regulate cardiac 
development directed differentiation protocols have been developed. These protocols use 
defined factors from the Wnt family or the Transforming Growth Factor β (TGF-β)  
superfamily, such as TGF-β itself, Activin and Bone Morphogenic Proteins (BMP) (Filipczyk 
et al., 2007). 
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TGF-β and BMP have been shown to promote cardiomyogenesis in all species (Olson, 2001, 
Schuldiner et al., 2000) and are thought to be important in promoting mesoderm formation 
and myocardial lineage commitment during hESC differentiation (Yang et al., 2008, 
Laflamme et al., 2007, Nostro et al., 2008, Pal and Khanna, 2007, Schuldiner et al., 2000, 
Yao et al., 2006, Zhang et al., 2008). Activin A has also been shown to promote hESC 
cardiac differentiation (Yang et al., 2008, Laflamme et al., 2007, Yao et al., 2006) and a 
differentiation system which combines Activin and BMP 4 has been reported to improve the 
efficiency of hESC cardiac differentiation to over 30% cardiomyocytes using serum-free 
defined medium (Laflamme et al., 2007).  
 
The Wnt signaling pathway is important for cardiogenesis, however, it has not been widely 
utilized for in vitro directed cardiac differentiation as unlike BMP and Activin pathways, Wnt 
signaling pathway can both promote and inhibit differentiation into cardiomyocytes at 
different stages of cardiogenesis. It has been shown to be important in maintaining 
pluripotency (Sato et al., 2004). In early differentiation and prior to gastrulation it leads to 
enhanced cardiomyogenesis, probably by promoting formation of mesoderm, but 
subsequently will inhibit cardiomyogenesis (Ueno et al., 2007, Yang et al., 2008). Finally, 
whilst it has been shown to be important in promoting the formation of cardiac progenitor 
cells, it negatively affects differentiation of these cells into cardiomyocytes (Cohen et al., 
2007, Qyang et al., 2007). By contrast, activation of non-canonical Wnt signaling has been 
shown to promote cardiac differentiation (Flaherty et al., 2008).  Early treatment of iPSC-CM 
with BMP-4 followed by late treatment with small molecule Wnt inhibitors has been shown 
to increase the production of cardiomyocytes in vitro (Ren et al., 2011). More recently iPSC 
have been differentiated into functional cardiomyocytes using a serum-free system by 
sequential regulation of the canonical Wnt pathway using glycogen synthase kinase 3 (GSK3) 
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inhibitor, combined with the expression of β-catenin shRNA or a chemical Wnt inhibitor 
(Lian et al., 2013). This system is reported to yield 80-98% cardiomyocyte differentiation 
without cell sorting or selection (Lian et al., 2013). 
 
Several other compounds, such as specific p38 Mitogen-activated protein (MAP) kinase 
inhibitors (Graichen et al., 2008), apelin (Wang et al., 2012), and trichostatin A, a histone 
deacetylase inhibitor (Lim et al., 2013), have been found to promote cardiac differentiation in 
vivo. Research is currently underway using novel high-throughput screening technology and 
bioinformatic approaches to identify novel molecules that could further promote cardiac 
differentiation of hESC and iPSC (Takahashi et al., 2003, Wu et al., 2004, Willems et al., 
2009, Yoshida and Yamanaka, 2010, Vieira and Riley, 2013) and there are early reports of 
small molecules which improve the efficiency of cardiogenesis (Shen et al., 2012, Oh et al., 
2013). Finally there are reports that cardiogenesis can be directed using culture conditions 
(Moon et al., 2013), and plasmid-based over-expression of cardiac transcription factors 
(Hartung et al., 2013).  
 
1.3.3 Identification of cardiac progenitor cells derived from human embryonic 
stem cells and induced pluripotent stem cells 
 
Despite improvements in the efficiency of cardiomyocytes differentiation from hESC and 
iPSC, current directed differentiation protocols do not yield a pure population of 
cardiomyocytes. This is suboptimal for some envisaged applications and has resulted in 
considerable interest in developing methods for purifying cardiomyocytes without genetic 
modification which may compromise their utility (Hattori et al., 2010). These include 
identification of novel cell surface markers to facilitate conventional cell sorting (Dubois et 
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al., 2011), sorting using microfluidic techniques based on physical cell characteristics (Zhang 
et al., 2012), and novel bioengineering techniques (Terazono et al., 2012). There is also 
considerable interest in identifying lineage-committed cardiac progenitor populations that 
could be expanded in vitro and differentiated efficiently into homogeneous cardiomyocytes 
(Yang et al., 2008, Kattman et al., 2006, Mauritz et al., 2011). 
 
It is increasingly understood that cardiac tissue, containing cardiomyocytes, smooth muscle, 
endothelium and connective tissue; develops from common cardiovascular progenitor cells 
(Noseda et al., 2011). Consequently, there is considerable interest in identifying these cells 
(Vidarsson et al., 2010). In cells derived from murine ESC lines, a population of cells 
expressing both fetal liver kinase 1 (Flk1) and insulin gene enhancer protein (Isl1) have been 
identified which differentiate into cardiomyocytes, endothelial, and smooth muscle cell 
lineages (Kattman et al., 2006, Moretti et al., 2006). Similarly, using cells derived from 
murine ESC with a Green Fluorescent Protein (GFP) reporter targeting the brachyury (Bry) 
gene, a population of Flk1+/GFP-Bry+ cells which differentiate into cardiomyocytes, 
endothelial, and smooth muscle cells have been identified (Kattman et al., 2006).  More 
recently it has been demonstrated that murine ESC derivatives expressing the mast/stem cell 
growth factor receptor (SCFR/cKit) and homeodomain transcription factor 2.5 (Nkx2.5) can 
be expanded and differentiated into cardiomyocytes and smooth muscle cells (Wu et al., 
2006) (Figure 1.3).  
 
Similar cardiovascular progenitor cell populations have been identified in cell populations 
derived from hESC (Yang et al., 2008). Using a novel stage-specific, serum-free, defined 
medium, differentiation protocol involving the combination of Activin A, BMP 4, Basic 
Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF), and 
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Dickkopf-related protein 1 (DKK1) at different stages in the protocol, a population of cells 
with low Kinase Insert Domain Receptor (KDR) (Flk-1) and no c-kit expression (KDR low/ 
c-kit-) were derived from hESC. Over 50% of these cells subsequently differentiated into 
cardiac myocytes (Yang et al., 2008). 
 
 
Figure 1.3. Summary of gene expression during differentiation from pluripotent stem cells into cardiomyocytes. 
Figure reproduced with permission of Rao et al. Phenotype and Developmental Potential of Cardiomyocytes from 
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Induced Pluripotent Stem Cells and Human Embryonic Stem Cells. In: Ainscough J et al eds. Nuclear 
reprogramming and stem cells. Humana Press, 2011 (Rao et al., 2011). 
 
1.3.4 Direct transdifferentiation of fibroblasts into cardiomyocytes 
 
Concerns about the safety of iPSC, and the expense, inefficiency and cost of reprogramming, 
were the catalyst for development of techniques to directly transdifferentiate fibroblasts into 
cardiomyocytes. In 2010 Ieda et al, showed that adult murine fibroblasts could be trans-
differentiated into cardiomyocytes, without an intermediate pluripotent state, by retroviral 
delivery of 3 cardiac transcription factors: Gata4, Mef2c, and Tbx5 (Ieda et al., 2010). Direct 
differentiation has been shown to be considerably quicker and more efficient than generation 
of iPSC-CM from fibroblasts in murine cells (Ieda et al., 2010). Direct transdifferentiation of 
fibroblasts into induced cardiomyocytes (iCM) was replicated using different factors by an 
independent group using mouse embryonic fibroblasts (MEF) (Efe et al., 2011). The 
therapeutic potential of direct lineage reprogramming was demonstrated by a study which 
showed that endogenous murine cardiac fibroblasts could be transdifferentiated into 
cardiomyocytes in vivo using Gata4, Mef2c, and Tbx5 (Qian et al., 2012). The iCM 
infiltrated to the infarct border zone, electrically matured and coupled with endogenous 
cardiomyocytes, resulting in decreased infarct size and modestly improved cardiac function 
up to 3 months after coronary ligation (Qian et al., 2012).  
 
iCM technology represents an interesting development of iPSC technology, offering 
improved efficiency and safety by avoiding the tumorigenicity associated with pluripotent 
stem cells. However, its continued reliance on viral vectors means that many of the safety 
concerns that are associated with iPSC technology persist. Consequently, full characterization 
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of iCM needs to be undertaken. This includes comprehensive functional comparison with 
iPSC-CM, hESC-CM and adult cardiomyocytes.   
 
1.4 Structure and functional phenotype of human embryonic stem cell and 
induced pluripotent stem cell-derived cardiomyocytes 
 
The study of structure and function in cardiomyocytes derived from pluripotent stem cells is 
complicated by evidence that differentiation method (Pekkanen-Mattila et al., 2010a) and 
culture conditions (Otsuji et al., 2010) may strongly influence phenotype. It is also uncertain 
whether hESC-CM and iPSC-CM have different phenotypes. This may have significant 
implications both for their use in cell therapy and disease modelling. 
 
1.4.1 Structural properties 
 
The structure and function of cardiomyocytes are intimately related. Ultrastructural analysis 
shows that hESC-CM develop in vitro from spherical cells to elongated cells with a more 
organized sarcomeric pattern (Snir et al., 2003) (Figure 1.4). Transmission electron 
microscopy of the hESC-CM at varying developmental stages shows progressive 
ultrastructural maturation from an irregular myofilament distribution with parallel nascent z-
bands containing myofibrils to a more mature sarcomeric organization containing well-
defined sarcomeres with recognizable A, I, and M-bands in older hESC-CM (Otsuji et al., 
2010, Snir et al., 2003, Baharvand et al., 2006). iPSC-CM also have functional, albeit 
immature, sarcomeric structures (Zwi et al., 2009) and the finding that time in culture results 
in progressive ultrastructural maturation has also been demonstrated in iPSC-CM (Kamakura 
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et al., 2013). Finally, it has been suggested by some authors that maturation of the 
ultrastructure is associated with withdrawal from the cell-cycle in hESC-CM (Snir et al., 
2003).  
 
   
Figure 1.4. Myosin heavy chain (MHC, green) and nuclear 4',6-diamidino-2-phenylindole stain (DAPI, blue) staining 
of hESC-CM without (A) and with (B) characteristic sarcomeric striation patterns, compared with adult rat 
ventricular myocyte.  Scale bar is 20 µm. Figure reproduced with permission of Rao et al. Phenotype and 
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Developmental Potential of Cardiomyocytes from Induced Pluripotent Stem Cells and Human Embryonic Stem 
Cells. In: Ainscough J et al eds. Nuclear reprogramming and stem cells. Humana Press, 2011 (Rao et al., 2011).   
 
Most comparative studies of hESC-CM and iPSC-CM have not shown any difference in 
ultrastructural phenotype (Zhang et al., 2009).  Other studies, however, suggest that whilst 
iPSC-CM and hESC-CM have broadly similar ultrastructural phenotypes, the sarcoplasmic 
reticulum (SR) may be less developed in iPSC-CM of equivalent age (Gherghiceanu et al., 
2011). Interestingly, Gherghiceanu et al suggest that there was a marked difference between 
the structural maturity of cardiomyocytes on the periphery of beating clusters and the 
cardiomyocytes in the centre of beating clusters, and speculate that this may underlie the 
functional heterogeneity that is described in the following section (Gherghiceanu et al., 2011) 
(Section 1.4.2).  
 
 
Figure 1.5. Diagram of an idealized adult human ventricular action potential (AP). The phases of the AP are labeled 
(Phase 0–4). The predominant cardiac ion currents at each point in the AP are labeled (INa=Na
+ Current, 
Ito=Transient Outward K
+ Current, ICa=Ca
2+ Current, IKr=Rapidly Activating Delayed Rectifier K
+ Current, 
IKs=Slowly Activating Delayed Rectifier K
+ Current, IK1=Inward Rectifier K
+ Current). Figure reproduced with 
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permission of Rao et al. Phenotype and Developmental Potential of Cardiomyocytes from Induced Pluripotent Stem 
Cells and Human Embryonic Stem Cells. In: Ainscough J et al eds. Nuclear reprogramming and stem cells. Humana 
Press, 2011 (Rao et al., 2011).  
 
1.4.2 Functional properties 
 
hESC-CM and iPSC-CM form functional syncytia like adult myocardial tissue (Zhang et al., 
2009, Kong et al., 2010, Caspi et al., 2009), with evidence that cells which beat together in 
clusters are connected by gap junctions (Pekkanen-Mattila et al., 2010a, Caspi et al., 2009). 
Action Potential (AP) can be recorded either from clusters of beating cells using sharp 
pipettes (Zhang et al., 2009) or enzymatically isolated myocytes (Pekkanen-Mattila et al., 
2010a, Sartiani et al., 2007). It is suggested that even enzymatically isolated cells from the 
same cluster can have different AP characteristics (Denning and Anderson, 2008, Xu et al., 
2002, Zhang et al., 2009).  
 
hESC-CM and iPSC-CM are more heterogeneous than adult cardiomyocytes and have key 
functional differences (Zhang et al., 2009, Kong et al., 2010, Pekkanen-Mattila et al., 2010a). 
With the exception of a small number of cells within the pacemaker and conduction system 
(nodal cells), adult cardiomyocytes normally maintain a stable negative membrane potential 
and are electrically inactive until they are depolarized (Kleber and Rudy, 2004). This usually 
occurs by the passage of ions from adjacent myocytes through connecting gap-junctions 
(Desplantez et al., 2007). When cardiomyocytes are sufficiently depolarized an AP is 
initiated (Kleber and Rudy, 2004, Bers and Despa, 2009) (Figure 1.5). This consists of an 
initial influx of Na
+
 that further depolarizes the cell, followed by an influx of Ca
2+
 and efflux 
of K
+
 that maintain the cell in a depolarized state. The influx of intracellular Ca
2+
 causes the 
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SR to release stored Ca
2+
 and the cytoplasmic Ca
2+
 initiates contraction of the sarcomere 
(Bers, 2002) (Figure 1.6). Finally an efflux of K
+
 predominates which repolarizes the cell.  
 
 
 
 
Figure 1.6. Excitation-Contraction coupling. The AP triggers L-type Ca2+  channels to open during the plateau phase 
of the cardiac AP, causing an influx of Ca2+ into the cardiomyocyte. The increase in cytosolic Ca2+ increases the open 
probability of the ryanodine receptor, causing Ca2+ stored in the sarcoplasmic reticulum to be released into the 
cytoplasm. Increased cytoplasmic Ca2+ binds to Troponin C, changing the configuration of the tropomyosin complex 
and exposing the actin binding site. This allows the myosin head to bind to the actin filament, facilitating cross-bridge 
cycling and cell shortening. Cytoplasmic Ca2+ is taken up by the sarco/endoplasmic reticulum Ca2+-Adenosine-5'-
triphosphate (ATP)ase 2a (SERCA2a) pump into the sarcoplasm, or ejected from the cell by the sodium-calcium 
exchanger. Intracellular Ca2+ concentration subsequently drops and the tropomyosin complex again covers the actin 
binding site, ending contraction. The cell then relaxes and lengthens. Reproduced with permission of Bers D, Nature 
2002 (Bers, 2002). 
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A key difference between adult cardiomyocytes and hESC-CM or iPSC-CM is that although 
some are electrical inactive until stimulated, many exhibit a high degree of automaticity with 
spontaneous AP (Pekkanen-Mattila et al., 2010a, Kong et al., 2010, Zhang et al., 2009). In 
adult myocardium this is only seen in pacemaker cells (DiFrancesco, 2010). The mechanisms 
that underlie the automaticity in hESC-CM and iPSC-CM probably differ from the 
mechanisms that underlie automaticity in pacemaker cells. Hyperpolarization-activated 
Cyclic Nucleotide-gated (HCN) channels allow the passage of Na
+
/K
+
 into specialized 
pacemaker cells in the adult myocardium when the cell is repolarized in diastole. This slowly 
activating, inward “funny” current (If) (DiFrancesco, 2010) may play a role in the 
automaticity of hESC-CM; however, other mechanisms are probably more important (Satin et 
al., 2004). hESC-CM express a large Na
+
 current (INa) density and their AP duration is 
shortened by L-type Ca
2+
  channel blockade (Habib et al., 2008, Satin et al., 2004). It has 
been suggested that, whilst a diverse set of K
+
 channels are expressed in older hESC-CM 
compared to early-differentiated hESC-CM (Sartiani et al., 2007), the expression of the IK1 
remains low (Satin et al., 2004). Consequently, the presence of comparatively large INa and 
relatively small IK1 probably explains the increased automaticity of hESC-CM (Satin et al., 
2004). Fluctuations in intracellular Ca
2+
 play a critical part in the automaticity of developing 
murine myocardium (Viatchenko-Karpinski et al., 1999). Whilst they may also contribute to 
the automaticity of hESC-CM, it is not thought that they have a dominant role (Satin et al., 
2004). This is supported by studies which show that co-culture of Human Embryonic Kidney 
293 Cells (HEK-293) cells expressing IK1 electrically coupled to rat neonatal cardiomyocytes 
reversibly inhibits their automaticity (de Boer et al., 2006), and emerging evidence which 
suggests that forced expression of the KCNJ2 gene in hESC which encodes the Kir2.1 
channel, which mediates IK1, results in a more mature electrophysiological phenotype (Kong 
et al., 2010, Liao et al., 2013).  
22 
 
The AP measured in hESC-CM and iPSC-CM are often categorized as “ventricular”, “atrial” 
or “nodal” (pacemaker) based on their resemblance to adult AP. “Ventricular” cells are said 
to be characterized by a fast and large upstroke, and plateau phase. “Atrial” cells are said to 
have more triangular AP. “Nodal” cells are said to have a slower and smaller upstroke, 
prominent phase four depolarization and to be relatively depolarized in diastole. In some 
cases these phenotypes are also quantified using parameters such as AP duration (APD) at 
90% repolarization (APD90), maximum rise of the AP upstroke (dV/dtmax), AP amplitude 
(APA) and maximum diastolic potential (MDP) (He et al., 2003, Cao et al., 2008, Yoshida 
and Yamanaka, 2010, Zhang et al., 2009, Pekkanen-Mattila et al., 2010a, Mummery et al., 
2003, Satin et al., 2004, Sartiani et al., 2007). Whether “ventricular”, “atrial” and “nodal” 
cells represent distinct populations of cells, or a continuous range of AP characteristics within 
one population is yet to be shown. Some studies suggest there is considerable heterogeneity 
in AP characteristics within these groups and considerable overlap in the characteristics 
between groups (Pekkanen-Mattila et al., 2010a). It is also suggested that “atrial” cells have a 
higher rate of spontaneous contraction (Zhang et al., 2009); however this is not supported by 
all studies (Pekkanen-Mattila et al., 2010a). In addition to using the electrophysiological 
characteristics, attempts have been made to employ specific reporters to delineate subtypes of 
hESC-CM (Muller et al., 2000, Kuratomi et al., 2009, Kolossov et al., 2005, Blazeski et al., 
2012).  
 
Neither direct nor indirect comparison of the electrophysiological properties of hESC-CM 
and iPSC-CM suggests that there is any difference in phenotype, with both cell types 
exhibiting similar AP morphology and response to pacing at different rates (Zhang et al., 
2009). Finally, a number of studies have used either isolated cells (Pekkanen-Mattila et al., 
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2010a, Otsuji et al., 2010, Caspi et al., 2009, Moretti et al., 2010) or beating clusters plated 
onto multi-electrode arrays (Zwi et al., 2009, Kehat et al., 2001, Otsuji et al., 2010, Tanaka et 
al., 2009, Caspi et al., 2009) to demonstrate that hESC-CM and iPSC-CM have an 
appropriate chronotropic response and change in AP morphology in response to several 
pharmacological agents including adrenergic and cholinergic agents (Zwi et al., 2009, Kehat 
et al., 2001, Pekkanen-Mattila et al., 2010a, Tanaka et al., 2009, Moretti et al., 2010, Xu et 
al., 2002, Mummery et al., 2003), IKr channel blockade (Zwi et al., 2009, Pekkanen-Mattila et 
al., 2010a, Otsuji et al., 2010, Tanaka et al., 2009, Caspi et al., 2009, Moretti et al., 2010), IKs 
channel blockade (Zwi et al., 2009),  and Ca
2+
  channel blockade (Zwi et al., 2009, Tanaka et 
al., 2009).  These similarities to an authentic cardiac phenotype support the feasibility of 
using hESC-CM and iPSC-CM as in vitro model systems (Caspi et al., 2009, Moretti et al., 
2010).  
 
hESC-CM have intracellular Ca
2+
 transients that correspond to their beating activity (Kehat et 
al., 2001, Mummery et al., 2003, Satin et al., 2008). Experiments with murine ESC derived 
cardiomyocytes (ESC-CM) demonstrated that a functioning SR was essential for regulating 
contraction (Fu et al., 2006). However, early experiments with hESC-CM suggested that they 
did not respond to caffeine, which depletes SR Ca
2+
 stores, or ryanodine receptor (RyR) 
blockade (Dolnikov et al., 2006). This suggests that hESC-CM did not have functional SR 
and that their contractions result from influx of extracellular Ca
2+
 into the cell (Dolnikov et 
al., 2006). A subsequent study however, suggested 40% of hESC-CM were responsive to 
caffeine, ryanodine and the Sarco/Endoplasmic Reticulum Ca
2+
-ATPase pump (SERCA) 
inhibitor thapsigargin (Liu et al., 2007). Furthermore, in contrast to earlier work (Dolnikov et 
al., 2006), as in adult cardiomyocytes a positive force-frequency relationship was 
demonstrated in this population of cells (Liu et al., 2007). Other studies suggest that not only 
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is a functional SR  present, demonstrated by caffeine and ryanodine in hESC-CM, but as in 
murine cells (Fu et al., 2006) this is present from as early as two days following the 
commencement of beating (Satin et al., 2008).  
 
In adult human ventricular myocytes, the cell membrane has regular invaginations called t-
tubules which are considered critical for normal Ca
2+
 cycling (Brette and Orchard, 2003). 
Contraction is caused by a net flux of Ca
2+ 
ions into the cardiomyocyte through L-type Ca
2+
 
channels in t-tubules. The increase in cytoplasmic Ca
2+
 causes the RyR in the membrane of 
the SR to release stored Ca
2+
 into the cytoplasm. Ca
2+
-induced Ca
2+
-release (CICR) (Bers, 
2002) accounts for between 70 and 90% of the raise in cytoplasmic Ca
2+
 during contraction 
of the adult cardiomyocyte (Bers et al., 2006). Cytoplasmic Ca
2+
 binds to Troponin C, 
displacing tropomyosin and initiating contraction of the sarcomere. Cytoplasmic Ca
2+
 is taken 
up by the SERCA into the SR, or ejected from the cell by the sodium-calcium exchanger 
(NCX). Cytoplasmic Ca
2+
 drops and tropomyosin complex returns over the active site of the 
actin filament, ending contraction. This beat-to-beat rise and fall in Ca
2+
 is known as a Ca
2+
 
transient (Bers, 2002) (Figure 1.6). T-tubules ensure that the L-type Ca
2+
 channels are in 
close proximity to the RyR, minimizing the diffusion distance between the two ion 
transporters (Brette and Orchard, 2003, Brette and Orchard, 2007). This ensures that Ca
2+
 is 
released synchronously from RyR across the cell (Brette and Orchard, 2003), and that there is 
no delay in release of Ca
2+
 from RyR in the centre of the cell. In pathological cells 
detubulation occurs, resulting in a time delay in release of Ca
2+
 from the SR in the centre of 
the cell (Brette and Orchard, 2003, Brette and Orchard, 2007, Song et al., 2005). Some 
studies have been unable to detect t-tubules in hESC-CM (Lieu et al., 2009) while others find 
that they are present (Satin et al., 2008, Baharvand et al., 2006) but clearly less abundant and 
organized than in adult ventricular cardiomyocytes.  This may explain why Ca
2+
 handling of 
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hESC-CM resembles that of failing or atrial myocytes which have fewer and less organized t-
tubules (Satin et al., 2008). 
 
Finally, protein expression and functional data suggests that NCX expression is higher in 
hESC-CM compared to adult cardiomyocytes (Fu et al., 2010); by contrast expression of 
regulatory proteins such as junctin, triadin, and calsequestrin which are usually expressed in 
adult cardiomyocytes are completely absent in hESC-CM. Calsequestrin, in particular, plays 
a critical role in excitation contraction coupling, acting as a critically important Ca
2+
 buffer in 
some intracellular compartments (Beard et al., 2004) and regulating CICR (Lukyanenko et 
al., 1996, Shannon et al., 2000, Bassani et al., 1995).  
 
There is limited evidence to suggest that differentiation protocols may affect the 
electrophysiology of hESC-CM. In a study comparing the EB with the END-2 differentiation 
system, EB derived hESC-CM were found to be less likely to express an atrial phenotype, 
more likely to beat continuously, and to be significantly more polarized in diastole 
(Pekkanen-Mattila et al., 2010a). The effect of time in culture on the electrophysiological 
phenotype has not yet been fully characterized. Whilst it has been suggested that the AP 
maturity increases with time in culture (Sartiani et al., 2007), which is consistent with 
evidence from murine models (Hescheler et al., 1997), other studies show time in culture 
does not significantly affect the maturation of hESC-CM (Pekkanen-Mattila et al., 2010a). 
Whether or not hESC-CM and iPSC-CM mature in culture there is considerable interest in 
accelerating and homogenizing the maturation of cells derived from hESC and iPSC not only 
to facilitate representative disease models but also to ensure the safety of cell therapy. 
Promising techniques range from cyclical replanting and suspension of beating clusters in 
culture (Otsuji et al., 2010) to forced expression of the genes which encode the IKr channel or 
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calsequestrin in order to improve the maturity of the AP or intracellular Ca
2+
 handling 
respectively (Kong et al., 2010, Liao et al., 2013, Liu et al., 2009). 
 
1.4.3  Differences in gene-expression and differentiation potential of induced 
pluripotent stem cells and human embryonic stem cells 
 
During early cardiogenesis it is known that there is an initial reduction in the expression of 
pluripotency genes such as Oct-4 (Niwa et al., 2000) and NANOG (Mitsui et al., 2003, 
Chambers et al., 2003) following the initiation of differentiation, with a concomitant increase 
in the levels of mesodermal markers such as Bry (Marcellini et al., 2003). This is followed by 
expression of the cardiac transcription factors such as Nkx2.5 (Garg et al., 2003, Durocher et 
al., 1997), Myocyte-specific enhancer factor 2C (MEF2c) (Bi et al., 1999), and GATA4 
(Garg et al., 2003, Durocher et al., 1997). Finally, genes encoding cardiac-specific structural 
proteins are expressed such as cardiac troponin T (TNNT2) (Townsend et al., 1994), α-
myosin heavy chain (MYH6) (Brand et al., 1991), α-actinin (ACTN2) (Eldstrom et al., 2003), 
myosin light chain 2 atrial isoform (MYL7) (Kubalak et al., 1994) and myosin light chain 2 
ventricular isoform (MYL2) (Macera et al., 1992); atrial natriuretic factor (HPPA) (Saito et 
al., 1989); and phospholamban (PLN) (Tada et al., 1974) (Figure 1.3). Whilst this is broadly 
consistent with gene expression patterns in the differentiation of hESC and iPSC into cardiac 
myocytes (Pekkanen-Mattila et al., 2009, Mummery et al., 2003, Zhang et al., 2009, Zwi et 
al., 2009, He et al., 2003, Xu et al., 2002, Kehat et al., 2001, Xue et al., 2005, Pekkanen-
Mattila et al., 2010b, Habib et al., 2008) there are differences between gene expression 
patterns (Chin et al., 2009) and Deoxyribonucleic Acid (DNA) methylation patterns in hESC 
and iPSC (Deng et al., 2009). Furthermore, evidence has recently emerged that ESC may 
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differentiate into specific lineages more efficiently than iPSC (Deng et al., 2009, Hu et al., 
2010).  
 
Differences between iPSC and hESC in the expression of pluripotency genes have been 
reported, because of persistent transgene expression in iPSC during cardiogenesis (Zhang et 
al., 2009), however it is not clear if this affects either the potential of iPSC to differentiate 
into cardiomyocytes or the phenotype of the resulting iPSC-CM. Trends towards more 
efficient cardiac differentiation in hESC compared to iPSC have been reported (Zhang et al., 
2009). However, this must be interpreted in the context of data which suggests that there is 
considerable variation between the efficiency with which different hESC lines differentiate 
into cardiomyocytes. Consequently, observed variation in the differentiation potential 
between iPSC and hESC may just reflect differences between pluripotent stem cell lines 
rather than inherent characteristics of either iPSC or hESC (Moore et al., 2008, Osafune et al., 
2008, Adewumi et al., 2007, Pekkanen-Mattila et al., 2009). Whilst some studies suggest that 
there is no difference in the time taken for iPSC and hESC to differentiate into 
cardiomyocytes (Zhang et al., 2009, Narazaki et al., 2008), others report that iPSC take 
longer to differentiate into cardiomyocytes than hESC (Mauritz et al., 2008). It has been 
proposed by some authors that variation in the site of transgene integration may account for 
these differences (Zhang et al., 2009). This is not, however, consistent with reports that 
differences in gene expression between iPSC and hESC are independent of the method by 
which pluripotency is induced (Chin et al., 2009). As a consequence of concerns about 
continued expression of reprogramming factors, and the effect that this may have on the 
phenotype of iPSC-CM and hESC-CM, there is considerable interest in developing and 
refining methods to induce pluripotency without genetic manipulation (De Miguel et al., 
2010, Selvaraj et al., 2010).  
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1.5 Cell therapy 
 
The adult heart has limited regenerative capacity resulting in irreversible loss of myocardial 
tissue following injury (Bergmann et al., 2009). The resulting adaptive response of the 
myocardium to injury further worsens cardiac function resulting in permanent impairment of 
function (McMurray and Stewart, 2000). The associated clinical syndrome of heart failure is 
characterized by fatigue, oedema and dyspnea. The long-term prognosis is poor, with death 
often resulting from fatal arrhythmia in the pathological myocardium (McMurray and 
Stewart, 2000). Current therapies for heart failure are largely palliative, aiming to prevent 
progression of heart failure and to relieve symptoms (Yamada et al., 2008). In 2003, only 
25% of patients survived 5 years after their first heart-failure-associated hospital admission 
(Stewart et al., 2001). The only treatment for end-stage heart failure with established long-
term efficacy is cardiac transplantation (Taylor et al., 2007). However, the prevalence of 
heart failure is increasing and the supply of donor organs is insufficient to meet the current 
demand for transplant surgery (Gridelli and Remuzzi, 2000). Consequently, there is 
significant interest in developing novel regenerative strategies. Stem cell therapy, which aims 
to arrest further deterioration of cardiac function and induce recovery by replacing lost 
cardiomyocytes and improving the function of existing myocytes, is one of the more 
promising of these strategies (Bolli et al., 2011, Makkar et al., 2012). Cell therapy entails 
either mobilization of endogenous cardiac progenitor cells, or transplantation of exogenous 
stem cells; however, these therapies are not mutually exclusive and it has been widely 
suggested that cell transplantation promotes mobilization of endogenous stem cells (Mirotsou 
et al., 2011). The feasibility of cell therapy has been investigated using several stem cell 
populations (Nelson et al., 2009, Menasche et al., 2008, Abdel-Latif et al., 2007, Bolli et al., 
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2011, Makkar et al., 2012, van Laake et al., 2009). A full review of the use of these cell 
populations in cardiac cell therapy, their properties, and their relative advantages lies outside 
the scope of this work. However, when considering the role of tissue engineering in cell 
therapy it is impossible to ignore some of the general principles about cell therapy that we 
have learnt over the last two decades. 
 
Many cell types appear to induce a transient improvement in cardiac physiology in humans 
and animal models of cardiac disease (Menasche et al., 2001, Alaiti et al., 2010, Jiang et al., 
2010a, Abdel-Latif et al., 2007, Bai and Alt, 2010), Often, however little effect is seen in  
studies of chronic heart failure (Fernandes et al., 2010), and the initial functional 
improvement generally diminishes over time in most studies (van Laake et al., 2007, Singla 
et al., 2011). It is now considered unlikely that significant myogenesis alone is responsible 
for these limited improvements in function (Alaiti et al., 2010).  Improvements in function 
were often reported before significant myogenesis could have occurred (Gnecchi et al., 
2008).  Improvements in cardiac physiology were seen irrespective of cell type (Gersh and 
Simari, 2006) and delivery method, with over 6000-fold variations in the number of cells 
delivered (Murry et al., 2005). Despite promising early clinical reports (Makkar et al., 2012, 
Bolli et al., 2011), there has been a paucity of evidence demonstrating the presence of new 
cardiac myocytes significant enough to account fully for improvements in cardiac function 
(Nygren et al., 2004, Balsam et al., 2004, van Laake et al., 2009). Histological studies 
demonstrate widespread death of transplanted cells and an unpredictable distribution of cells, 
further suggesting that myogenesis alone does not account for improvements in function 
(Reinecke and Murry, 2000, Balsam et al., 2004, Zhang et al., 2009).  
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In the absence of significant evidence of myogenesis, it has been suggested that definite 
improvements in myocardial function are due to the secretion of soluble mediators by 
transplanted cells, termed “paracrine factors”.  It has been suggested that these factors may 
improve survival of existing myocardium, promote neovascularization, improve cellular 
metabolism and contractile function, modulate remodelling of the extracellular matrix 
(ECM), and promote activation of native progenitor cells (Mirotsou et al., 2011). The 
mechanisms by which this is accomplished are not fully understood, are likely to be multiple, 
and may vary between stem cell populations (Mirotsou et al., 2011, Shintani et al., 2009, 
Doyle et al., 2008, Lee et al., 2008). 
 
It has been suggested that the discrepancy between the impressive potential of stem cells to 
proliferate, differentiate and form beating syncytium in vitro, and disappointing in vivo 
studies could be explained by the environment of the pathological myocardium. Injected cells 
are exposed to significant mechanical forces in an often ischaemic, inflamed, biochemically 
hostile environment. Consequently, few cells survive, are retained at the site of injection, and 
proliferate (Dohmann et al., 2005, Nygren et al., 2004, Balsam et al., 2004, van Laake et al., 
2009). It is hypothesized that tissue engineering techniques could be used to modify the 
environment to make cell retention, and survival more likely, and this may improve the 
efficacy of cell therapy (Li and Guan, 2011). 
 
1.6 Disease modelling 
 
In addition to applications in cell therapy there is also considerable interest in using hESC-
CM (Abdul Kadir et al., 2009, Foldes et al., 2011), iPSC-CM (Carvajal-Vergara et al., 2010, 
Moretti et al., 2010, Caspi et al., 2009) and other immature cardiomyocytes such as neonatal 
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rat ventricular myocytes (NRVM) (Brand et al., 2010) as in vitro models of human 
physiology and disease (Tanaka et al., 2009).  
 
Many of the properties that make stem cell-derived cardiomyocytes suitable for cell therapy 
also make them particularly useful as disease models. Pluripotent stem cells can be 
differentiated into all cell types in the body (Thomson et al., 1998). In specific conditions 
stem cells can be propagated in vitro for many months without loss of normal karyotype 
(Ying et al., 2003), manipulated and transfected, and stem cell-derived cardiomyocytes, 
unlike adult cardiomyocytes can be readily cultured (Yoshida and Yamanaka, 2010, Rao et 
al., 2011). The feasibility of human pluripotent-derived cardiomyocyte disease models was 
demonstrated when hESC-CM were used to investigate potential mechanisms for the 
arrhythmogenic effect of bile acids on the fetal heart (Abdul Kadir et al., 2009). Older hESC-
CM were shown to be more resistant than early hESC-CM to bile acid-induced disruption of 
rhythm, depression of contraction and desynchronization of cell coupling, paralleling the 
difference between fetal and maternal susceptibilities (Abdul Kadir et al., 2009).  
 
More recently described cell types such as iPSC-CM could be used to create patient-specific, 
disease-specific models (Carvajal-Vergara et al., 2010, Matsa et al., 2011), which could be 
used to elucidate the molecular mechanisms that underlie inherited disease phenotypes 
(Carvajal-Vergara et al., 2010), and suggest novel therapies (Matsa et al., 2011). 
Furthermore, as they can be easily obtained from any individual, they may also facilitate 
personalized medicine, the study of a genetic background on a disease process, and the study 
of pharmacogenetics at a cellular level (Inoue and Yamanaka, 2011). 
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1.6.1 Modelling inherited arrhythmias 
 
The feasibility of using iPSC-CM to create disease-specific models for inherited myocardial 
disorders was first demonstrated when the prolonged AP duration seen in patients with 
inherited long-QT syndrome, type 1 (LQTS1), caused by mutation of the KCNQ1 gene 
encoding voltage-gated potassium channel, Kv7.1, was replicated in vitro using iPSC-CM 
(Moretti et al., 2010). The susceptibility to catecholamine-induced tachyarrhythmia which 
can be fatal in patients was also replicated in vitro (Moretti et al., 2010). Other groups have 
subsequently replicated the long-QT syndrome phenotype in vitro using iPSC-CM for 
LQTS1 (Egashira et al., 2011), LQTS2 caused by mutation of the KCNH2 gene (also known 
as the Human Ether-à-go-go Related Gene – hERG) encoding the alpha subunit of the voltage 
gated K
+
 channel, Kv11.1 (Itzhaki et al., 2011a, Matsa et al., 2011, Lahti et al., 2012), LQTS3 
caused by mutation of the SCN5 gene encoding the voltage gated Na
+
 channel Nav1.5 
(Terrenoire et al., 2013, Malan et al., 2011), and LQTS8 caused by mutation in the 
CACNA1C gene encoding the subunit Cav1.2 of the voltage-gated Ca
2+
 channel (Timothy 
syndrome) (Yazawa et al., 2011). Similarly, disease phenotypes have been replicated in vitro 
using iPSC-CM for overlap syndromes caused by SCN5A mutation (Davis et al., 2012), 
catecholaminergic polymorphic ventricular tachycardia type 1 caused by mutation of the 
RYR2 gene encoding the RyR (Kujala et al., 2012, Jung et al., 2012, Itzhaki et al., 2012, 
Fatima et al., 2011), and catecholaminergic polymorphic ventricular tachycardia type 2 
caused by mutation of the CASQ2 gene encoding calsequestrin (Novak et al., 2012). 
 
Significantly many of these studies suggested novel mechanisms that may underlie the 
development of the disease phenotype (Itzhaki et al., 2011a, Yazawa et al., 2011, Egashira et 
al., 2011, Jung et al., 2012, Terrenoire et al., 2013, Kujala et al., 2012), and in one study this 
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was validated in an index patient (Kujala et al., 2012). In several studies the pathogenicity of 
a novel mutation was established (Moretti et al., 2010, Jung et al., 2012, Egashira et al., 
2011). Many studies suggested novel therapeutic drug approaches (Itzhaki et al., 2011a, 
Matsa et al., 2011, Yazawa et al., 2011, Itzhaki et al., 2012, Jung et al., 2012). One study 
suggested a novel approach to myocardial pacing (Terrenoire et al., 2013). Finally, one study 
suggested that Ribonucleic Acid (RNA) interference may theoretically be an effective 
therapy in the clinic (Matsa et al., 2013). 
 
1.6.2 Modelling inherited cardiomyopathies 
 
Arguably, existing experimental tools are sufficient to model single ion channel disorders, 
and consequently the challenge is to leverage the potential of iPSC to model more 
complicated disease phenotypes. One of the earliest attempts to do this was for Syndrome of 
Lentigines, Electrocardiographic conduction abnormalities, Ocular hypertelorism, Pulmonary 
stenosis, Abnormal genitalia, Retarded growth, and Deafness (LEOPARD syndrome), an 
autosomal dominant multisystem disorder resulting from a missense mutation in the PTPN11 
gene resulting in abnormalities of the skin, skeletal muscle and cardiovascular system 
(Carvajal-Vergara et al., 2010). The most commonly life-threatening cardiac anomaly 
associated with LEOPARD syndrome is hypertrophic cardiomyopathy (HCM). Carvajal-
Vergara et al showed that compared to controls iPSC lines, iPSC derived CMs from a 
LEOPARD syndrome patient had a higher mean cell surface area, a greater degree of 
sarcomeric assembly and a nuclear localization of the nuclear factor of activated T-cells, 
cytoplasmic 4 (NFATC4) transcription factor. In addition, phospho-proteomic assays of these 
cardiomyocytes revealed a notable abundance or increased phosphorylation of proteins that 
could be involved in the cardiac hypertrophy observed in these patients. The observed 
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hypertrophic phenotype could not be fully characterized because of the heterogeneity of the 
iPSC-CM population. In a subsequent study, iPSC lines were created from a family with 
familial HCM who carried a missense mutation of the MYH7 gene. Despite mutations of 
genes encoding sarcomeric proteins being the classical cause for familial HCM, the 
mechanisms that lead to the development of the HCM phenotype is unclear. This study was 
able to replicate the HCM phenotype at the cellular level showing cellular enlargement, 
contractile and electrophysiological dysfunction (Lan et al., 2013). Unlike the previously 
mentioned study the authors were also able to demonstrate activation of a hypertrophic gene 
expression pattern; significantly this was achieved using single-cell gene expression analysis, 
negating the effect of population heterogeneity. Furthermore, not only were the authors able 
to demonstrate that deranged Ca
2+
 homeostasis was critical to the development of the HCM 
phenotype, but pharmacological normalization of Ca
2+
 homeostasis was able to prevent the 
development of the HCM phenotype, suggesting novel therapeutic mechanisms (Lan et al., 
2013).  
 
Similarly, iPSC cell lines have been generated from a family with familial dilated 
cardiomyopathy (DCM), caused by a mutation of the gene encoding cardiac troponin T (Sun 
et al., 2012). iPSC-CM differentiated from patients with DCM, exhibited a DCM phenotype 
with deranged sarcomeric organization, altered Ca
2+
 handling and an increased susceptibility 
to biomechanical stress and adrenergic stimulation (Sun et al., 2012). The authors found that 
β-adrenoceptor blockade and SERCA2a overexpression partially normalized the adverse 
phenotype observed in DCM iPSC-CM (Sun et al., 2012). There are even early results to 
suggest that it may be theoretically possible to modify the inherited cardiac gene expression 
profile associated with Duchenne muscular dystrophy in vitro using iPSC-CM, supporting the 
efficacy of gene therapy for this condition (Dick et al., 2013).    
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A further study, which created iPSC-CM from patients with DCM demonstrated a different 
application in cardiovascular disease modelling (Tse et al., 2013). In this study recreation of 
the DCM cellular phenotype using iPSC derived cardiomyocytes from a patient with a novel 
mutation of the gene encoding desmin was used to support the assertion that this mutation 
was responsible for the development of the DCM phenotype (Tse et al., 2013). Interesting 
developing areas include work to replicate the cellular phenotype of diseases which have a 
complex anatomical basis such as arrhythmogenic right ventricular cardiomyopathy 
associated with plakophylin-2 mutation, in order to better understand disease mechanisms 
(Ma et al., 2013).  
 
1.6.3 Drug development 
 
The lack of suitable in vitro models makes drug development expensive (Gunaseeli et al., 
2010, Dickson and Gagnon, 2004) and up to 80% of medications which enter clinical testing 
do not make it to the clinic (Dickson and Gagnon, 2004). The average cost of drug 
development is now estimated to exceed US $800 million (Dickson and Gagnon, 2004).  In 
half of cases this is because of lack of efficacy, however in half of cases this is as a result of 
toxicity, most commonly cardiac or hepatic toxicity (Inoue and Yamanaka, 2011). Cardiac 
toxicity can lead to reactive oxygen species formation, altered contractility, arrhythmia, 
impaired gene expression, and cell death. Despite current best practice the toxicity of several 
medications is only discovered when they have made it to market or during phase 3 clinical 
trials, representing a significant monetary cost and associated morbidity (Gunaseeli et al., 
2010, Tanaka et al., 2009). The considerable cost associated with drug development can be 
largely attributed to the “failures” (Dickson and Gagnon, 2004). Whilst pre-clinical 
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development costs probably only account for 2-3% of the cost of a drug’s development 
(Dickson and Gagnon, 2004), if the number of drugs which fail in late drug development 
could be reduced this would significantly reduce the average cost of drug development and 
the accessibility of novel therapeutic compounds.  
 
The difficulty in obtaining and culturing human myocardial tissue makes studying 
pathophysiology and therapeutic mechanisms using standard techniques problematic. The 
current models used in the pharmaceutical industry for cardiac drug development and toxicity 
screening rely on animal cardiomyocytes, immortalized human cell lines, and animal models 
(Gunaseeli et al., 2010). Although these models provide useful information in evaluating the 
safety and efficacy of the drugs, they have a number of limitations. Firstly drug metabolism 
and mechanism of action can differ substantially between humans and even large animals. 
The effect of altered physiology seen in elderly and unwell patients cannot easily be modeled. 
Similarly, toxicity associated with combination pharmacotherapy can also not be studied. 
Consequently, a representative human in vitro myocardial model could have significant 
value, resulting in a more accurate description of the effects of novel drugs in a more cost-
effective fashion (Gunaseeli et al., 2010, Dickson and Gagnon, 2004, Tanaka et al., 2009).  
 
iPSC-CM from patients with a range of genetic backgrounds and disease phenotypes could 
potentially provide a high-throughput platform for toxicology screening and drug 
development (Zhang et al., 2009, Shiba et al., 2009), their utility is already being investigated 
by industry (Harris et al., 2013), and several studies have already demonstrated the utility of 
iPSC-CM for this application (Braam et al., 2013, Liang et al., 2013). 
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1.6.4 Limitations of immature cardiomyocytes as disease models 
 
Despite promising evidence from these studies that complex cellular phenotypes can be 
modeled using iPSC-CM, and whilst they are an improvement on non-human cell types such 
as NRVM, there remain issues that need to be addressed. Firstly, all the cell types mentioned 
have the structural and functional properties of developing cardiomyocytes, including 
immature gene expression, immature electrophysiological properties, ultrastructural 
phenotype and altered Ca
2+
 handling (Section 1.4). Furthermore, human iPSC-CM and hESC-
CM have a heterogeneous phenotype (Matsa et al., 2011). This heterogeneous phenotype may 
make iPSC-CM unsuitable for disease modelling. Several of these studies suggest that there 
was heterogeneity in the population of iPSC-CM, or inclusion of a significant population of 
non-cardiomyocytes following the use of common differentiation techniques (Carvajal-
Vergara et al., 2010). This limits the utility of iPSC-CM for multicellular assays which are 
the mainstay of molecular biological and cellular physiology, and consequently limited their 
utility as disease models. Some studies were able to recreate subcellular phenotypes (Hick et 
al., 2013, Ho et al., 2011) or gene expression patterns (Dick et al., 2013) in iPSC-CM whilst 
failing to recreate cellular phenotypes, suggesting that culture conditions, or cell-cell 
interaction may be critical in developing disease phenotypes (Hick et al., 2013, Ho et al., 
2011). 
 
Many of the caveats that apply to the use of iPSC-CM as disease models equally apply to 
their use in toxicology screening and drug development tools. As iPSC-CM have an 
immature and heterogeneous phenotype experimental findings will need to be triangulated 
with other experimental data.  In reality this will mean that iPSC are likely to be used as an 
adjunct to animal models rather than as a replacement. 
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It has been suggested that a tissue engineering approach may be used to promote a more 
mature phenotype, which could not only improve the efficacy of cell therapy but make stem 
cell-derived cardiomyocytes more representative disease models, and thus improve their 
efficacy in drug development and toxicology screening. 
 
1.7 Myocardial tissue engineering 
 
Refinement of cell delivery may potentially improve the efficacy and durability of cell 
therapy (Singla et al., 2011). Novel tissue engineering approaches aims not only to optimize 
cell delivery by improving cell survival and retention, but also to promote beneficial reverse 
remodelling by manipulating the mechanical and chemical micro-environment of the heart. 
Additionally, a tissue engineering approach may be used to promote a more advantageous 
phenotype, which could not only improve the efficacy of cell therapy but make stem cell-
derived cardiomyocytes more representative disease models (Rao et al., 2013). In this 
introductory chapter the field of myocardial tissue engineering is not comprehensively 
reviewed. This is huge field, a multitude of different approaches have been adopted and there 
are several existing reviews on this subject (Rao et al., 2013). However, in the following 
sections the technology and studies relevant to this work are briefly discussed. 
 
1.7.1 Synthetic tissue culture substrates 
 
Physical and chemical properties of synthetic polymers can easily be modified, altering 
characteristics of synthetic tissue culture substrates such as stiffness, water affinity, 
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degradation rate, geometry and porosity, making it possible to mimic myocardial 
characteristics in engineered heart tissue (EHT). However, cellular interaction with synthetic 
materials is limited, consequently substrates usually have to be coated in ECM components to 
promote cell adhesion (Li and Guan, 2011).  
 
Electrospinning allows 3D synthetic tissue culture substrates to be fabricated from several 
synthetic biodegradable polymers including poly(urethane) (PU), poly(caprolactone) (PCL), 
poly(L-lactic acid) (PLA), poly(glycolic acid) (PGA). These substrates generally have a high 
surface area to volume ratio, form a porous network that mimics the fibrous architecture of 
ECM and promotes cell adhesion and support (Rockwood et al., 2008, Krupnick et al., 2002, 
Zong et al., 2005, Ishii et al., 2005, Papadaki et al., 2001, Xing et al., 2012, Shin et al., 2004). 
By altering the fabrication parameters the mechanical and physical properties can be 
manipulated, potentially effecting cellular or host organ function (Zong et al., 2005, 
Rockwood et al., 2008). Many of these materials have regulatory approval for in vitro use in 
humans (Zong et al., 2005), and there is evidence that electrospun 3D synthetic constructs, 
coated in ECM components can support NRVM in culture (Ishii et al., 2005, Rockwood et 
al., 2008), often for long periods of time, and promote greater cell maturation than standard 
culture techniques (Papadaki et al., 2001, Zong et al., 2005, Xing et al., 2012). Some studies 
suggest that electrospun substrates are flexible enough not to impede cardiomyocyte 
contractions (Shin et al., 2004, Ishii et al., 2005), and allow cardiomyocytes to generate force 
(Ishii et al., 2005), but are robust enough to survive surgical implantation (Shin et al., 2004) 
or use in bioreactors (Papadaki et al., 2001). In vivo characterization of electrospun polymers 
is limited, however PLA seeded with bone marrow derived stem cells was used in rats after 
ventriculotomy. PLA constructs contracted with the native myocardium and there was no 
evidence of arrhythmia development (Krupnick et al., 2002). There are however limitations 
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of electrospun substrates. Some persist in vivo for long periods of time whilst others elicit a 
significant host inflammatory response (Krupnick et al., 2002). Finally, several studies have 
suggested that thick constructs do not support cell culture in their core, with cell proliferation 
focused on the surface of the construct (Ishii et al., 2005). 
  
1.7.2 Biological tissue culture substrates 
 
Biological tissue culture substrates have historically been an integral part of almost all tissue 
culture. In order to facilitate cell therapy, 3D tissue culture substrates derived from 
extracellular matrix components such as collagen (Kutschka et al., 2006, Zimmermann et al., 
2002), Matrigel (Kofidis et al., 2004b), gelatin (Li et al., 1999) and others have been used to 
fabricate constructs suitable for delivery and support of transplanted cells. Additionally, 
experimental studies have also been performed with other biological compounds such as 
fibrin (Birla et al., 2005), chitosan (Lu et al., 2010) and alginates (Dvir et al., 2009), which 
have been deemed to have properties suitable for the delivery and support of transplanted 
cells. The discussion of the relative advantages and efficacy of these constructs lies outside of 
the scope of this work, however several studies highlight key experimental findings. Firstly, 
whilst cell therapy appears to have at least transient efficacy (as previously discussed in 
Section 1.5), and modification of the mechanical properties of the diseased myocardium with 
an unseeded construct alone has been shown in several cases to be beneficial, the 
combination of cell therapy with tissue engineered constructs has been shown to be more 
effective in several studies (Kofidis et al., 2004b, Kutschka et al., 2006, Lu et al., 2010, Dvir 
et al., 2009). Secondly, several in vitro studies using tissue engineered biological constructs 
suggest that the cellular function (Zhao et al., 2005, Kofidis et al., 2004a, Zimmermann et al., 
2002, Birla et al., 2005) or structure of immature cardiomyocytes (Birla et al., 2005, Yost et 
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al., 2004, Zhao et al., 2005) may be more representative of adult myocytes than immature 
cardiomyocytes cultured using conventional tissue culture methods (Yuan Ye et al., 2011, 
Zimmermann et al., 2002).  
 
Since NRVM were used to recellularize a decellularized adult rat heart, there has been 
increasing interest in using decellularized ECM as a tissue engineering scaffold (Ott et al., 
2008). Cells have been shown to infiltrate decellularized ECM and distribute evenly 
throughout the construct (Wang et al., 2010). Cells contract spontaneously and synchronously 
(Ott et al., 2008). Reseeded constructs generate more force comparable to that of artificial 
ECM constructs seeded with NRVM and a recellularized whole rat heart produces 
approximately 2% of the force produced by an adult rat heart (Ott et al., 2008). 
Decellularized porcine ECM has been used to support sheets of NRVM (Hata et al., 2010) 
and once added to the ECM the cells within the sheet align in the direction of the ECM fibers 
(Hata et al., 2010). Other tissue, including urinary bladder matrix has been used as an 
alternative to decellularized heart tissue. NRVM grow well on this substrate forming mature 
tissue with developed sarcomeres and striations (Shah et al., 2010b). Recently, a 
decellularized mouse heart has been successfully recellularized using iPSC-CM, raising the 
possibility that recellularized constructs may be well suited tissue culture substrates for in 
vitro disease modelling with iPSC-CM (Lu et al., 2013).  
 
1.7.3 “Engineering” the phenotype of immature cardiomyocytes 
 
Substrate stiffness (Shimazaki et al., 2008, Kraehenbuehl et al., 2008), mechanical (Tulloch 
et al., 2011, Fink et al., 2000) and electrical simulation (Chiu et al., 2011, Radisic et al., 
2004) have all been shown to make aspects of immature cardiomyocyte function and 
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structure more representative of adult cardiomyocytes. Substrate geometry also has been 
shown to affect the phenotype of immature cardiomyocytes. The effect of substrate geometry 
is better characterized than stiffness, and has been suggested to have a more significant effect 
on cellular function (Wang et al., 2011b). Furthermore, unlike electrical and mechanical 
stimulation, specialist cell culture equipment are generally not required making experiments 
readily reproducible and experimental techniques readily applicable to high-throughput 
toxicology screening and drug development. 
 
Synthetic substrates such as Poly(dimethylsiloxane) (PDMS) can be fabricated with micro or 
nanogrooves, using techniques such as photolithography. NRVM cultured on microgrooves 
are more elongated and aligned with well-organized sarcomeres (Yin et al., 2004, Bien et al., 
2003). NRVM have more mature connexin 43 (Cx43) expression and the monolayer displays 
highly anisotropic conduction velocities. NRVM Ca
2+
 transient is altered with higher peak 
systolic levels and increased SR Ca
2+
 load (Yin et al., 2004, Bien et al., 2003).  
 
Nanogrooved constructs have also been shown to elongate NRVM (Wang et al., 2011b). 
Anisotropic focal adhesion complexes form parallel to the grooves (Wang et al., 2011b) and 
cells develop anisotropic sarcomeres and actin cytoskeleton (Wang et al., 2011b, Kim et al., 
2010b). Whilst cells form confluent monolayers, NRVM have a higher conduction velocity in 
the longitudinal direction and elliptical anisotropic propagation of the wavefront (Kim et al., 
2010b). Synchronous beating rate is also higher in NRVM cultured on nanogrooves (Wang et 
al., 2011b). 
 
The necessity to cover synthetic substrates with ECM components allows cell behavior to be 
manipulated by deposition of ECM proteins in a predetermined pattern on tissue culture 
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substrates producing an area of geometric control. Generally this technique is used to produce 
“lanes” of ECM proteins, commonly fibronectin and laminin, to produce anisotropic tissue. 
Cells cultured on lanes are spindle shaped (Kaji et al., 2003, Pong et al., 2011). Lanes induce 
myofibrillar alignment along the major axis of the cell (Pong et al., 2011), polarizing the 
contractile cytoskeleton of cardiac myocytes (Parker et al., 2008), increase binucleation, and 
promote more elliptical nuclei and higher nuclear eccentricity, similar to adult 
cardiomyocytes (Pong et al., 2011). Tissue alignment increases longitudinal conduction 
velocity and increases the maximum capture rate in response to electrical stimulation 
(Feinberg et al., 2012). More systolic stress is generated by anisotropically aligned cells 
(Feinberg et al., 2012). Cells cultured on lanes have lower diastolic Ca
2+
 concentration, 
greater Ca
2+
 transient amplitude, a faster Ca
2+
 transient increase and faster Ca
2+
 transient 
decay (Kaji et al., 2003, Feinberg et al., 2012). Lanes also alter the distribution of Cx43 on 
the cell membrane with increased Cx43 at bipolar ends of cells resembling the distribution on 
adult tissue (McDevitt et al., 2003).  
 
Some studies have attempted to optimize lane micropatterning. One observation is that, when 
lane width exceeds 30μm, cells do not elongate and more than one cell attaches to the lane at 
each point (McDevitt et al., 2002). There is greater synchrony of beating between lanes with 
a smaller separation, 5-15μm, because of the formation of a monolayer as cells are close 
enough to interact (McDevitt et al., 2002). Diastolic Ca
2+
 is altered more in NRVM seeded on 
lanes with 10μm-width than 20μm width (Kaji et al., 2003). Diffusion tensor magnetic 
resonance imaging patterns can be reproduced to form sheets of myocytes with representative 
tissue boundaries and fiber directions (Badie and Bursac, 2009, Badie et al., 2012). This 
technique uses lines with spacing of between 2-10μm (Badie et al., 2012). Cells have clear 
cross striations and abundant intercellular coupling with smooth transitions between the 
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subregions within the monolayer. Cell culture on these designs increases spatial 
nonuniformity of conduction (Badie and Bursac, 2009). Wavefronts have the pointed 
characteristic of elliptical anisotropic propagation (Badie and Bursac, 2009). This technique 
has been used to study ventricular conduction block in vitro, suggesting that anatomical 
features can act as independent contributors to conduction failures and could precipitate 
arrhythmias which may be important when considering results from in vitro disease 
modelling (Badie et al., 2012).   
 
1.7.4 Limitations of current tissue engineering approaches 
 
There is a clear clinical need for tissue engineering approaches in cell therapy to improve cell 
homing and survival. Tissue engineering approaches are also required for disease modelling, 
in order to improve both the homogeneity of the cellular phenotype, and the degree to which 
in vitro disease models could be considered to be representative of adult human myocardium.  
Despite promising early results, the potential of tissue engineering approaches to contribute 
to myocardial disease modelling remains speculative and is yet to be definitively 
demonstrated. Evidence of the applicability of these techniques to iPSC-CM in the literature 
is limited. Finally, where improvements in the function of immature cardiomyocytes have 
been achieved, the mechanisms remain unclear.  
 
1.8 Thesis aims 
 
Although the potential of cell therapy has historically driven cardiac stem cell research, 
myocardial disease modelling is now an equally important, perhaps more significant 
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application for this technology. Consequently, the general aim of this thesis was to explore 
the feasibility of using iPSC-CM as in vitro models. In particular, we aimed to explore the 
limitations of current iPSC-CM technology and how they could be overcome. 
 
As discussed previously, several studies suggest that iPSC-CM and hESC-CM are 
sufficiently comparable to adult myocardium to facilitate application in a wide range of 
toxicology, drug development and disease modelling applications (Sections 1.4.2 and 1.6.). 
However, the evidence highlighted in Section 1.4.1 and 1.4.2 suggests that the literature 
asserting that iPSC-CM and hESC-CM have a mature, representative phenotype is sometimes 
weak and inconsistent.   
 
Consequently, we aimed to test the hypothesis that iPSC-CM and hESC-CM have a 
predictable and consistent response to pharmacological manipulation. We investigated 
whether differentiation protocols affect the response to pharmacological manipulation, and 
whether iPSC-CM and hESC-CM have different responses to pharmacological manipulation. 
We used currently-available high-throughput tools to undertake this work, in order to 
demonstrate the efficacy of iPSC-CM as drug development and toxicology screening tools.  
 
Given the large body of literature (Section 1.4) which suggested that iPSC-CM have an 
immature phenotype we were keen to investigate if the phenotype of iPSC-CM could be 
manipulated to make iPSC-CM more representative of adult myocardium. Several techniques 
have been suggested to manipulate the phenotype of immature cardiomyocytes in culture 
(Section 1.7.3). We decided to focus on the effect of substrate geometry on the phenotype of 
immature cardiomyocytes as these techniques are readily replicated. Furthermore, we 
envisaged that these techniques could easily be applied to high-throughput drug development 
46 
or toxicology screening. Consequently, we investigated whether alignment using a range of 
methods could modulate the physiological properties of immature cardiomyocytes. In 
particular we focused on intra-cellular Ca
2+
 cycling, which is central to excitation contraction 
coupling, a fundamental component of cardiomyocyte physiology. Therefore, we tested the 
specific hypothesis that alignment of immature cardiomyocytes, in a fashion analogous to the 
adult myocardium, will improve intra-cellular Ca
2+
 cycling. 
 
For much of the exploratory work and validation of the techniques we used NRVM as they 
are more readily available than iPSC-CM. The multitude of studies in the existing literature 
which demonstrate that cellular alignment has a positive effect on the Ca
2+
 cycling of NRVM, 
suggest that the positive effect of cell alignment on Ca
2+
 cycling may be generic to all 
methods of aligning the cells. We aimed to validate the reproducibility of these techniques in 
our laboratory and to conclusively establish that cell alignment, irrespective of the method 
used, has a positive effect on Ca
2+
 cycling in NRVM.  
 
Although NRVM are readily accessible, and extremely cost-effective, they do not represent a 
human model, and are increasingly being superseded by iPSC-CM. This trend is likely to 
increase as iPSC technology becomes more cost-effective and widely accessible. 
Consequently, after validating the tissue engineering techniques required to promote cellular 
alignment, we aimed to test the hypothesis that cell alignment will also promote improved 
Ca
2+
 cycling properties of human iPSC-CM, making them more representative of adult 
myocardium. We also sought to elucidate any sub-cellular mechanisms that may underlie 
changes in cellular Ca
2+
 cycling brought about by cellular alignment of iPSC-CM. 
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Finally we aimed to explore how tissue engineering approaches could be further improved to 
optimize the Ca
2+
 cycling properties of immature cardiomyocytes, comparing the effect of 
cell alignment on Ca
2+
 cycling with the impact of 3D biological and synthetic constructs.
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2 General Material and Methods 
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2.1 Tissue culture methods 
2.1.1 Isolation and culture of neonatal rat ventricular myocytes 
 
NRVM were isolated and cultured from Sprague Dawley neonatal rats 3 days after birth with 
complete compliance to United Kingdom (UK) Home Office regulations as determined by 
the Animals (Scientific Procedures) Act of 1986, as previously described (Brand et al., 2010).  
 
Briefly, the rats were euthanized by cervical dislocation and the head was excised. A median 
sternotomy was performed taking care not to open abdominal viscous. The mediastinum was 
then exposed by applying simultaneous posterior traction to both forelimbs. The heart 
ventricles were excised by blunt traction with curved forceps to the great vessels. The 
ventricles were then cut in half with sterile forceps and placed in a 50ml Falcon tube 
containing ice cold 1x Ads buffer solution (2500ml 1x Ads solution containing 17g NaCl, 
11.9g 4-(2-hydroxyethyl)-1-piperazineethanesulfonic Acid (HEPES), 0.3g NaH2PO4, 2.5g 
glucose, 1g KCl, 0.25g MgSO4 and adjusted to pH 7.35 with NaOH (all from WVR)) for 
transfer to the tissue culture laboratory. The ventricular tissue was washed twice with 1x Ads 
buffer and minced into smaller pieces 2-3mm in diameter and then transferred into an 
upstanding culture flask. 10ml enzyme containing solution (containing 24mg collagenase 
type 2 (Worthington) and 38.4mg pancreatin (Sigma-Aldrich) dissolved in 50ml Ads buffer) 
was added to the flask, and the flask was agitated in a 37°C water bath for 5mins to remove 
blood cells and non-myocyte tissue. The supernatant was removed and replaced with a further 
10ml enzyme containing solution and the flask was agitated for 20mins in a 37°C water bath.  
Enzymatic digestion was performed at intervals of 20mins, 25mins, 25mins, 15mins and 
20mins. After each digestion the supernatant, containing detached cells, was transferred to a 
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50ml centrifuge tube (Corning) containing 2ml foetal bovine serum (FBS) and centrifuged at 
800rpm for 5mins. The supernatant was then removed and the pellet of cells was re-
suspended in 4ml FBS, before being incubated in a 5% CO2 incubator at 37°C. Following 
collection of the final isolation, the FBS containing suspended isolated cells was centrifuged 
at 800rpm for 5mins. The FBS was removed and the pellet containing the cells was 
resuspended in Complete Medium (Dulbecco’s Modified Eagle Medium (DMEM) solution 
(Invitrogen), 25% medium 199 (Sigma-Aldrich), 100U/ml penicillin (Sigma-Aldrich), 
50μg/ml streptomycin (Sigma-Aldrich), 15% horse serum (Invitrogen), 7% FBS (Invitrogen) 
and 3.4% HEPES (Sigma-Aldrich)) and pre-plated for 45 minutes in two 10cm petri-dishes. 
The myocytes were then swept with complete medium and counted using a Malassez 
hemocytometer (Fisher Scientific) to ensure sufficient numbers and adequate morphology 
before plating at a density according to the required application (Section 2.1). 48 hours 
following plating, non-adherent cells and debris were removed by banging the plate several 
times on the base of a tissue culture hood without spilling the medium and then gently 
washing the bottom of the plate twice with 37°C complete medium. Complete medium was 
then changed every other day after plating. Cardiomyocytes were cultured in a standard cell 
culture incubator in 5% CO2 at 37°C. 
 
2.1.2 Differentiation and maintenance of induced pluripotent stem cell-derived 
cardiomyocytes and human embryonic stem cell-derived cardiomyocytes  
2.1.2.1 Maintenance of undifferentiated human embryonic stem cells 
 
hESC from the ethically derived H7 line (Geron Corporation, USA) was imported with 
permission from the UK Stem Cell Bank. Undifferentiated hESC were cultured on plates 
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coated with Matrigel (BD Sciences) using MEF conditioned medium (MEF-CM) 
(supplemented with 8ng/ml recombinant bFGF (Invitrogen), 50U/ml penicillin and 50μg/ml 
streptomycin (both from Sigma-Aldrich)) which was changed daily, except for the first two 
days following passaging. The cells were passaged weekly. MEF-CM was made using MEF 
isolated from 13-day post coitum MF-1 strain mouse embryos which, after the fourth 
passage, were treated with 0.01mg/ml mitomycin C (Sigma-Aldrich) to mitotically inactivate 
them. hESC medium (containing 80% Knock Out Dulbecco’s Modified Eagle Medium (KO-
DMEM), 20%  Knock Out Serum replacement (KOSR), 1mM L-glutamine, 10mM non-
essential amino acids (NEAA), 0.1mM β-mercaptoethanol, 4ng/ml bFGF (all from 
Invitrogen), 50U/ml penicillin and 50μg/ml streptomycin (both from Sigma-Aldrich)) was 
conditioned by adding 150ml to T225 flasks containing 1.88×10
7
  mitotically inactivated 
MEF (Foldes et al., 2011, Xu et al., 2001).  
 
2.1.2.2 Differentiation of human embryonic stem cell-derived cardiomyocytes by the 
embryoid body method 
 
hESC-CM were differentiated from hESC line H7, using the embryoid body (EB) technique 
as previously described (Foldes et al., 2011, Xu et al., 2001, Brito-Martins et al., 2008). 
Briefly, colonies of hESC were mechanically disrupted after 3–10min of collagenase IV 
(Invitrogen) treatment to remove spontaneously differentiated cells. The resulting hESC EB 
were then cultured in suspension using low adherence plates for 4 days in differentiation 
medium (hESC medium in which KOSR had been replaced by non-heat-inactivated FBS). 
The EB were plated out onto 0.5% gelatin-coated plastic dishes. Spontaneously beating 
clusters of hESC-CM appeared from day-9 after EB formation in outgrowths of cells from 
EB (Foldes et al., 2011, Xu et al., 2001, Brito-Martins et al., 2008). Spontaneously beating 
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clusters of hESC-CM were micro-dissected and seeded onto gelatinized dishes overnight 
before being used in experiments (Foldes et al., 2011).  
 
2.1.2.3 Directed differentiation techniques  
 
hESC-CM were differentiated from dense mono-layers of hESC as previously described 
(Laflamme et al., 2007, Foldes et al., 2011). Briefly, hESC-CM were cultured in RMPI-B27 
medium (Sigma-Aldrich), and treated with 100ng/ml human recombinant Activin A (R&D 
Systems) for 24 hours, and 10ng/ml BMP 4 (R&D Systems) for 4 days (Laflamme et al., 
2007, Foldes et al., 2011). Spontaneously beating areas appeared after 1–2 weeks. Plates 
containing beating areas were enzymatically disassociated using 0.025% trypsin 
ethylenediaminetetraacetic (EDTA) (Sigma-Aldrich) and seeded onto gelatinized dishes 
overnight before being used in experiments (Foldes et al., 2011). 
 
2.1.3 Thawing and maintenance of i-Cell cardiomyocytes 
 
iCell cardiomyocytes (Cellular Dynamics, Wisconsin) are a commercially available 
population of iPSC-CM differentiated and purified using proprietary protocols. The cells 
express monomeric red fluorescent protein (mRFP) and blasticidin resistance, with an MYH6 
promoter that facilitates cardiomyocyte purification and identification.  
 
iCell cardiomyocytes were thawed and maintained according to manufacturer’s guidelines 
(Cellular Dynamics International., 2011). Briefly, vials containing 1ml cryopreserved single-
cell suspensions of iCell Cardiomyocytes were stored in liquid nitrogen storage until 
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immediately before use. Prior to plating the frozen iCell Cardiomyocytes were removed from 
liquid nitrogen and placed stationary in a 37°C water bath for 4 minutes. The iCell 
cardiomyocytes were then gently transferred into a 50ml centrifuge tube (Corning). The 
empty iCell Cardiomyocytes vial was then washed with 1ml of room temperature iCell 
Plating Medium (Cellular Dynamics) to recover residual cells. This plating medium was then 
added to the 50ml centrifuge tube drop-wise over at least 90s while gently swirling the tube. 
This was then repeated. A further 7ml plating medium was added to the centrifuge tube drop-
wise fashion over 30-60s while gently swirling the tube. The contents of the 50ml centrifuge 
tube were then mixed by gently inverting the tube 2-3 times. The thawed iCell 
cardiomyocytes were than counted with a Malassez hemocytometer (Fisher Scientific) using 
trypan blue (Sigma-Aldrich) to identify non-viable cells. Additional plating medium was then 
added to achieve the cell density required (Section 2.1) according to the following formula 
(Formula 2.1). If a higher cell density was required iCell Cardiomyocytes were pelleted by 
centrifuging at 180g for 5 minutes, removing the necessary volume of plating medium and 
then re-suspending the iCell Cardiomyocytes. 48 hours following plating, non-adherent cells 
and debris were removed by banging the plate several times on the base of a tissue culture 
hood without spilling the plating medium and then gently washing the bottom of the plate 
twice with 37°C iCell Maintenance Medium (Cellular Dynamics). Maintenance medium was 
then changed every other day after plating. iCell Cardiomyocytes were cultured in a standard 
cell culture incubator in 5% CO2 at 37°C.  
 
                                 
                       
 
                                            
                                   (
     
  )                     
 
 
Formula 2.1. Plating efficiency is a batch-specific quality metric defined by cellular dynamics representing the 
proportion of viable cells introduced into a well suspended in plating medium which will adhere to the bottom of each 
tissue culture well. 
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2.2 Tissue engineering methods 
2.2.1 Fabrication of structured silicone culture substrates 
 
Structured flexible microgrooved polydimethylsiloxane (PDMS) tissue culture substrates 
were fabricated by Miss Tatiana Trantidou and Dr Themistoklis Prodromakis at the Centre 
for Bio-Inspired Technology, Imperial College London. The fabrication of the PDMS 
constructs is described in Appendix A. 
 
2.2.2 Fabrication of micro-patterned fibronectin lines 
 
Micro-patterned fibronectin lines were fabricated on flat PDMS membranes (PDMS sheets 
0.25mm in thickness; Specialty Manufacturing) (Figure 2.1) (Camelliti et al., 2006). A micro-
grooved PDMS stamp was fabricated using standard photolithography rules as described in 
Appendix A. The stamp was 2cm x 3cm in dimension with parallel grooves 30µm in width 
and 10µm in depth, 300µm apart running lengthwise along the entire surface of the stamp. 
The stamp was sterilized by emersion in 70% alcohol and exposure to UV light overnight 
prior to use, and was washed several times with sterile water. Flat PDMS membrane was cut 
to an appropriate size to fit onto the bottom of a 60mm petri dish with a 1-2mm margin 
around the edge of the stamp when placed on top of the flat PDMS membrane. The flat 
PDMS membranes were pressed onto the bottom of 60mm petri dishes taking care to avoid 
bubbles and then were sterilized by immersion in 70% alcohol and exposure to UV light 
overnight.  
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Figure 2.1. Schematic diagram, not drawn to scale illustrating the fabrication of fibronectin lined constructs (With 
thanks to Umar Chaudhry for assistance in producing this figure) 
56 
 
The stamp was then pressed onto the PDMS membrane with the grooved surface placed 
downwards. Fibronectin lines were formed by microfluidic patterning whereby 50μg/ml 
fibronectin was flushed between the microgrooves of the stamp and the flat PDMS membrane 
by applying negative pressure using a standard tissue culture suction pump. Without 
removing the stamp the PDMS membrane was incubated at 37°C for 1hour. The stamp was 
then removed, and the dish incubated at 37°C overnight prior to plating of the cells. 1 million 
NRVM were seeded onto each construct.  Flat PDMS membrane coated with fibronectin of 
the same concentration were used as control constructs. Following use the stamps were 
sonicated at 37°C degree in collagenase (Worthington) for at least 15 minutes and were then 
rinsed thoroughly with distilled water before being cleaned as previously described.  
 
Photolithography and PDMS molding was performed by Tatiana Trantidou and Themistoklis 
Prodromakis at the Centre for Bio-Inspired Technology, Imperial College London. This 
technique was optimized by Patrizia Camelliti, Laboratory of Cellular Electrophysiology, 
Imperial College London (Camelliti et al., 2006). 
 
2.2.3 Fabrication of Parylene-C constructs 
 
Oxygen plasma-treated structured Parylene-C constructs were fabricated by Tatiana 
Trantidou with the assistance of Themistoklis Prodromakis at the Centre for Bio-Inspired 
Technology, Imperial College London. The fabrication of the Parylene-C constructs is 
described in Appendix B. 
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2.2.4 Fabrication of three-dimensional polycaprolactone constructs 
 
Three Dimensional Polycaprolactone (PCL) constructs were fabricated by Jermone Sohier, at 
the Harefield Heart Science Centre Tissue Engineering Group, Imperial College London. The 
fabrication of these constructs is described in Appendix C.  
 
2.2.5 Decellularization of cardiac tissue slices 
 
Heart slices were produced from canine ventricular tissue, obtained from control animals in 
toxicology trials performed at GlaxoSmithKline. All experiments strictly complied with UK 
Home Office regulations as determined by the Animals (Scientific Procedures) Act of 1986. 
Human heart slices were obtained either from the core of tissue removed from the apex of the 
left ventricle in patients with end-stage heart failure which is necessarily removed in order to 
insert a left-ventricular assist device, or from explanted hearts in patients with end stage heart 
failure who underwent heart transplant. In all cases appropriate consent was obtained and 
institutional ethical guidelines were adhered to (Royal Brompton and Harefield NHS Trust 
Ethics Committee permission number 02–039). Organotypic slices were cut as previously 
described (Camelliti et al., 2011). Briefly, tissue slices were cut parallel to the epicardial 
plane with a high precision vibrating microtome (7000smz, Campden Instruments Ltd., UK). 
350μm slices were cut with a steel blade with vibration frequency 75Hz, amplitude 2mm and 
an advance speed 0.04mm/s in cold (4°C) oxygenated (100% O2) Normal Tyrode (NT) 
solution (containing 140mM NaCl, 6mM KCl, 10mM glucose, 10mM HEPES, 1mM MgCl2, 
1.8mM CaCl2, adjusted to pH7.4 with 2M NaOH ((all Sigma–Aldrich)) with 10mM of the 
excitation–contraction un-coupler 2,3-butanedione monoxime (BDM) added (Camelliti et al., 
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2011). Slices were decellularized by placing them on a shaker (Platform Shaker STR6, Stuart 
Scientific, UK), agitating them at 70 rev/min, in 1% Sodium dodecyl sulfate (SDS) (Sigma-
Aldrich) at room temperature for 24 hours then washing with PBS before being left on a 
shaker, agitating them at 70 rev/min, at room temperature for 4 hours in 1% Triton (Sigma-
Aldrich) (Ott et al., 2008, Godier-Furnemont et al., 2011). These slices were then washed 
with PBS and frozen at -20ºC in Freezing Medium (Containing 90% FBS (Invitrogen) and 
10% Dimethyl sulfoxide (DMSO) (Sigma-Aldrich)) until required. Once defrosted the 
constructs were then stretched over a Scaffdex ‘cell crown’ (Scaffdex) and transferred to a 
new sterile plate. They were then sterilized by immersion in 100% ethanol for 10 minutes 
then washed with sterile PBS. 1 million NRVM were seeded onto each construct. 
 
2.3 Electrophysiological techniques 
2.3.1 Multi-electrode arrays 
 
To characterize the electrophysiological properties of multi-cellular preparations of hESC-
CM and iPSC-CM, a multi-electrode array (MEA) recording system (MEA1060, Multi-
Channel Systems, Reutlingen, Germany) was used as previously described (Zwi et al., 2009). 
The MEA recording system allows simultaneous field potential recording with high temporal 
resolution, from 60 titanium nitride-coated electrodes, 30μm in diameter and 200μm apart 
(Nisch et al., 1994, Igelmund et al., 1999) embedded into the bottom a glass tissue culture 
dish (Figure 2.2).  
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Figure 2.2. A) A MEA dish showing the position of the electrode inserted into the bottom of the dish to facilitate 
superfusion of the cultured cells with physiological solutions or pharmacological agents. B) A beating cluster of iPSC-
CM, differentiated using the EB method plated onto the electrodes of an MEA. C) The same cluster of iPSC-CM 
enlarged. D) hESC-CM differentiated using a directed differentiation monolayer technique plated onto a MEA at a 
similar magnification for comparison. 
 
Clusters of contracting hESC-CM and iPSC-CM differentiated using the EB method were 
micro-dissected, plated on gelatin-coated MEA plates, and cultured for at least 8 hours in 
human differentiation medium before experiments were undertaken. hESC-CM differentiated 
using a directed differentiation mono-layer culture system were enzymatically digested with 
0.025% trypsin EDTA (Sigma-Aldrich); after the trypsin was inactivated with FBS the 
suspension containing hESC-CM was centrifuged at 800rpm for 5mins and then re-suspended 
in human differentiation medium before being seeded onto the MEA. All hESC-CM and 
iPSC-CM were used between 40 and 80 days post differentiation. They were then maintained 
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in culture with human differentiation medium for a minimum 4 days until a beating mono-
layer of cells had been re-established. hESC-CM and iPSC-CM differentiated using both the 
EB and directed differentiation method were cultured on the MEA dish for 5-7 days before 
recordings were made. Field potentials recordings necessitate removing the MEA dish from 
the incubator, in order to place the MEA dishes in the recording system. Whilst recordings 
are made the MEA dishes are held on a temperature controlled plate. The hESC-CM and 
iPSC-CM clusters are superfused the with oxygenated NT solution at 37°C during recordings 
(Figure 2.2). 
 
  
Figure 2.3. The field potential measured from a spontaneously beating cluster of iPSC-CM measured using a MEA. 
 
The recorded field potentials were used to determine the local field potential (FP) duration 
(FPD). This parameter has been shown to correlate with the AP duration (APD) (Halbach et 
al., 2003, Meiry et al., 2001). The estimated FPD was defined as the time interval between 
the initial deflections of the FP to timing of the maximum of the local T wave (QT Interval) ( 
Figure 2.3). FPD measurements were normalized to the beating rate of the contracting areas 
with the Bazett's correction formula which has been validated in patients (Yap and Camm, 
2003), animal models (Farkas et al., 2002), and hESC-CM (Caspi et al., 2009). Custom 
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software was used to analyze field-potential recordings (MEA-Tools, version 2.8. University 
of Freiburg, Germany)(Egert et al., 2002).  
 
For pharmacological studies, drugs were superfused dissolved in NT. The tested drugs 
included isoproterenol hydrochloride (or Isoprenaline), a non-selective beta-adrenergic 
agonist (3nM for 5mins, 30nM for 5mins, 300nM for 5mins) (Sigma-Aldrich); E-4031, a 
selective antagonist of the Kv11.1 or hERG channel which mediates IKr (1nM for 5mins, 
10nM for 5mins, 100nM for 5mins, 1M for 5mins) (Sigma-Aldrich); chromanol 293B, a 
selective antagonist of the Kv7.1 channel which mediates IKs (10M for 5mins, 20M for 
5mins) (Sigma-Aldrich); and ivabradine hydrochloride, a selective antagonist of If (300nM 
for 5mins, 3M for 5mins, 30M for 5mins, 300M for 5mins) (Servier). Prior to 
superfusion with drugs, cardiomyocytes were superfused with NT for 10 minutes to obtain 
baseline readings, and an NT wash-out was performed afterwards until measured parameters 
returned towards baseline. 
 
2.3.2 Action potential measurement 
 
AP were measured using the perforated-patch technique, as previously described (Shah et al., 
2010a). Briefly, adult ventricular myocytes were enzymatically isolated from Lewis rats and 
control-dogs sacrificed during drug development safety trials (Siedlecka et al., 2008). 
Ventricular myocytes were then attached to the top of a glass cover-slip freshly covered with 
laminin (Sigma-Aldrich) by incubating 1-2 drops of a suspension of cells in buffer solution 
on the cover slip for 5-10 minutes. hESC-CM were enzymatically digested either between 15-
40 days or following 40 days following differentiation using the EB technique using 0.025% 
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trypsin EDTA (Sigma-Aldrich). Afterwards the trypsin was inactivated with FBS and the 
suspension containing hESC-CM was centrifuged at 800rpm for 5 minutes and then re-
suspended in human differentiation medium before being seeded onto laminin-covered 10mm 
glass-bottomed sections of 35mm MatTek dishes (MatTek corporation). Cells were then 
superfused with NT solution and studied using a Multiclamp 2B amplifier (Axon 
Instruments, CA, USA). The pipette resistance was less than 2MΩ. The pipette-filling 
solution contained 10mM NaCl, 20mM KCl, 125mM KCH3O3S, 10mM HEPES, 5mM 
MgCl2, (All VWR) 240µg/ml
 
amphotericin-B (Sigma-Aldrich), and adjusted to pH 7.2 with 
2M NaOH. AP were measured in current-clamp mode after stimulation at 1Hz, 3Hz and 5Hz 
using a 1ms, 0.6-1.8nA pulse. During recording the cells were superfused with NT at 37ºC. 
Under direct vision the pipette tip was moved in close proximity to the target cell and then 
brought into contact using micro-manipulators (Burleigh Instruments), a seal was formed 
between the cell and the pipette, and after approximately 20s to allow the amphotericin to 
form micro-perforations without dialyzing the cell, recordings were commenced. The AP 
measured were analyzed using pCLAMP 10.3 software (Molecular Devices, Sunnyvale, CA). 
Traces were averaged with reference to the stimulation signal. The time-to-peak 
depolarization (TTP), time from peak depolarization to 50% repolarization (T50), time from 
peak depolarization to 90% repolarization (T90), and amplitude measured from resting 
membrane potential to peak depolarization in each group were compared (Peng et al., 2010, 
Shah et al., 2010a). 
 
We were unable to patch clamp cells on opaque or translucent tissue culture constructs, 
consequently AP characteristics were measured by impalement with sharp pipettes, using 
floating electrodes, as previously described (Terracciano et al., 2002). Briefly, AP 
measurements were performed using an Axoclamp 2B system (Axon Instruments). High 
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resistance microelectrodes were used (15–25MΩ) (Harvard Apparatus). Cells were 
superfused with NT solution at 37ºC and the microelectrode filling solution contained: 2M 
KCl, 0.1mM EGTA, 5mM HEPES adjusted to pH 7.2 with 2M NaOH (All Sigma-Aldrich). 
As the construct material was opaque, and the pipettes were exceedingly fine it was not 
possible to perform impalement under direct vision. After confirming the approximate 
location of the pipette tip it was lowered to the surface of the construct using 
micromanipulators whilst recording was performed. AP were recorded in current clamp mode 
and measured AP were analyzed using pCLAMP 10.3 software (Molecular Devices).  
 
2.3.3 Measurement of calcium transients 
 
NRVM and iCell cardiomyocytes (Cellular Dynamics) were seeded onto constructs described 
in (Section 2.1). At day 4 following seeding of NRVM, 1 week and 2 weeks following 
seeding for iCell cardiomyocytes the cells were loaded with the Ca
2+
 sensitive dyes  Rhod-2 
AM (10µM, Invitrogen) or  Fluo-4 AM (10µM, Invitrogen) using 4µl (250nM) probenecid 
(Invitrogen) and 0.2% Pluronic acid (Invitrogen), in pre-warmed DMEM at 37°C for 
30minutes. The myocytes were then washed and incubated with pre-warmed DMEM 
containing 2% FBS (Invitrogen) and 250nM probenecid for 30minutes to de-esterify.  
 
The experimental dish was mounted on the stage of an upright Zeiss LSM510 confocal 
microscope (Carl Zeiss) and myocytes were observed through a x40 water-immersion 
magnification lens. Rhod-2 AM was excited at 552-nm of a HeNe1 laser, and the emitted 
fluorescence was collected through a 581-nm long-pass filter. Fluo-4 AM was excited using 
the 488-nm line of an argon laser, and the emitted fluorescence was collected through a 505-
nm long-pass filter.  
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Figure 2.4. Above: RVNM loaded with Rhod-2 AM seeded onto non-structured PDMS and microgrooved PDMS 
tissue culture substrates. Below: Representative line scan images of the same cell taken at 90 degrees to the long axis 
of the cell showing Ca2+ transients whilst the cell is field stimulated and beats spontaneously.  
 
Line scanning was performed at suitable regions with the myocytes spontaneously beating or 
under field stimulation at 0.5Hz, 1Hz and 2Hz using an external pacing generator (IonOptix) 
(Figure 2.4). Charge-balanced biphasic pulses 10ms in duration typically of 1V amplitude 
were used for field stimulation. On the rare occasions when no electrical capture was 
achieved initially the amplitude of the pulses was increased incrementally to a maximum of 
5V. During recording the cells were superfused with 37ºC NT or low Na
+
 and Ca
2+
 solution 
(containing 140mM LiCl, 6mM KOH, 1mM MgCl2, 10mM glucose, 10mM HEPES, 0.1mM 
EGTA adjusted to pH7.4 with 2M NaOH (all Sigma–Aldrich)). RyR mediated SR Ca2+ 
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release was elicited by spritzing the cells with solutions containing 50mM caffeine (Sigma–
Aldrich).  
 
 
Figure 2.5. Line scan images such as those shown in Figure 2.4 are quantified, to facilitate measurement of time to 
peak, time to 50% and 90% decay and amplitude. 
 
Linear time-length images were converted into Ca
2+
 transients using ImageJ (National 
Institutes of Health, USA) and analyzed using pCLAMP10.3 (Molecular Devices, Sunnyvale, 
CA). Fluorescent values were normalized to baseline fluorescence (F/F0). TTP was taken as 
the time taken for the ratio signal to reach peak fluorescence from baseline fluorescence. 
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Similarly, T50 and T90 were taken as the time taken for the peak fluorescent transient to 
decline by 50% and 90% of the transient amplitude. The presence of spontaneous beating and 
the beating rate were also noted (Stagg et al., 2008) (Figure 2.5). 
 
2.4 Molecular biology and cell imaging techniques 
2.4.1 Gene expression 
 
Total RNA from iCell cardiomyocytes was isolated using the RNeasy Mini Kit (Qiagen) 
according to manufactures guidelines (Qiagen, 2010). Briefly, the structured constructs 
(Section 2.2.1) seeded with iCell cardiomyocytes were placed in new culture dishes 2 weeks 
following seeding of the myocytes, and remaining iCell maintenance medium (Cellular 
Dynamics) was removed by washing with PBS (Sigma-Aldrich).  
 
After PBS was removed 350μl of lysis Buffer RLT (Qiagen) was added to each well to the 
cell-culture dish. The lysate was collected with a rubber policeman (Fisher Scientific) and 
pipetted into a micro-centrifuge tube (Eppendorf) and vortexed for one minute (Proscientific). 
The lysate was then pipetted into a QIAshredder spin column (Qiagen), placed in a 2ml 
collection tube, and centrifuged for 2min at full speed. 350μl of 70% ethanol was then added 
to the homogenized lysate, and the mixture was added to an RNeasy spin column (Qiagen) 
placed in a 2ml collection tube (supplied) and centrifuged for 15s at 8000g. 700μl of RW1 
wash buffer (Qiagen) was added to the RNeasy spin column before centrifuging again for 15s 
at 8000g. Twice 500μl of RPE buffer (Qiagen) was then added to the RNeasy spin column 
before centrifuging for 15s at 8000g on the first occasion and 2min on the second occasion.  
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Gene Encoding Primer sequence 
(F)orward  (5’ to 3’) 
(R)everse (5’ to 3’) 
ACTB Beta actin (β-actin) (F)CCAACCGCGAGAAGATGA 
(R)CCAGAGGCGTACAGGGATAG 
AMPH2 Bridging Integrator 1 (BIN1) (F)ACGGGAGCAACACCTTCA 
(R)GCCGCGAAAACAGTTTACTT 
ATP2A2 SERCA2a (F)AACGTCGGGGAAGTTGTCT 
(R)GAATCAAAGCCTCGGGAAAT 
CACNA1C L-type voltage-dependent Ca
2+
 channel (Cav1.2), alpha 1C subunit (F)TGACATCGAGGGAGAAAACT 
(R)ACATTAGACTTGACTGCGGC 
CACNA1G T-type voltage-dependent Ca
2+
 channel (Cav3.1), alpha 1G subunit (F)TGCTCTTCAATTTGCTGGTC 
(R)TCTTCCCGTTTGCTGATTTC 
CALR Calreticulin (F)CTATGATAACTTTGGCGTGCTG 
(R)CTCCTCAGCGTATGCCTCAT 
CASQ2 Calsequestrin 2  (F)GAGTTTGATGGCGAGTTTGC 
(R)TTGCTGCTGATGATCTCCAC 
CAV3 Caveolin 3 (F)GAGGCCCAGATCGTCAAG 
(R)TCACGTCTTCAAAATCCACCT 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (F)GTC AGT GGT GGA CCT GAC CT 
(R)CCC TGT TGC TGT AGC CAA AT 
GATA4 GATA binding protein 4 (GATA4) (F)GGAAGCCCAAGAACCTGAAT 
(R)GTTGCTGGAGTTGCTGGAA 
ITPR2 Inositol 1,4,5-trisphosphate receptor, type 2 (IP3R) (F)CCTACTCCAAAACTGCACAGG 
(R)GTCTGACATTGATATCCCCATCT 
JPH2  Junctophilin 2 (F)AACATTGCTCGCACTTTGG 
(R)GCTTCTGATATTCCGGACCTG 
MYH6 Myosin Heavy Chain 6 (α-MHC) (F)CTCAAGCTCATGGCCACTCT 
(R)GCCTCCTTTGCTTTTACCACT 
MYH7 Myosin Heavy Chain 7 (β-MHC) (F)ACACCCTGACTAAGGCCAAA 
(R)TCCAGGGATCCTTCCAGAT 
MYL2 Ventricular Myosin Light Chain 2 (MLC2v) (F)ACA TCA TCA CCC ACG GAG AAG AGA 
(R)ATT GGA ACA TGG CCT CTG GAT GGA 
NKX2-5 Homeobox protein Nkx-2.5 (Nkx-2.5) (F)ACC TCA ACA GCT CCC TGA CTC T 
(R)ATA ATC GCC GCC ACA AAC TCT CC 
NPPA Natriuretic Peptide A (ANF) (F)CAGGATGGACAGGATTGGAG 
(R)TCCTCCCTGGCTGTTATCTTC 
PLN Phospholamban (F)TGATGATCACAGCTGCCAAG 
(R)TGAGCGAGTGAGGTATTGGA 
PPIG Peptidylprolyl isomerase G (Cyclophilin G) (F)CTTGTCAATGGCCAACAGAGG 
(R)GCCCATCTAAATGAGGAGTTGGT 
RN18S 18S ribosomal RNA (18S) (F)GCAATTATTCCCCATGAACG 
(R)GGGACTTAATCAACGCAAGC 
RYR2 RyR 2 (F)CTGCGCCATTCCTATAGTGG 
(R)AGTTGAAGACCGGGAGGTG 
SLC8A1 Solute carrier family 8 (Na
+
/Ca
2+
 exchanger), member 1 (NCX) (F)GGTTGGGACTAACAGCTGGA 
(R)CCACATTCATCGTCGTCATC 
TCAP Titin-cap (Telethonin) (F)GGCAGAATGGAAGGATCTGA 
(R) TCTCATGTCTCTGGGTGTCCT 
TNNT2 Troponin T type 2 (Cardiac) (cTnT) (F)TTC ACC AAA GAT CTG CTC CTC GCT 
(R)TTA TTA CTG GTG TGG AGT GGG TGT GG 
TRDN Triadin (F)ACATATTTGTCCATGGGGATTT 
(R)TGGAAGCTTGTTCTGTCGGTA 
Table 2.1. Summary of PCR primers used in gene expression analysis. 
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The collection tubes were then changed before the RNeasy spin column was centrifuged 
again at full speed for 1 min. The RNeasy spin column was then placed in a new 1.5ml 
collection tube and 30–50μl of Ribonuclease-free water (Qiagen) was twice added to the spin 
column before centrifuging for 1 min at 8000g to elute the RNA. 
 
Genomic DNA was removed by DNase I (Invitrogen) treatment and total RNA (500ng) was 
reversed transcribed into Complementary DNA (cDNA). Quantitative Polymerase Chain 
Reaction (qPCR) was performed using 150ng of cDNA using SensiMix SYBR No-ROX Kit 
(Bioline, UK) on the Rotor-Gene™ 6000 (Corbett Research) according to manufacturer’s 
guidelines (Life Technologies, 2011). The primers used are summarized in Table 2.1. Total 
RNA from human adult and foetal heart tissue (Agilent) was used to evaluate gene expression 
levels in iCell cardiomyocytes. All values were normalized with respect to Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) expression.  
 
SYBR green primers were designed by Ljudmila Kolker, National Heart and Lung Institute, 
Imperial College London and National Institute for Biological Standards. Additionally, she 
assisted with all of the gene expression studies described in this thesis.  
 
2.4.2 Immunocytochemistry 
 
In order to evaluate cell structure on the surface of constructs, the constructs were fixed in 
4% paraformaldehyde in 0.1M phosphate buffer (Agar Scientific) for 10 minutes, washed in 
PBS (Sigma-Aldrich) and permeabilized using 0.2% triton-X (Sigma-Aldrich) in PBS for 3 
minutes followed by two PBS washes. The coverslips were then incubated with blocking 
solution containing 3% Bovine Serum Albumin (BSA) (Sigma-Aldrich) in PBS for 30 
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minutes. Various primary antibodies (Mouse α-Actinin IgG Ascites, 1:100, Sigma-Aldrich; 
Mouse RyR IgG 1mg/ml, 1:500, Abcam; Rabbit Cav1.2 IgG 0.8mg/ml, 1:100, Alomone 
Labs; Mouse PLN IgG 1mg/ml, 1:200, Badrilla; Rabbit Cx43 IgG 0.5mg/ml, 1:50, Millipore) 
were added for 1 hour at room temperature. The constructs were than washed at least 3 times 
in PBS for 3-5 minutes each. Secondary antibodies were then added (Alexa Fluor 488 anti-
mouse, Alexa Fluor 488 anti-rabbit, Alexa Fluor 555 anti-mouse, and Alexa Fluor 555 anti-
rabbit; all goat IgG, 2mg/ml, 1:800; Invitrogen) and incubated for 1hr at room temperature. 
The constructs were than washed again at least 3 times in PBS for 3-5 minutes each. This was 
repeated for each subsequent label. Finally constructs were washed twice with 300nM DAPI 
(Invitrogen) in PBS for 3-5 minutes each. Fluorescence imaging was performed using 
LSM510 confocal microscope using a x40 oil-immersion lens (Carl Zeiss). 
 
Immunohistochemistry was performed with the assistance of Padmini Sarathchandra, 
Harefield Heart Science Centre and Ljudmila Kolker, National Heart and Lung Institute, 
Imperial College London and National Institute for Biological Standards. 
 
2.4.2.1 Frozen Sections 
 
Frozen sections were performed in order to evaluate cell structure throughout the entire 
thickness of 3D constructs. Briefly, the PCL constructs were coated with OCT (Sakura 
Finetek) and snap frozen by immersion in liquid nitrogen. 8μm thick section where cut using 
a cryostat at −20°C. The section was transferred to a room temperature microscope slide and 
immunohistochemistry was performed as described above.  
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2.4.2.2 Cell alignment 
 
 
Figure 2.6. Figure illustrating the binary DAPI images used to calculated nuclear alignment. The images show DAPI 
stained nuclei in non-structured and microgrooved PDMS constructs  
   
Cell alignment was quantified using DAPI images which were converted into binary images 
using ImageJ (Figure 2.6). The long axis of each nucleus was measured relative to the 
horizontal axis of the image field using NIS-Elements AR3.2 software (Laboratory Imaging, 
Nikon Instruments, Melville, NY). Objects were gated according to size to exclude non-
nucleus or composite structures. Alignment was defined as the lack of deviation in the axis of 
individual nucleus from the mean axis of all individual nuclei. In order to quantify cell 
alignment, the mean axis was first calculated and then the variance of the minimum angle 
between the long axis of each nucleus and the mean axis of all nuclei was compared using an 
F-test of equality of variances. The mean angle between the long axis of each nucleus and the 
mean axis of all nuclei was calculated. Analysis of colocalization was performed using the 
WCIF ImageJ plugin bundle (Wright Cell Imaging Facility, Toronto Research Institute). 
Alignment was defined as the lack of deviation in the axis of individual nucleus from the 
average axis. In order to quantify the alignment the average axis was first calculated, and then 
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the standard deviation of the difference in alignment between the average axis and the axis of 
each individual nucleus was calculated. 
 
2.4.3 Second Harmonic Generation Imaging 
 
Second harmonic generation (SHG) imaging was performed to visualize the extracellular 
matrix in myocardial tissue slices as previously described (Caorsi et al., 2013).  Two-photon 
excitation and SHG imaging was performed using a Leica TCS SP5 upright laser scanning 
system (Leica Microsystem), coupled to a titanium-sapphire laser (Spectraphysics Mai Tai 
690–1020nm, 90MHz; Spectra-Physics, Santa Clara, CA). All imaging was performed with 
an excitation wavelength of 900nm (except for the spectra collection) with an average power 
of 10–12mW using a long working distance immersion objective 25×0.9NA. The SHG was 
collected in the backward direction by selecting the 440–460nm range while auto-
fluorescence light was collected in the 500–700nm range. All SHG imaging was undertaken 
with the assistance of Valentina Caorsi, National Heart and Lung Institute 
 
2.4.4 Transmission electron microscopy 
 
Constructs were fixed as previously described (Cloyd et al., 2012). Briefly, constructs were 
immersed in 4% glutaraldehyde (Agar Scientific) in 0.1M piperazine-N,N′-bis(2-
ethanesulfonic acid) (PIPES) buffer (pH 7.4) at 4°C for at least two hours followed by 2 
buffer washes. Specimens were post fixed with 1% osmium tetroxide (Agar Scientific) in 
0.1M PIPES buffer for 1 hour at room temperature. After 2 buffer washes, specimens were 
incubated with 1% Tannic acid (Sigma-Aldrich) in 0.1M PIPES buffer for 1 hour. After 2 
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buffer washes specimens were dehydrated through ascending series of ethanol from 25% to 
100% followed by drying with HMDS (Hexamethyldisilazane) (Agar Scientific). Specimens 
were then air-dried and mounted on Stubbs with Acheson Silver Dag (Agar Scientific). 
Transmission electron microscopy (TEM) was performed using the JEOL 2000 microscope 
operated at 120 kV (JEOL). Sample preparation was performed by Padmini Sarathchandra, 
Harefield Heart Science Centre. 
 
2.4.5 Scanning electron microscopy 
 
Constructs were fixed as previously described (Cloyd et al., 2012). Briefly, constructs were 
immersed in 4% formaldehyde diluted with PBS for 45 minutes at 4°C. After 2 buffer washes 
specimens were dehydrated through ascending series of ethanol from 25% to 100% followed 
by drying with HMDS (Hexamethyldisilazane) (Agar Scientific). Samples were sputter-
coated with gold and Scanning Electron Microscopy (SEM) was performed using a Leo 1525 
Gemini scanning electron microscope with an EDX detector operated at 15 kV (Carl Zeiss). 
Sample preparation was performed by Padmini Sarathchandra, Harefield Heart Science 
Centre. 
 
2.5  Statistical analysis 
 
Statistical analysis was performed using an unpaired Mann-Whitney U test, Student’s t-test, 
Fisher’s exact test, or 1-way Analysis of Variance (ANOVA) where appropriate. Data are 
expressed as mean ± standard error of the mean (SEM) unless specified otherwise. For Ca
2+
 
transient studies, AP measurements, and cell alignment, n represents the number of myocytes. 
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For experiments using MEA, n represents the number of spontaneously beating clusters. In 
the figures, * indicates p<0.05; ** p<0.01; and ***, p<0.001. 
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3 The Phenotype of Cardiomyocytes 
Differentiated from Pluripotent Stem Cells 
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3.1 Introduction 
 
Comparative characterization of the phenotype of hESC-CM and iPSC-CM is currently 
limited. Given, the emerging albeit limited evidence that there are differences between hESC 
and iPSC (Section 1.4.3), this must be further evaluated to ensure that knowledge about 
hESC-CM physiology can be readily applied to iPSC-CM. 
 
Differentiation protocols also continue to evolve, in particular with emergence of directed 
differentiation protocols. Although the evidence suggesting that differentiation method may 
affect the phenotype of hESC-CM is weak (Section 1.4.2), the effect of differentiation 
method on the phenotype of iPSC-CM and hESC-CM needs to be characterized to ensure that 
they are robust and reproducible disease models.   
 
In this chapter we aim to compare the electrophysiological properties of hESC-CM and iPSC-
CM differentiated using an EB protocol and by directed differentiation protocols. We also 
aim to compare the electrophysiological properties of hESC-CM and iPSC-CM with adult 
myocardium. As human tissue is scarce and often represents end-pathological states, animal 
tissue will also be characterized and compared to hESC-CM and iPSC-CM. 
 
The primary focus of this chapter is the response of hESC-CM and iPSC-CM to blockade of 
the IKr with the selective antagonist E-4031. This was for several reasons; firstly there is 
considerable interest in using hESC-CM and iPSC-CM as models to study the pathogenesis 
and novel therapies for inherited cardiomyopathies (Wu and Hochedlinger, 2011, Inoue and 
Yamanaka, 2011). IKr is an import starting point as mutation of the hERG channel is 
responsible for some forms of long-QT syndrome, a well-characterized inherited disorder that 
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predisposes patients to fatal arrhythmia (Prystowsky et al., 2012) (Section 1.6.1). Showing 
the presence of an IKr and response to pharmacological blockade in the hESC-CM and iPSC-
CM is an important first step. Secondly, the cardiotoxicity of several potentially therapeutic 
compounds is because of arrhythmia caused by prolonged APD due to binding of the drug to 
the hERG channels (Ponte et al., 2010). Consequently if hESC-CM or iPSC-CM are to be 
used as toxicology screens to assist in drug development then it is important that it can be 
demonstrated that APD is sensitive to pharmacological agents known to prolong the APD. 
Finally, expression of K
+
 channels has been shown to be highly variable during development 
(Krishnamurthy et al., 2004, Nerbonne, 1998) and consequently differential response to IKr 
blockade between experimental groups may highlight differences in phenotype, in particular 
cardiac differentiation, development and maturation. 
 
Supplementary experiments were also performed with chromanol 293B, a selective blocker 
of IKs which, like IKr, contributes to repolarization of cardiomyocytes (Strutz-Seebohm et al., 
2011, Jespersen et al., 2005). IKs, like IKr, is differentially expressed during development 
(Krishnamurthy et al., 2004, Nerbonne, 1998) and is thought to be important in the 
pathogenesis of inherited arrhythmia such as the long QT-syndrome (Tsai et al., 2008, Lu and 
Kass, 2010). Whilst the potential for IKs-associated drug toxicity has historically been 
overlooked compared to IKr-associated toxicity (Curtis, 2004), there is evidence to suggest 
that impairment of IKs function may also be clinically important (Nakashima et al., 2004).  
 
As we will discuss in Sections 3.3.1 and 3.3.2, blockade of repolarizing K
+
 channels can have 
a marked effect on the spontaneous beating rate of iPSC-CM and hESC-CM. Consequently 
further experiments with the selective antagonist of the If, ivabradine, were performed to 
investigate pacemaker mechanisms in iPSC-CM and hESC-CM. If is an inward current which 
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is highly expressed in cardiomyocytes in the pacemaker and conduction system of the heart 
(the sinoatrial node (SAN), the atrioventricular node (AVN) and the Purkinje fibers). The 
molecular determinant of the pacemaker is the HCN channel (Baruscotti et al., 2005). The 
current is called the “funny current” because of several unusual features. Firstly, it is a mixed 
Na
+
 and K
+
 current. Secondly, it becomes active when the cell repolarizes below the If 
threshold of approximately -40/-50 mV, supplying an inward current which is responsible for 
starting depolarization of the myocyte in diastole. This mechanism is responsible for the 
spontaneous activity of myocytes within the SAN myocytes, and consequently the whole 
heart (Baruscotti et al., 2005, DiFrancesco and Ojeda, 1980). Finally, the “funny current” is 
activated by cyclic nucleotides in addition to voltage. The second messenger cyclic adenosine 
monophosphate (cAMP), which is produced in response to adrenaline and noradrenaline 
binding to β1 and β2 adrenoceptors, activates the HCN channels increasing their open 
probability (DiFrancesco and Tortora, 1991). Therefore, sympathetic stimulation by raising 
the level of cAMP molecules increases the If at diastolic voltages and consequently the speed 
of depolarization and beating rate. Ivabradine blocks If in a dose-dependent manner (Thollon 
et al., 1994) which is attenuated with reducing rate (Baruscotti et al., 2005). To investigate 
the maturity of pacemaker mechanisms in spontaneously beating iPSC-CM, they were 
superfused with increasing concentrations of ivabradine, isoproterenol (a non-selective beta-
adrenergic agonist structurally similar to epinephrine), or a combination of both.  
 
3.2 Materials and methods  
 
hESC from the H7 line were differentiated into hESC-CM using directed differentiation or 
the EB technique and plated onto MEA or MatTek dishes as previously described (Section 
2.1.2.). iPSC-CM fully differentiated using the EB method were obtained from ReproCELL 
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(ReproCELL, Japan) and plated onto MEA over 40 days following differentiation. MEA and 
patch clamp experiments were performed as previously described (Sections 2.3.1 and 2.3.2). 
 
For pharmacological studies briefly, spontaneously beating hESC-CM and iPSC-CM plated 
onto MEA dishes were superfused with NT alone, E-4031, chromanol 293B, ivabradine or 
isoproterenol dissolved in NT. In the case of E-4031, hESC-CM or iPSC-CM were 
superfused with NT for 10 minutes to obtain baseline readings. Cardiomyocytes were then 
superfused with NT containing 1nM E-4031 for 5mins, 10nM E-4031 for 5mins, 100nM E-
4031 for 5mins, 1M E-4031 for 5mins, before E-4031 was washed out with NT until a 
return to baseline readings were observed. For experiments with chromanol 293B, 
cardiomyocytes were superfused with NT for 10 minutes to obtain baseline readings, then 
superfused with NT containing 10M chromanol 293B for 5mins, then 20M chromanol 
293B for 5mins, before the chromanol 293B was washed out with NT until a return to 
baseline readings were observed. For experiments with ivabradine, cardiomyocytes were 
superfused with NT for 10 minutes to obtain baseline readings, then superfused with NT 
containing 300nM ivabradine for 5mins, 3µM ivabradine for 5mins, 30µM ivabradine for 
5mins, 300µM ivabradine for 5mins, before the ivabradine was washed out with NT until a 
return to baseline readings were observed. This experimental protocol was repeated with 
30nM isoproterenol added to the ivabradine to investigate if the effect of ivabradine was 
attenuated by adrenergic stimulation (Section 2.3.1). 
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Figure 3.1. Representative MEA traces showing the effect of IKr blockade on field potential duration in iPSC-CM 
 
3.3 Characterization of human embryonic stem cell and induced pluripotent 
stem cell-derived cardiomyocytes using multi-electrode arrays 
3.3.1 The effect of IKr current blockade 
 
Representative field potential recordings are shown in Figure 3.1. The predominant effect of 
E-4031 was to reduce the spontaneous beating rate in a dose-dependent fashion in hESC-CM 
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differentiated using both the EB and directed differentiation techniques. Similarly the 
spontaneous beating rate of iPSC-CM differentiated using the EB technique was also 
significantly reduced in response to IKr blockade. Our data does not suggest that the effect of 
IKr blockade on beating rate differed in any of the three groups (Figure 3.2). This is discussed 
further in Section 3.5.1, however the effect on beating rate is likely to be an effect of the cell 
being maintained below threshold potential for longer because of delayed repolarization. 
 
 
Figure 3.2. Effect of IKr blockade on beating rate of cardiomyocytes differentiated from hESC-CM differentiated 
using a directed differentiation protocol (Top Right), the EB method (Bottom Right), and iPSC-CM differentiated 
using the EB method (Bottom Left).  
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Figure 3.3. Effect of IKr blockade on corrected FPD (Solid Bars) and uncorrected FPD (Striped Bars) of 
cardiomyocytes differentiated from hESC-CM and iPSC-CM (A). hESC-CM differentiated using a directed 
differentiation protocol (B) and the EB method (D). iPSC-CM differentiated using the EB method (C). EB 
A     B 
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E           F 
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differentiated iPSC-CM and hESC-CM compared with hESC-CM differentiated using a directed differentiation 
protocol (E). Multi-cellular adult slice preparation demonstrating a mature response to IKr blockade (F)(Camelliti et 
al., 2011).  
 
There was prolongation of the FPD in hESC-CM and iPSC-CM obtained using directed 
differentiation and the EB method in response to IKr blockade at 100μm (Figure 3.3).  
However, in contrast to adult multi-cellular preparations treated with E-4031 (Figure 3.3F) 
there was no prolongation in FPD in hESC-CM or iPSC-CM obtained using directed 
differentiation or the EB method in response to IKr blockade when the FPD was corrected for 
rate (Figure 3.3) (Section 2.3.1).  In Figure 3.3 both the corrected and uncorrected beating 
rate are shown. No clear relationship was seen between spontaneous beating rate and field 
potential duration in spontaneously beating hESC-CM and iPSC-CM (Spearman correlation 
coefficient=0.2571) (Figure 3.4). As with the spontaneous beating rate, there was no 
significant difference in the effect of IKr blockade on FPD between iPSC-CM and hESC-CM 
differentiated using different methods (Figure 3.3). 
 
Figure 3.4. Plot of FPD against spontaneous beating rate in hESC-CM and iPSC-CM, showing no clear relationship 
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As many of the beating clusters did not have a discernible repolarization wave (contrast 
Figure 3.1 and Figure 3.5) there were fewer beating clusters in this dataset. The field potential 
recordings when a repolarization wave was not visible could be classified into three groups. 
In a few experiments the background noise was large relative to the typically recorded field 
potential amplitude (Figure 3.5A). In many experiments, particularly in directed 
differentiation monolayer cultures or when the beating cluster was small, the amplitude of the 
recorded field potential was much smaller than usually observed (Figure 3.5B). Finally in 
some experiments the repolarization wave was simply not visible (Figure 3.5C).  
  
Figure 3.5. Field potential recordings of spontaneously beating hESC-CM showing examples of traces in which FPD 
could not be measured, either because the amplitude of the background noise was too large (A); the amplitude of the 
recorded trace was not sufficiently large (B); or simply because there was no discernible repolarization wave (C).   
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Figure 3.6. MEA traces showing the effect of IKs blockade on field potential duration in hESC-CM 
 
3.3.2 The effect of IKs current blockade 
 
Whilst repolarization waves were visible in some experiments (Figure 3.6) most recordings 
resembled those shown in Figure 3.5. The effect of IKs current blockade on spontaneous 
beating rate was investigated in hESC-CM clusters differentiated using directed 
differentiation. Similar to IKr blockade there was a reduction in the spontaneous beating rate, 
which was statistically significant at higher doses of chromanol 293B (p=0.0121) (Figure 
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3.7). The mechanisms underlying this reduction in spontaneous beating rate are likely to be 
similar to IKr blockade (Section 3.3.1) and are discussed in more detail in Section 3.5.1. 
  
 
Figure 3.7. Effect of IKs blockade on the beating rate of spontaneously beating hESC-CM 
 
Unfortunately it was not possible to fully assess the effect of IKs blockade on FPD as only one 
of the clusters had a clear repolarization wave (Figure 3.6). Consequently, we were unable to 
assess if this was statistically significant. Furthermore, when adjusted for rate in this 
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experiment there was no clear relationship between increasing doses of chromanol 293B and 
FPD (Figure 3.8). 
 
              
 
Figure 3.8. Effect of IKs blockade on the FPD of spontaneously beating hESC-CM 
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Figure 3.9. Representative MEA traces showing the effect of If blockade on beating rate in iPSC-CM 
 
3.3.3 The effect of hyperpolarization-activated cyclic nucleotide-gated channel 
blockade 
 
Ivabradine reduced the spontaneous beating rate of iPSC-CM in a dose dependent fashion 
and at higher concentrations spontaneous beating completely stopped (Figure 3.10A). The 
effect of ivabradine was also not attenuated with isoproterenol (Figure 3.10C), unlike in 
humans and large animals, despite isoproterenol having a dose-dependent effect on the 
spontaneous beating rate of iPSC-CM (Figure 3.10B and Figure 3.11).  
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Figure 3.10. Effect of ivabradine (A), isoproterenol (B) and combined administration on the spontaneous beating rate 
of iPSC-CM (C). 
A                  B 
 
 
 
 
 
 
                  C 
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89 
 
 
Figure 3.11. Representative MEA traces showing the effect of β-adrenergic stimulation on beating rate in iPSC-CM 
 
3.4 Characterization of human embryonic stem cell and induced pluripotent 
stem cell-derived cardiomyocytes using the perforated patch-clamp 
technique 
 
Representative AP recordings are shown in Figure 3.12. The absence of any effect of E-4031 
on FPD measured with MEA, when adjusted for rate, was consistent with data from isolated 
hESC-CM (Figure 3.13). No change in hESC-CM APD was recorded using the perforated 
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patch technique. In contrast, both adult rat (p=0.0029) and dog (p=0.0124) ventricular 
cardiomyocytes had prolonged APD90 in response to E-4031. Adult dog ventricular 
cardiomyocytes also had prolonged APD50 because of their longer plateau phase (p=0.043).  
 
 
Figure 3.12 Representative AP phenotypes recorded from hESC-CM (with Acknowledgment to Cesare Terracciano). 
Figure reproduced with permission of Rao et al. Phenotype and Developmental Potential of Cardiomyocytes from 
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Induced Pluripotent Stem Cells and Human Embryonic Stem Cells. In: Ainscough J et al eds. Nuclear 
reprogramming and stem cells. Humana Press, 2011 (Rao et al., 2011). 
 
 
 
Figure 3.13. Effect of E-4031 on enzymatically isolated cardiomyocytes differentiated using directed differentiation 
protocols and the EB technique from hESC and iPSC compared to adult rat and dog ventricular myocytes (with 
Acknowledgment to Fiona Mead). 
 
3.5 Discussion 
3.5.1 The effect of IKs and IKr current blockade on human embryonic stem cell 
and induced pluripotent stem cell-derived cardiomyocytes 
 
There was significant heterogeneity in the response of hESC-CM and iPSC-CM to IKr 
blockade even within experimental groups. This can be seen from the wide confidence 
intervals associated with estimates of the effect of E-4031 (Figure 3.2 and Figure 3.3). 
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E-4031 however, consistently reduced the spontaneous beating rate of iPSC-CM and hESC-
CM (Figure 3.2). Whilst this may at first appear surprising as K
+
 channel blockade does not 
generally have this effect in patients and animal models, it is important to remember that 
these experiments occur in isolated cells without autonomic or electro-mechanical regulation 
of beating rate. The effect of E-4031 on spontaneous beating rate is supported by the 
literature where in isolated rabbit SAN myocytes E-4031 has been shown to significantly 
reduce the rate of spontaneous AP, in many cases completely stopping AP potentials at 
concentrations of 100nmol/L (Verheijck et al., 1995). The mechanisms underlying this are 
complex. E-4031 has been shown to have no direct effect at concentrations up to 10μmol/L 
on pacemaker currents such as If (Verheijck et al., 1995), no effect on the INa (Wettwer et al., 
1991, Verheijck et al., 1995), and no effect on the long-lasting inward ICa (ICa,L) at 
concentrations up to 5μmol/L (well above the maximum concentration used), and only a 
partial effect on peak ICa,L thereafter (Verheijck et al., 1995, Wettwer et al., 1991). However, 
E-4031 probably has a marked indirect effect on these pacemaker currents by modifying 
repolarization, and the resting membrane potential, and consequently changing the size of 
several other key currents. At concentrations of 100nmol/L in isolated rabbit SAN myocytes, 
E-4031 increased the interval between spontaneous AP, increased APD, depolarized the 
MDP, depressed dV/dtmax, and reduced diastolic depolarization rate, stopping spontaneous 
AP in 50% of myocytes (Verheijck et al., 1995). By contrast in ventricular guinea pig 
myocytes the diastolic membrane potential was unchanged by E-4031 at concentrations of up 
to 10μmol/L, however the APD was markedly increased (Wettwer et al., 1991). Our 
experiments clearly suggest that prolongation of the APD occurs at least to some extent in 
some iPSC-CM and hESC-CM (Figure 3.3). Increasing the APD in itself could theoretically 
cause a reduction in the spontaneous beating rate by increasing the time each cell spends in a 
non-excitable depolarized state. 
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The hypothesis that the observed effect in beating rate can be entirely explained by APD 
prolongation in all cells was not supported by data from single cell perforated patch 
experiments (Figure 3.13) or the data from MEA experiments (Figure 3.3). AP recorded 
using perforated patch from isolated hESC-CM suggest that there was significant 
heterogeneity in APD in hESC-CM (Figure 3.12 and  Figure 3.13), supported by similar 
studies from the literature conducted in both hESC-CM and iPSC-CM (Kong et al., 2010, 
Schenke-Layland and MacLellan, 2009, Sartiani et al., 2007, Zhang et al., 2009, Matsa et al., 
2011, Pekkanen-Mattila et al., 2010a). This highlights the heterogeneous phenotype of 
cardiomyocytes differentiated from pluripotent stem cells and suggests that the mechanisms 
by which E-4031 reduces the beating rate of iPSC-CM and hESC-CM may be multiple and 
vary between populations of cells, or even between cells within populations. In some cells 
where IKr is the predominant repolarizing current, E-4031 may help to maintain them in a 
relatively un-excitable depolarized state for a prolonged period by significantly slowing 
repolarization through IKr blockade. In other cells, however, E-4031 may indirectly inhibit 
other pacemaker currents such as If, ICa,L and INa by reducing the maximum diastolic potential 
and consequently reducing the excitability of hESC-CM and iPSC-CM in diastole, by a 
similar mechanism by which E-4031 reduces the excitability of isolated rabbit SAN cells 
(Verheijck et al., 1995). For this to occur however without significant prolongation of the 
APD, other repolarizing K
+
 currents must be present. 
 
As E-4031 consistently reduced the beating rate, E-4031 also resulted in prolongation of the 
FPD of hESC-CM and iPSC-CM (Figure 3.3). Reduction in the beating rate of 
cardiomyocytes is a consequence of the refractory phase of the cardiac cycle. Consequently, 
it is expected that reduced beating rate will result in longer APD. To determine whether 
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prolongation in APD is as a consequence of the effect of E-4031 prolonging repolarization, or 
simply reducing the beating rate of iPSC-CM and hESC-CM, APD was corrected for the 
beating rate using Bazett’s formula (Yap and Camm, 2003) 
 
When adjusted for the rate using Bazett’s formula most of the hESC-CM and iPSC-CM 
experiments did not show prolongation of the FPD. This is well illustrated in Figure 3.4 
where there is no correlation between FPD and rate in either hESC-CM (Spearman's rank 
correlation coefficient (ρ) -0.2000, p=0.7833), iPSC-CM (ρ 0.2571, p=0.6583), 
cardiomyocytes differentiated using the EB technique (ρ 0.1667, p=0.7033), or all the 
experimental results pooled (ρ -0.1455, p=0.6731). Single cell perforated patch experiments 
with hESC-CM also suggest there is not a consistent effect of E-4031 on APD (Figure 3.13). 
This is in marked contrast to experiments conducted with multicellular preparations 
(Camelliti et al., 2011), isolated adult myocytes from animal models (Follmer and Colatsky, 
1990, Sanguinetti et al., 1991) (Figure 3.13), large animal studies (Wallace et al., 1991), and 
from clinical studies (Isomoto et al., 1993) (Figure 3.3). It is also in marked contrast with 
several studies published following the start of this work which have demonstrated 
prolongation of APD in response to IKr blockade in single cell experiments (Liang et al., 
2013, Braam et al., 2013) and in MEA experiments where FPD is adjusted for rate (Harris et 
al., 2013, Zwi et al., 2009). 
 
A factor which made the investigation of the effect not only of E-4031, but the investigation 
of the effect of all pharmacological agents on FPD problematic was the absence in many 
MEA experiments of an obvious repolarization wave (contrast Figure 3.1 and Figure 3.5). 
The field potential recordings when a repolarization wave was not visible could be classified 
into three groups. In a few experiments the background noise was large relative to the 
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typically recorded field potential amplitude (Figure 3.5A). This was probably due to technical 
problems with the superfusion of the hESC-CM, and iPSC-CM. In these circumstances the 
recordings were only accepted after extensive attempts were made to eradicate or reduce the 
background noise. In many experiments, particularly in directed differentiation monolayer 
cultures or when the beating cluster was small, the amplitude of the recorded field potential 
was much smaller than usually observed (Figure 3.5B); in these circumstances not much 
could be done to optimize the recordings. Finally in some experiments the repolarization 
wave was simply not visible (Figure 3.5C). As the FP recording could be considered to be 
analogous to the differential of the AP, large deflections in membrane potential with respect 
to time would result in large waves in the FP recording. Many cells may have had phenotypes 
analogous to human atrial or nodal AP which are characterized by a limited plateau phase 
(Phase 2) or “triangulation” of the action potential (See Figure 1.5). This would result in an 
absence of repolarization wave distinct from the “QRS complex” or larger depolarization 
wave.   Single cell perforated patch performed in hESC-CM and iPSC-CM confirm that many 
cells do have triangular AP morphologies (Figure 3.12) (Kong et al., 2010, Schenke-Layland 
and MacLellan, 2009, Zhang et al., 2009, Matsa et al., 2011, Pekkanen-Mattila et al., 2010a). 
Whilst some studies appear to consider the return to baseline following the depolarization 
wave as being analogous to the APD (Zwi et al., 2009, Banach et al., 2003), and thus make 
estimations of APD based on field potential records without discernible repolarization waves, 
in other studies this is not clear (Yamamoto et al., 1998) and is of debatable validity.  
 
Characterization of the electrophysiological properties of isolated hESC-CM was also 
technically difficult. In particular, hESC-CM with specific and distinct morphological 
characteristics were far more amenable to patching than others. This raised the possibility that 
the hESC-CM patched represent only a sub-population in each cluster. 
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Finally, arguably at the concentrations of E-4031 used, a complete block of IKr was not 
achieved. Higher concentrations of E-4031 may have achieved greater prolongation of FPD. 
However, at 1µm/L concentration of E-4031 96% of the IKr is selectively blocked and above 
1µm/L concentration E-4031 is no-longer a specific blocker of IKr (Verheijck et al., 1995). 
Furthermore, studying hESC-CM and iPSC-CM using MEA when they are no longer 
spontaneously beating is technically problematic as they cannot be readily point-stimulated. 
 
The experiments with chromanol 293B were more limited because of a paucity of material, 
and as repolarization waves were not visible in most of the preparations. There appeared to be 
however, a reduction in beating rate at higher concentrations of chromanol 293B (Figure 3.7). 
This can be less easily understood than the effect of E-4031 on beating rate. It is unlikely that 
chromanol 293B was acting non-specifically on pace-maker currents such as IK1, IKr, or ICa,L 
as several studies have shown that at concentrations well in excess of the concentrations used 
(20μM) chromanol 293B did not block these channels (Sun et al., 2001). It has been 
suggested that IKs does not significantly affect, even indirectly, the important pacemaker 
currents in SAN cells. For example, by modifying the resting membrane potential (Verheijck 
et al., 1995). Several studies however have shown that chromanol 293B can affect other 
repolarizing currents such as the Ultra-Rapid delayed rectifier K
+
 current (IKur) and the 
transient outward K
+
 current (Ito1) (Sun et al., 2001, Du et al., 2003) which are variably 
expressed in adult cardiomyocytes and may be expressed in hESC-CM and iPSC-CM 
depending on their phenotype and age (Sartiani et al., 2007, Du et al., 2003). The direct effect 
of chromanol 293B on prolonging repolarization through IKs, and potentially IKur and Ito1, is 
therefore probably the most likely explanation for the reduced beating rate by increasing the 
time that cells are in a non-excitable refractory depolarized state. Several studies which have 
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shown that chromanol 293B prolongs APD in hESC-CM or iPSC-CM appear to support this 
(Peng et al., 2010, Wang et al., 2011a, Zwi et al., 2009) although this is contradicted by other 
studies (Ma et al., 2011, Braam et al., 2013). Very limited data from one beating cluster 
suggested that chromanol 293B prolonged the FPD in hESC-CM (Figure 3.6 and Figure 3.8), 
with the important caveats that this is data only from one cluster, and secondly, like the 
experiments with IKr blockade, when corrected for rate an effect on FPD was not observed.  
 
Data from Braam et al suggest that IKs is only important for repolarization in iPSC-CM with 
reduced repolarization reserve. In the case of their study this was iPSC-CM with an IKr loss of 
function mutation resulting in long-QT syndrome (Braam et al., 2013). Reduced 
repolarization reserve compared to iPSC-CM in the literature highlighted by responsiveness 
to IKs may highlight the relative immaturity of the cells we used in our experiments, which 
could perhaps explain differences between our data and that in the published literature. 
 
The results of our experiments with E-4031 are contradicted by several reports in the 
literature, in particular the failure to demonstrate prolongation of the corrected FPD and APD 
in response to E-4031. Several studies have shown that hESC-CM (Caspi et al., 2009) and 
iPSC-CM (Zwi et al., 2009) have prolongation of single-cell APD recordings (Braam et al., 
2013, Liang et al., 2013) or FPD when corrected for rate (Zwi et al., 2009, Harris et al., 
2013), in response to IKr channel blockade with E-4031. Furthermore, the effects on beating 
rates that were evident in our experiments are not reported in most studies, despite other 
studies reporting the effect on rate of other pharmacological agents (Zwi et al., 2009).  
 
The differences between our data and the existing literature can only be explained by one of 
two reasons: either the properties of the cells used in our experiments were different, or the 
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differences reported are an experimental artifact. Several mechanisms are suggested to 
undelay rate-dependent APD prolongation. Homeostatic mechanisms regulating cardiac 
output at the level of the organism affect cAMP levels in cardiomyocytes, which in turn 
regulate K
+
 channel open probability and repolarization. At a cellular level accumulation of 
intracellular Ca
2+
 and extracellular K
+
 at higher rates may also play a role. Finally the direct 
effect of refractory time-dependent K
+
 channels are also important in APD shortening at 
faster beating rates (Boyett and Jewell, 1978). Of these mechanisms, probably only the direct 
properties of sarcolemmal K
+
 channels and intracellular Ca
2+
 are relevant in our experiments. 
There is no autonomic pressure to maintain cardiac output in cultured cardiomyocytes and as 
the cells were superfused with NT there would be no extracellular accumulation of K
+
.  
 
The expression of K
+
 channels has been shown to increase with the age of hESC-CM 
(Sartiani et al., 2007). Whilst this suggests that the time from differentiation may be a 
significant confounding factor in experiments of this type, this is not supported by other 
studies which have not found an association between time since differentiation and phenotype 
(Pekkanen-Mattila et al., 2010a, Pekkanen-Mattila et al., 2009). Taken together these studies 
highlight heterogeneous K
+
 channel expression in stem cell-derived cardiomyocytes. 
Pekkanen-Mattila et al. even suggest that there is variation between cells differentiated using 
the same method in the same batch (Pekkanen-Mattila et al., 2009). Other authors suggest 
there may be variation between cells in the same cluster (Denning and Anderson, 2008, Xu et 
al., 2002). Similarly the debate about the extent to which in vitro stem cell-derived 
cardiomyocytes recapitulate adult cardiomyocyte Ca
2+
 cycling properties suggests that 
heterogeneity in Ca
2+
 handling properties could also feasibly explain differences between our 
experimental data and the existing literature (Dolnikov et al., 2006, Liu et al., 2007, Fu et al., 
2006, Satin et al., 2008). 
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The differences between our experimental results and published data may also be due to 
differences in experimental protocols. Whilst some studies have corrected the FPD for rate 
(Caspi et al., 2009, Zwi et al., 2009), in many of these reports the FPD does not appear to 
have been corrected for rate (Matsa et al., 2011, Otsuji et al., 2010, Tanaka et al., 2009).  
 
In summary, the cause for differences between our data and the published literature, and the 
differences between studies within the published literature with respect to the response of 
hESC-CM and iPSC-CM to E-4031 and chromanol 293 B are not clear. These differences 
could be explained by the heterogeneous phenotype of iPSC-CM and hESC-CM. It may be 
that differences in the cell lines used (Pekkanen-Mattila et al., 2009), contribution of non-
cardiac cells (Kim et al., 2010a), differentiation protocol, culture conditions (Otsuji et al., 
2010), age of the cardiomyocytes (Sartiani et al., 2007), or experimental conditions may also 
contribute to these findings. Consequently whilst pluripotent stem cells unquestionably have 
tremendous potential as in vitro myocardial models, if iPSC-CM and hESC-CM are to be 
widely applied to toxicology screening and drug development, experimental protocols will 
have to encompass methodology which will control for potential confounding factors.  
 
3.5.2 The effect of hyperpolarization-activated cyclic nucleotide-gated channel 
blockade on induced pluripotent stem cell-derived cardiomyocytes 
 
Automaticity is a characteristic feature of immature cardiomyocytes (Liang et al., 2010, 
Tuganowski and Tendera, 1973, Janse et al., 1976). Consequently, unlike in the healthy adult 
myocardium where usually only pacemaker cells in the SAN have autonomous AP 
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(DiFrancesco, 2010), most hESC-CM and iPSC-CM exhibit a high degree of automaticity 
(Pekkanen-Mattila et al., 2010a, Kong et al., 2010, Zhang et al., 2009). 
 
Experiments designed to investigate the mechanisms underlying this automaticity 
demonstrated that the spontaneous beating rate of iPSC-CM was reduced in a dose-dependent 
manner by ivabradine. The effect of ivabradine on the spontaneous beating rate of iPSC-CM 
was not attenuated at low rates, in contrast with data from clinical studies (Borer and Le 
Heuzey, 2008, Savelieva and Camm, 2006). Furthermore, isoproterenol did not appear to 
attenuate the effect of ivabradine as one may expect from previous experimental studies 
(DiFrancesco and Tortora, 1991). These later findings are perhaps not surprising. Attenuation 
of the effect of ivabradine with reducing rate should probably not be expected when there is 
no intracellular raise in cAMP, caused by increased sympathetic activity in response to 
reduced cardiac output caused by reduced beating rate (Stieber et al., 2003). Furthermore, the 
dose of isoproterenol used may have been too small, and the heterogeneity and resulting 
confidence intervals too large to be sure that there was no attenuation of the effect of 
isoproterenol with ivabradine. The finding that spontaneous beating rate was reduced in a 
dose dependent manner, and in particular that at high concentrations beating ceased 
completely is more problematic as it appears to suggest that in the iPSC-CM the most critical 
determinant of their automaticity was If. As the mechanisms underlying the automaticity of 
human iPSC-CM have not currently been investigated in the literature, indeed there is even 
limited data from hESC-CM, we must look to experiments largely performed in vitro and 
using murine ESC-CM to explain these findings. 
 
The mechanisms underlying automaticity in SAN cardiomyocytes is complex, and far from 
being completely understood (Lau et al., 2011, Lakatta et al., 2010). Much of the existing 
101 
literature appears to suggest that a complex interaction between spontaneous intracellular 
Ca
2+
 cycling associated with the SR, and fluctuations in sarcolemma membrane potential, due 
to the activity of several pacemaker currents including If, IKr, and ICa, L, probably underlie 
spontaneous AP in the SAN (Lakatta et al., 2010, Verheijck et al., 1995). It is debatable to 
what extent this is the case in hESC-CM and iPSC-CM. It is likely, however, given their 
generally immature phenotype that the mechanisms underlying automaticity are more 
analogous to those seen in developing cardiomyocytes.  
 
There is general consensus that in murine cardiomyocytes IK1 expression is a feature of 
terminal differentiation (Satin et al., 2004). Although the electrophysiology of developing 
human cardiomyocytes is very poorly characterized for obvious reasons this appears to be 
supported by the limited available data (Tuganowski and Tendera, 1973, Janse et al., 1976). 
Consequently, small Na
+
 or Ca
2+
 currents may potentially depolarize the cell (Satin et al., 
2004). Evidence that extracellular Ca
2+
 cycling causing oscillations in membrane potential is 
the dominant pacemaker mechanism in immature cardiomyocytes is demonstrated by 
experiments in which blockade of ICa,L, T-type Ca
2+
 current (ICa,T)  and NCX all completely 
stop beating in murine embryonic cardiomyocytes at day 8.5. By contrast, blockade of the If 
current at day 8.5 does not stop beating in murine embryonic cardiomyocytes, suggesting that 
in less mature cells automaticity is completely related to extracellular Ca
2+
 cycling or 
“oscillations” (Liang et al., 2010). It has been suggested that If becomes critically important 
later in development, assuming a dominant role in pacemaker activity from day 9.5 in murine 
embryonic cardiomyocytes (Stieber et al., 2003). The HCN4 gene encodes the HCN channel 
predominantly expressed in the pacemaker regions of the heart. HCN4 Knockout mice have a 
reduced heart rate and death in utero occurs by day 11.5 (Stieber et al., 2003). However 
despite the significant reduction in HCN4 expression (75-90%) the hearts of HCN4 knockout 
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mice continued to beat after day 9.5, and mortality at day 11.5 may equally have been 
because of an indirect consequence of the reduced heart rate, rather than a direct absence of 
autonomic activity. Furthermore isolated cardiomyocytes with “atrial” and “ventricular” 
phenotypes from HCN4 knockout mice, rather like hESC-CM and iPSC-CM, had 
spontaneous AP. This suggests either other HCN isoforms are responsible for spontaneous 
membrane depolarization or other pacemaker mechanisms continue to be important (Stieber 
et al., 2003). 
 
It has been suggested at least in cardiomyocytes differentiated from murine embryonic stem 
cells that normal, in utero development is recapitulated (Doevendans et al., 2000); however, 
there are several difficulties with this. Firstly, several mechanisms are suggested to be 
important in murine ESC-CM that have not been described in embryonic cardiomyocytes.   
For example, experiments performed on murine ESC-CM suggest that fluctuations in 
intracellular Ca
2+
 cycling play a critical part in the automaticity of developing murine 
myocardium (Viatchenko-Karpinski et al., 1999, Zahanich et al.), or that in very early 
development Ito1 is a critical pacemaker current (Hescheler et al., 1997). Explanations of this 
have focused on the relative maturity of the embryos (Viatchenko-Karpinski et al., 1999). 
However, it seems unlikely that intracellular Ca
2+
 oscillations are important (Viatchenko-
Karpinski et al., 1999), and then become less important as the cells mature (Liang et al., 
2010), before then becoming important in adult cells again (Lau et al., 2011, Lakatta et al., 
2010).  
 
Some authors suggest that experimental artifacts may account for discrepant findings relating 
to intracellular Ca
2+
 cycling in stem cell-derived cardiomyocytes (Satin et al., 2008), however 
if we take the published literature at face value then these findings could probably be 
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explained by the suggestion that ESC-CM are a heterogeneous cell population and that some 
of these cells may not recapitulate in utero development. Satin et al suggest hESC-CM have 
relatively immature expression of IK1 but mature expression of the voltage gated Na
+
 channel, 
Nav1.5 (Satin et al., 2004). Consequently the dominant pacemaker mechanism is the 
depolarizing effect of INa, and blockade with tetrodotoxin (TTX) abolishes the automaticity of 
hESC-CM, unlike Ca
2+
 channel blockade. It is suggested that while the If may be present 
(they were unable to detect HCN-4 mRNA expression), it is unlikely to play a significant role 
in the automaticity of hESC-CM. These findings are in direct contradiction to studies in 
murine ESC-CM which suggest that If along with ICa,T is the dominant pacemaker mechanism 
at day 13.5, and that HCN expression in fact declined with time, although significantly FACS 
sorting was performed to purify the population of ESC-CM (Yanagi et al., 2007).  The 
importance of If is supported by other studies performed with murine ESC-CM (Qu et al., 
2008, Barbuti et al., 2009). A recent study suggests that three populations of hESC-CM exist 
with distinct pacemaker mechanisms (Weisbrod et al., 2013). Approximately 30% had If 
dependent automaticity, 41% had If independent automaticity (Ca
2+
 dependent) and the 
remainder of cells had mixed pacemaker mechanism (Weisbrod et al., 2013). In both If-
dependent and independent cells suppression of pacemaker mechanisms resulted in 
depolarization of the maximal diastolic potential. In individual cells suppression of If in If-
independent cells would not result in cessation of beating. However, as we performed our 
experiments on clusters of electrically coupled cells significant depolarization of the MDP in 
one third of the cells could potentially reduce the excitability of the whole cluster. 
 
The complexity of the mechanisms underlying automaticity in iPSC-CM may not easily be 
resolved. If we assume iPSC-CM and hESC-CM to be functionally equivalent (Section 
3.5.3), the finding that these mechanisms are not homogeneous is important. Furthermore, 
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this finding is supported by data from the existing literature. Variation in the mechanisms that 
underlie automaticity may potentially confound experiments in which hESC-CM or iPSC-
CM are used as models of arrhythmia, or to investigate aspects of cardiomyocyte metabolism 
and function.  
 
3.5.3 The effect of pluripotent stem cell type and method of differentiation on 
the functional properties of pluripotent stem cell-derived cardiomyocytes 
 
There is limited evidence to suggest that differentiation protocols may affect the 
electrophysiology of hESC-CM (Pekkanen-Mattila et al., 2010a). There is evidence to 
suggest that there are differences between gene expression patterns (Chin et al., 2009) and 
DNA methylation in hESC and iPSC (Deng et al., 2009), and there are differences in the 
efficiency (Zhang et al., 2009) and time (Mauritz et al., 2008) it takes to differentiate iPSC-
CM compared with hESC-CM.  
 
For these reasons we were very keen to compare the response of hESC-CM and iPSC-CM to 
E-4031, as well as the response of hESC-CM differentiated using different methods. Our 
experiments did not suggest that there was a significant difference in the properties of hESC-
CM and iPSC-CM measured. This is supported by most (Mandel et al., 2012, Gherghiceanu 
et al., 2011, Xi et al., 2010, Zhang et al., 2009), but not all studies in the literature (Jiang et 
al., 2010b). 
 
We must however continue to be vigilant that the properties of hESC-CM and iPSC-CM 
could vary significantly. Our experiments were significantly limited by a restricted supply of 
hESC-CM and iPSC-CM, limiting both the number of times an experiment could be repeated 
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and the number of different experiments that could be undertaken. More generally robust 
comparison between the properties of hESC-CM and iPSC-CM in the literature has been 
confounded by the significant heterogeneity within experimental groups and the number of 
potentially confounding factors (Section 3.5.1). This has precluded the use of historical data 
or pooling data from different groups.  
 
3.6 Conclusion 
 
In this chapter we have demonstrated that there is significant heterogeneity in the functional 
properties of iPSC-CM and hESC-CM. Our data appears to contradict the existing literature 
in some respects, such as the responsiveness of hESC-CM and iPSC-CM to IKr blockade. 
However, there is significant evidence within the literature to support the contention that 
hESC-CM and iPSC-CM have an immature and heterogeneous phenotype when the 
experimental data is examined more closely. This may make the application of iPSC-CM and 
hESC-CM unsuitable for some applications. Consequently, we would strongly argue that 
there is significant value in developing tools which could improve the homogeneity and 
maturity of the phenotype of cardiomyocytes differentiated in vitro from pluripotent stem 
cells. 
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4 Structured Tissue Culture Constructs to 
Modulate the Calcium Cycling Properties of 
Immature Cardiomyocytes  
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4.1 Introduction 
 
The immature, heterogeneous phenotype of iPSC-CM remains problematic despite the 
promise of iPSC-CM as in vitro models. Experimental results described in Sections 3.3 and 
3.4, suggest that both iPSC-CM and hESC-CM have an immature, heterogeneous phenotype, 
unrepresentative of adult human myocardium. This is supported by evidence from the 
literature which suggests that iPSC-CM have gene expression characteristics of developing 
cardiomyocytes (Gai et al., 2009), immature ultrastructural phenotypes (Gherghiceanu et al., 
2011, Itzhaki et al., 2011b), immature electrophysiological properties (Zhang et al., 2009, Ma 
et al., 2011) and abnormal Ca
2+
 cycling (Lee et al., 2011).  As the practical value of hESC-
CM, and iPSC-CM in particular, falls below their theoretical potential (Oh et al., 2012), we 
felt that there would be significant value in modifying the phenotype of iPSC-CM and hESC-
CM in order to make them more representative of adult myocardium.  
 
Approaches to modify the phenotype of iPSC-CM and hESC-CM can broadly be classified as 
methods that aim to modify the phenotype of cells through modification of gene expression 
(Kong et al., 2010), or those that use culture conditions to modify the expression of the 
immature phenotypes (Otsuji et al., 2010). We felt that for any tool which promotes a more 
mature phenotype in iPSC-CM or hESC-CM to be widely applied it must fulfill a number of 
criteria. Firstly, it must not further impair their application as disease models. Secondly, it 
must be readily reproducible without specialist techniques or equipment. Finally, it should be 
relatively economical in terms of laboratory time and other resources. For these reasons we 
chose not to investigate approaches in which genetic manipulation of the cells was a critical 
component. For iPSC-CM, in particular, where the patient-specific genetic background is a 
critical component of their value over other disease models, genetic manipulation would 
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significantly undermine their utility. Evidence of the effect of culture conditions on iPSC-CM 
and hESC-CM is limited. For other immature cardiomyocytes, in particular NRVM there is 
evidence that several aspects of cardiomyocyte culture could be modified to promote a more 
mature phenotype. Substrate geometry (Wang et al., 2011b, Yin et al., 2004, Bien et al., 
2003, Kim et al., 2010b, Kaji et al., 2003, Pong et al., 2011, Parker et al., 2008, Feinberg et 
al., 2012, McDevitt et al., 2003, Badie and Bursac, 2009, Badie et al., 2012), substrate 
stiffness (Wang et al., 2011b, Shimazaki et al., 2008, Lieu et al., 2013), electrical (Chiu et al., 
2011, Radisic et al., 2004) and mechanical stimulation (Tulloch et al., 2011, Fink et al., 2000, 
Gwak et al., 2008, Hecker et al., 2008, Brown et al., 2008), for example, have all been shown 
to modify the phenotype of NRVM. These methods can be thought of as representing a 
spectrum of complexity from relatively simple cell alignment (Yin et al., 2004, Bien et al., 
2003), to cyclical mechanical or electrical stimulation which can be performed with 
proprietorial systems (Fink et al., 2000, Radisic et al., 2004), to novel culture systems which 
modify several aspects of cardiomyocyte culture in order to promote a more mature 
phenotype (Boudou et al., 2012, Zimmermann et al., 2000, McCain et al., 2013).  With 
increasing complexity culture systems require more expertise, resources, and time to develop 
and use. It also becomes increasingly difficult to apply many of the techniques widely used in 
cell culture, molecular biology, cell imaging and physiology to investigate the phenotype of 
the cultured cells as the complexity of the culture system increases. Ironically, this may mean 
that whilst a mature phenotype may be achieved the difficulty of interrogating the phenotype 
of the cultured cardiomyocytes becomes as complicated as evaluating cellular physiology in 
existing animal models. This obviously significantly limits the utility of such models. As 
there was existing evidence from NRVM that cell alignment was both easily achieved and 
had a positive effect on their phenotype of immature cardiomyocytes (Yin et al., 2004, Bien 
et al., 2003), we aimed to investigate whether iPSC-CM cultured in an aligned fashion, 
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analogous to adult myocardium, would exhibit a matured phenotype that could be considered 
more representative of adult myocardium.  
 
The experimental results described in Chapter 3 (Section 3.3 and Section 3.4), suggest that 
iPSC-CM and hESC-CM had an immature phenotype. However, in many ways we felt that 
the differential response to K
+
 channel blockade was not necessarily the best experiment to 
demonstrate or quantify differences in cellular phenotype. Our concern was that despite 
significant “maturation” of the phenotype of iPSC-CM, their response to IKr blockade may 
not be significantly modified, and so the efficacy of any modification in culture technique 
would not be recognized. Conversely, modification of the culture condition of iPSC-CM may 
have only a marginal effect on the global phenotype of iPSC-CM, however if it modified IKr 
activity the effect of modification of culture conditions may be overestimated. As we need a 
more global indication of the functional maturity of iPSC-CM and the effect of changes in 
culture conditions on the phenotype of iPSC-CM, we chose to focus on the effect on the Ca
2+ 
cycling properties of these cells. Intracellular Ca
2+
 cycling is central to excitation-contraction 
coupling, and is therefore a fundamental component of cardiomyocyte physiology. For these 
reasons, we felt that if cell alignment had any effect on cardiomyocyte physiology it would be 
evident from changes in cardiomyocyte Ca
2+
 cycling properties.  
 
Several methods have been described to align cells, many of which appear to have a positive 
effect on the functional properties of immature cells such as NRVM. These include using 
substrates coated in micropatterned extracellular matrix components such as fibronectin (Kaji 
et al., 2003, Feinberg et al., 2012), microgrooved substrates (Yin et al., 2004) and 
nanogrooved culture substrates (Kim et al., 2010b), in addition to more sophisticated three-
dimensional constructs (Dvir et al., 2011, Boudou et al., 2012). Structured tissue culture 
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substrates that bring about regular alignment and anisotropy of the cell culture have been 
previously used to improve Ca
2+
 cycling properties and sarcomeric organization in NRVM 
(Kaji et al., 2003, Feinberg et al., 2012, Yin et al., 2004, Kim et al., 2010b, Dvir et al., 2011, 
Boudou et al., 2012). There is no evidence in the literature either that these strategies can be 
used to align iPSC-CM, or modify their functional properties. With the ultimate aim of 
applying these techniques to iPSC-CM, in this chapter we aimed to test the validity and 
feasibility of these techniques in our laboratory. Pilot experiments to test the reproducibility 
of these techniques were performed using NRVM. NRVM are more readily available and less 
costly than iPSC-CM. However, as NRVM are also immature cardiomyocytes they have 
many similar properties.  
 
The specific aims of the work presented in this chapter were to test the reproducibility of two 
methods to align NRVM in a fashion analogous to adult myocardium: the use of 
micropatterned fibronectin (Camelliti et al., 2006) and the use of microgrooved constructs 
(McDonald and Whitesides, 2002). We also aimed to determine if these methods would 
promote Ca
2+
 cycling properties which were more representative of adult myocardium. 
Therefore we aimed to test the hypotheses that structured tissue culture using micropatterned 
fibronectin and microgrooved substrates would have a positive effect on the Ca
2+
 cycling of 
NRVM.  
 
4.2 Materials and methods 
 
NRVM were used to validate methods used to promote cellular alignment and perform pilot 
Ca
2+
 cycling experiments. NRVM, like hESC-CM and iPSC-CM are immature 
cardiomyocytes and have many similar properties.  
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NRVM were isolated according to Home Office guidelines (Chapter 2.1.1) and aligned using 
micropatterned fibronectin lines (Chapter 2.2.2), or microgrooved tissue culture substrates 
(Chapter 2.2.1). Immunohistochemistry (Chapter 2.4.2), SEM (Chapter 2.4.5) and TEM 
(Chapter 2.4.4) were performed to confirm cell alignment, and to evaluate cell structure.  
 
Ca
2+
 transient properties were measured in non-structured and structured NRVM cultures 
using confocal microscopy, after loading the cells with Rhod-2 AM, a fluorescent Ca
2+ 
indicator. Recordings were performed when the cells were beating spontaneously and field 
stimulated at 0.5Hz, 1Hz and 2Hz (Chapter 2.3.3).  
 
4.3 Results  
4.3.1 Fibronectin lines 
4.3.1.1 Effect of culture on fibronectin lines on neonatal rat ventricular myocyte 
structure 
 
Micropatterned fibronectin lines were spaced 300µm apart and were 30µm wide. 
Immunofluorescence staining confirmed that NRVM exclusively attached to fibronectin 
lines. Consequently, although NRVM cultured on micropatterned fibronectin lines appeared 
to be electro-mechanically coupled (Section 4.3.2), NRVM in adjacent lines were not 
coupled. Therefore, unlike non-structured cells and cells cultured on microgrooved PDMS 
substrates (Section 4.3.2) NRVM cultured on fibronectin lines did not form a syncytial 
monolayer (Figure 4.1). 
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Figure 4.1. A) Bright field image showing geometry of micropatterned NRVM cultured on fibronectin lines. B) 
Immunohistochemistry of micropatterned NRVM. Green - Fibronectin, Red - Myosin Heavy Chain, Blue – DAPI 
(With Acknowledgment to Patrizia Camelliti). Bright field images contrasting the structured and non-structured 
constructs - Scale bar 30µm . (C and D) 
 
NRVM cultured on micropatterned lines were more aligned than NRVM cultured on non-
structured PDMS (Mann-Whitney U, p<0.0001, F=16.17, p<0.0001 – F-test) (Figure 4.2). 
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Figure 4.2. Quantification of cell alignment of NRVM on micropatterned fibronectin lines compared with NRVM 
cultured on non-structured PDMS. Alignment is quantified by measuring variation of the long-axis of each nucleus 
from the mean long-axis of all the nuclei. The graph on the left is a comparison in the variation in alignment (F-test), 
the graph on the right shows difference in average alignment (Mann-Whitney U). 
 
4.3.1.2 Effect of culture on fibronectin lines on neonatal rat ventricular myocyte 
calcium cycling 
 
 
Figure 4.3. Representative Ca2+ transient from NRVM cultured on micropatterned fibronectin lines (green) and non-
structured constructs (grey) recorded with confocal microscopy in cells loaded with the Ca2+ indicator Rhod-2 AM 
and field stimulated at 0.5Hz. A Ca2+ transient recorded from an adult rat myocyte is shown for comparison (rust). 
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Micropatterned fibronectin lines did not have a clear beneficial effect on the Ca
2+ 
cycling 
properties of the cells on the structured constructs compared to the cells on the non-structured 
constructs. In the micropatterned fibronectin lines there was no significant difference in Ca
2+ 
transient parameters between NRVM cultured on flat PDMS membrane and those on 
fibronectin lines when the cells were beating at 1Hz or 0.5Hz (Figure 4.3 and Figure 4.4).  
 
There was a significant increase in the TTP of the Ca
2+
 transient when the cells cultured on 
the fibronectin lines were stimulated at 2Hz compared to the non-structured constructs 
(p=0.0056), and there was a statistically significant reduction in Ca
2+
 transient amplitude in 
the micropatterned group at 0.5Hz (p=0.001), 1Hz (p=0.0004) and 2Hz (p=0.0008). When the 
NRVM were beating spontaneously the TTP (p=0.0135), T50 (p=0.0093), and T90 
(p=0.0029) were all significantly shorter in the non-structured NRVM, however the 
amplitude was not significantly changed (p=0.1433).  
 
This data must be interpreted in the context of the significantly reduced spontaneous beating 
rate on the micropatterned grooves compared to the non-structured constructs (p=0.0010). 
Fewer NRVM beat spontaneously on the fibronectin lines compared to NRVM seeded on 
non-structured PDMS (13% versus 37%) (Fisher’s Exact Test p= 0.0178) (Figure 4.4 and 
Figure 4.3). 
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Figure 4.4. The effect of micropatterned fibronectin lines on Ca2+ transients. Time to Ca2+ transient peak, 50% decay, 
90% decay, and amplitude of fluorescence (F/F0) of NRVM cultured on flat membrane compared with 
micropatterned fibronectin lines (Mann-Whitney U). 
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4.3.2 Microgrooved polydimethylsiloxane tissue culture substrates 
4.3.2.1 Effect of grooved polydimethylsiloxane tissue culture substrates on neonatal rat 
ventricular myocyte structure 
 
 
 
Figure 4.5. Geometrical and structural characterization of micropatterned culture substrates. Bright field image of 
NRVM cultured on flat PDMS surface (Top Left); NRVM on flat surface stained with green Di-8-ANEPPS (Top 
Middle); Representative immunohistochemistry of NRVM on control surface,  Green - α-actinin, Blue – DAPI (Top 
Right). Bright field image of NRVM cultured on microgrooved scaffold (Bottom Left); NRVM stained with green Di-
8-ANEPPS cultured on 10µm microgrooves (Bottom Middle) ; Representative immunohistochemistry of NRVM 
cultured on 20µm microgrooves, Green - α-actinin, Blue – DAPI (Bottom Right) (With Acknowledgment to Patrizia 
Camelliti). 
 
NRVM seeded onto fibronectin coated PDMS formed a confluent spontaneously beating 
syncytial monolayer unlike NRVM aligned using micropatterned fibronectin lines (Section 
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4.3.1.1.) Cells within the microgrooves were longitudinally orientated (Figure 4.5).  Whilst 
there was a suggestion that sarcomeres and intercalated disks were better organized in 
structured cultures when visualized using TEM, we were not able to quantify this (Figure 
4.6), and overall no clear differences were found between the ultra-structural properties of 
structured and non-structured NRVM cultures. In particular, no evidence of t-tubule structure 
was seen in either the structured or the non-structured cultures stained with Di-8-ANEPPS 
(Figure 4.5) or visualized with SEM (Figure 4.7 and Figure 4.8), however given the highly 
irregular membrane (Figure 4.7 and Figure 4.8) and lack of sarcomeric organization even in 
the aligned cells this was probably not surprising (Figure 4.6). 
 
 
Figure 4.6. Representative TEM of NRVM grown on structured constructs (A) and non-structured constructs (B) 
highlighting improvement in organization of sarcomeric proteins and intercalated disks seen in the structured 
constructs.  
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Figure 4.7. SEM of NRVM cultured on non-structured PDMS tissue culture substrates. Cell membranes were 
irregular and no clear organized t-tubular structures were visible at higher magnification. 
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Figure 4.8. SEM of NRVM cultured on structured PDMS tissue culture substrates, showing alignment of cells in 
directed on substrate grooves (A and B). Cell membrane was very irregular and no clear organized t-tubular 
structures were seen on higher magnification despite improved sarcomeric organization (C and D). 
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NRVM were aligned in the direction of the PDMS grooves on both the 10µm (p<0.001 – 
Kurskal-Wallis, F=2.826 p<0.0001 – F-test) and 20µm (p<0.001 Kurskal-Wallis, F=2.115 
p<0.0001 – F-test) microgrooved constructs (Figure 4.9, Figure 4.10 and  
Figure 4.11), resulting in more anisotropic cultures.  
 
Cells that were seeded on top of the base layer of cells were still aligned in the direction of 
the grooves; however they were less strictly aligned than the cells which were directly in 
contact with the PDMS groves (Figure 4.9 and Figure 4.10).  
 
On those constructs in which the grooves were 20m in width the cells were less strictly 
aligned than in the constructs in which the grooves where 10m in width (F=1.336, p=0.0436 
– F-test). Unsurprisingly, on both the 20m and 10m constructs the NRVM were more 
aligned than on the non-structured constructs (Figure 4.11).  
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Figure 4.9. Immunohistochemistry Z-stack of NRVM cultured on 10µm microgrooves stained green for myosin heavy 
chain. Each slice is 1µm thick; the lowest slice is shown in the bottom right, the highest slice in the top left. Scale bar 
40µm. 
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Figure 4.10. Immunohistochemistry Z-stack of NRVM cultured on 20µm microgrooves stained green for myosin 
heavy chain. Each slice is 1µm thick; the lowest slice is shown in the bottom right, the highest slice in the top left. 
Scale bar 40µm. 
123 
 
 
Figure 4.11. Quantification of cell alignment of NRVM on microgrooved PDMS constructs. Immunohistochemistry 
DAPI images are converted into binary images (see representative examples top), alignment is quantified by 
measuring variation of the long-axis of each nucleus from the mean long-axis of all the nuclei. The graph on the left is 
a comparison in the variation in alignment (F-test), the graph on the right shows difference in average alignment 
(Kruskal-Wallis test with Dunn’s Multiple Comparison test). 
 
4.3.2.2 Effect of grooved polydimethylsiloxane tissue culture substrates on neonatal rat 
ventricular myocyte calcium cycling 
 
The TTP Ca
2+
 transient was significantly shorter in the 10µm groove constructs compared 
with non-structured constructs (p<0.001), as was the T50 (p<0.01) and T90 (p<0.01) when 
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the NRVM were paced at 1Hz. At 1Hz, the TTP was significantly shorter in the 20µm 
grooves (p<0.05), compared with the non-structured constructs, but there were no significant 
changes between the two groups in T50 or T90. At 0.5Hz the 10µm constructs also had 
shorter TTP and T50 than the non-structured constructs (p<0.01), whilst there was no 
difference between the 20µm constructs and the non-structured constructs. There were no 
significant changes in T90 between the three groups at 0.5Hz. Similar findings were seen 
when the cells beat spontaneously, with a shorter TTP, T50 and T90 in the 10µm group 
(p<0.05), despite no difference in the rate of spontaneous beating. There was no difference 
between the 20µm grooved constructs and the non-structured constructs (Figure 4.12 and 
Figure 4.13).  
 
The NRVM cultured on the 10µm appeared to have better Ca
2+
 cycling properties than the 
NRVM cultured on the 20µm constructs. Specifically the T50 was significantly reduced at 
1Hz, 0.5Hz and when beating spontaneously despite no difference in spontaneous beating 
rate (p<0.05). The T90 was also reduced at 1Hz and when beating spontaneously (p<0.05), 
however not significantly so at 0.5Hz (Figure 4.13). 
 
Interestingly, there was no difference between the three groups when paced at 2Hz. This was 
because the cells did not return to a baseline diastolic Ca
2+
 level when paced at this 
frequency, suggesting immature cytosolic Ca
2+
 extrusion mechanisms. The amplitude (F/F0) 
was not significantly different between the three groups. It was noted that as the stimulation 
rate increased, the amplitude decreased in all three experimental groups, suggesting that these 
cells had a negative force frequency relationship at these beating rates (Figure 4.13). 
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Figure 4.12. Representative Ca2+ transient from NRVM cultured on microgrooved tissue culture substrates with 
10µm grooves, 10µm apart (blue); on microgrooved tissue culture substrates with 20µm grooves, 20µm apart (red); 
and non-structured constructs (grey) recorded with confocal microscopy in cells loaded with the Ca2+ indicator Rhod-
2 AM and field stimulated at 0.5Hz. A Ca2+ transient recorded from an adult rat myocyte is shown for comparison 
(rust). 
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Figure 4.13. Effect of microgrooved tissue culture substrates on Ca2+ transients. TTP, T50, T90, and F/F0 of NRVM 
cultured on non-structured PDMS, 10µm and 20µm grooved constructs field-stimulated at 2Hz, 1Hz, 0.5Hz, and 
beating spontaneously (Kruskal-Wallis test with Dunn’s Multiple Comparison test). 
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4.4 Discussion 
 
The data presented in this chapter confirms that we can successfully fabricate a syncytial 
monolayer of beating cardiomyocytes on microgrooved PDMS culture substrates using 
NRVM. The NRVM cultured on microgrooved substrates were more strictly aligned in a 
longitudinal orientation than NRVM cultured on non-structured PDMS substrates (Figure 4.5 
and Figure 4.11). NRVM were also successfully aligned using micropatterned fibronectin 
lines, although there were no cells between lines, and consequently adjacent lines were not 
electromechanically coupled. Consequently structured constructs fabricated using 
micropatterning could not really be considered to be a single beating syncytium (Figure 4.1). 
NRVM are more strictly longitudinally aligned in micropatterned fibronectin lines than when 
cultured on microgrooved tissue culture substrates, and more strictly aligned on 10µm 
microgrooves than on 20µm microgrooves (Figure 4.2 and Figure 4.11).  The finding that 
structured tissue culture substrates promote alignment of NRVM is supported by several 
studies in the literature in which NRVM have been aligned in an anisotropic fashion using 
micro (Bien et al., 2003) and nanogrooved tissue culture substrates (Kim et al., 2010b), 
substrate stiffness (Wang et al., 2011b) and patterning of extracellular matrix components 
(Parker et al., 2008). All these methods appear to promote homogeneously aligned cells, with 
a major axis parallel to the direction of alignment (Bien et al., 2003, Kaji et al., 2003, Pong et 
al., 2011).  
 
It has been suggested that anisotropic focal adhesion complexes form parallel to the grooves 
(Wang et al., 2011b), and this, together with evidence of the strain exerted on the substrate at 
sub-cellular level (Boudou et al., 2012), implies that the load that the cells exert on 
themselves may be an important factor in the development of elongated cells with aligned 
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myofibrillar, cytoskeletal and sarcomeric structures. There is also evidence to suggest that 
nuclear morphology is also altered. Cell alignment with external stimuli appears to promote 
binucleation, and higher nuclear eccentricity such as in adult cardiomyocytes (Pong et al., 
2011, Bray et al., 2010). We did not find any evidence for an increase in binucleation; 
however, the nuclei in the structured group were more elliptical.    
 
There is an overall shortening of Ca
2+
 transients in NRVM cultured on 10µm microgrooves 
compared to control experiments, with shortening of both TTP and Ca
2+
 extrusion that was 
not observed in NRVM cultured on the 20µm microgrooves or the micropatterned fibronectin 
lines (Figure 4.4, Figure 4.3, Figure 4.12 and Figure 4.13). The finding that structured 
constructs with specific geometries, and not others, affect the speed of Ca
2+
 transients is 
supported by evidence from the literature which suggest that culture conditions alter the Ca
2+
 
handling properties of immature cardiomyocytes (Zimmermann et al., 2002). Structured 
substrates with specific geometry have been shown to reduce diastolic Ca
2+
 levels in several 
(Kaji et al., 2003, Feinberg et al., 2012, Pong et al., 2011) but not all studies (Bien et al., 
2003).  Microgrooved substrates in particular have been shown to elevate systolic Ca
2+
 (Bien 
et al., 2003). Cell elongation using aligned collagen constructs increases ICa and alters ICa 
regulatory properties (Walsh and Parks, 2002). NRVM cultured on structured constructs 
generally have faster TTP (Kaji et al., 2003, Feinberg et al., 2012, Pong et al., 2011), larger 
Ca
2+
 transient amplitude, and a trend towards faster Ca
2+
 removal (Yin et al., 2004, Bien et 
al., 2003, Pong et al., 2011). Many studies also report increased SR Ca
2+
 content (Yin et al., 
2004, Bien et al., 2003). The changes in Ca
2+
 handling reported with NRVM culture on 
microcontact printed constructs are particularly interesting (Pong et al., 2011). Not only do 
the authors of this study also report similar findings to our results, confirming that structured 
constructs improve Ca
2+
 cycling of NRVM, they also have similar findings on the differential 
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effects of substrate geometry (Pong et al., 2011). Our finding that 10µm microgrooves and 
not 20µm microgrooves modify the Ca
2+
 handling is supported by the findings of Pong et al 
who suggest that constructs with 10µm geometry more successfully modify the Ca
2+
 cycling 
properties of NRVM than constructs with 20µm geometry (Pong et al., 2011). 
 
The change in TTP in NRVM cells is likely to be because of alterations in SR Ca
2+
 
regulation, given the relative importance of SR Ca
2+
 to CICR in rats and mice (Shattock and 
Bers, 1989). Increased SR Ca
2+
 load has been shown to increase the rate of SR Ca
2+
 release 
(Terracciano et al., 1995, Venetucci et al., 2007). Alternatively, improved RyR function itself 
may also increase the TTP. We cannot, however, exclude the possibility that these changes 
are not due to changes in SR function and are due to the contribution of extracellular Ca
2+
, in 
particular Ca
2+ 
entry via the ICa, L, and further experiments are required to demonstrate that 
improvements in Ca
2+
 cycling are a consequence of improved SR function. 
 
The ability to shorten Ca
2+ 
extrusion at higher frequencies, as the consequence of a shorter 
AP and other adaptations of the excitation-contraction coupling machinery, are fundamental 
properties of mature myocardium (Carmeliet, 2004). This phenomenon was clearly enhanced 
in the NRVM cultured on the 10µm microgrooved tissue culture substrates. A reduction in 
SERCA function has been shown to reduce the rate constant of Ca
2+
 transient decay (Stokke 
et al., 2010). It would be expected that a change in SERCA function, improving reuptake into 
the SR, would alter decay time at 50%. As the reduction was also significant for the 90% 
decay time at most frequencies, other Ca
2+
 extrusion mechanisms such as the NCX, 
mitochondrial Ca
2+
 handling or the sarcolemmal Ca
2+
  ATPase may also be implicated.  
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Studies in animal models (Montgomery et al., 1998, Tobita and Keller, 2000b, Tobita and 
Keller, 2000a, Voronov et al., 2004) and cultured cells (Tulloch et al., 2011, Kira et al., 1994) 
suggest that mechanical load plays a crucial role in the development of heart tissue. It is 
thought that, once cardiac tissue becomes longitudinally oriented, they form bundles, which 
are electrically and mechanically coupled. This creates a substrate for homogenous load 
(Zimmermann et al., 2002). Several studies suggest that aligned cells generate greater force 
(Bien et al., 2003, Feinberg et al., 2012), and we hypothesize that the load that cells exert on 
themselves (Boudou et al., 2012) may have a role in promoting cellular maturation. 
Mechanical stretch is known to enhance contraction force and velocity, and the expression of 
sarcomeric proteins of neonatal rat cardiomyocytes (Fink et al., 2000). It is this factor which 
could explain the greater efficacy of the 10µm microgrooves compared to 20µm 
microgrooves and non-structured tissue culture substrates.  NRVM cultured on the 10µm 
microgrooves were more strictly aligned, perhaps resulting in more homogeneous load, and 
consequently a more mature phenotype. This does not really explain why improvements were 
not seen in the Ca
2+
 cycling of NRVM cultured in micropatterned fibronectin lines. In fact, 
many of the parameters were actually worse in the micropatterned cultures than in the control 
cultures, despite the NRVM in fibronectin lines being more strictly aligned than the NRVM 
on 10µm microgrooves (Figure 4.2, Figure 4.4 and Figure 4.11). Perhaps, the absence of cells 
between the lines prevents the formation of a single beating syncytium, and this may cause 
the NRVM cultured in this fashion to experience less longitudinal load or lack some of the 
other electro-mechanical cues that prompt cellular maturation. Despite the evidence showing 
an association between cellular alignment and improved Ca
2+
 cycling in NRVM it is not clear 
why this should occur. Cytoskeletal reorganization in response to external cues has 
previously been demonstrated in several studies (Bray et al., 2010, Geisse et al., 2009, Parker 
et al., 2008). It has been suggested that this occurs as a result of actin cytoskeletal 
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reorganization in response to mechanical load (Parker et al., 2008). It may be that this 
reorganization promotes better SR organization which influences Ca
2+
 cycling, or that Ca
2+
 
cycling is modified by independent mechanisms. Further research needs to be undertaken to 
elucidate this. Whilst it is theoretically possible that closer opposition of the L-type Ca
2+
 
channel and the RyR may improve the efficacy of CICR, it is debatable whether this could 
fully explain the observed differences in Ca
2+
 cycling. Furthermore, there is no evidence from 
the limited structural characterization that we undertook that cell alignment on the 10µm 
significantly improved ultrastructural properties of NRVM compared to NRVM cultured in 
other conditions.  
 
The mechanisms underlying the experimental results observed in this chapter clearly need to 
be better elucidated, and experiments will be performed in subsequent chapters with this aim 
(Chapter 5). The pilot data presented here, however, is evidence that we have successfully 
fabricated constructs to align immature cardiomyocytes, and optimized the culture of 
immature cardiomyocytes in these conditions. We also optimized the experimental conditions 
to examine the Ca
2+
 cycling of these cells, including the loading of Ca
2+ 
indicators and the 
use of confocal microscopy. The protocol described, using 10µm microgrooves represents a 
robust, reproducible and non-genetic strategy to improve the structure and function of 
immature cardiomyocytes. Moreover,  the tissue engineering approach that we have adopted 
may be more amenable to further interrogation of the physiological mechanisms that underlie 
changes in the functional properties of cells than existing “more sophisticated” approaches 
(Tiburcy et al., 2011, Tulloch et al., 2011, Taylor, 2009, Hansen et al., 2010). 
 
Whilst the finding that NRVM can be modified in this fashion is interesting, given the 
limitations of NRVM as a non-human disease model, the findings presented in this chapter 
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are only of secondary importance. More importantly, the experiments presented in this 
chapter are evidence that these techniques may be readily applied to iPSC-CM in our 
laboratory. It has not previously been demonstrated that the phenotype of iPSC-CM can be 
modified by structured culture. Consequently, the focus of the next chapter will be to 
demonstrate that the techniques characterized using NRVM can be applied to iPSC-CM. 
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5 Improved Calcium Cycling Properties of 
Induced Pluripotent Stem Cell-derived 
Cardiomyocytes Cultured on Structured 
Tissue Culture Constructs 
 
 134 
5.1 Introduction 
  
The data presented in Chapter 4.3.2, supported by the evidence form the literature (Kaji et al., 
2003, Feinberg et al., 2012, Yin et al., 2004, Kim et al., 2010b, Dvir et al., 2011, Boudou et 
al., 2012) suggest that the Ca
2+
 cycling properties of immature cardiomyocytes can be 
enhanced by applying tissue culture techniques which encourage structured culture. There is, 
however, no evidence that these techniques will be effective for iPSC-CM. 
 
Consequently, we aim to promote a matured phenotype in iPSC-CM using structured tissue 
culture substrates, and hypothesize that Ca
2+
 cycling of iPSC-CM is influenced by the 10µm 
microgrooved tissue culture substrates, described in Chapter 4.3.2 and Chapter 2.2.1.  Whilst 
the data presented in Chapter 4.3.2 represents very clear evidence that in NRVM structured 
tissue culture substrates of a particular geometry improve their global Ca
2+
 cycling properties, 
we did not elucidate any of the underlying mechanisms. Consequently, in addition to 
studying the effect of microgrooved tissue culture substrates on iPSC-CM Ca
2+
 cycling, we 
also aim to examine SR Ca
2+
 regulation, AP properties, immunohistochemistry and gene 
expression, to investigate the mechanisms by which structured culture substrates may modify 
Ca
2+
 cycling in iPSC-CM.  
 
5.2 Materials and methods 
 
Structured microgrooved culture substrates with 10µm grooves, 10µm apart were fabricated 
from PDMS, as described previously (Chapter 2.2.1). iCell Cardiomyocytes, a commercially 
available frozen iPSC-CM line were seeded and maintained according to manufactures 
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guidelines (Chapter 2.1.3). 1/3 million iPSC-CM, were seeded in each well in the 12 well-
plate. 1/6 million iPSC-CM were seeded in each well in the 24 well-pate (Chapter 2.2.1). As 
a consequence of the pilot data presented in Section 5.3.2.1, all subsequent experiments were 
performed 2 weeks following the recovery and seeding of iPSC-CM onto the PDMS 
constructs.  
 
Immunohistochemistry (Chapter 2.4.2), assessment of cell alignment (Chapter 2.4.2.2), gene 
expression analysis (Chapter 2.4.1), and recording of AP characteristics was performed as 
previously described (Chapter 2.3.2). 
 
iPSC-CM Ca
2+
 transients were recorded according to the optimized protocols previously 
described (Chapter 2.3.2 and Chapter 4.3.2). Addition experiments were performed to 
investigate SR Ca
2+
 release mechanisms using high concentration caffeine dissolved in NT or 
low Na
+
 and Ca
2+
 buffered solutions. Apart from the pilot experiments described in Section 
5.3.2.1, in which Rhod-2 AM was used, Fluo-4 AM was used in all subsequent Ca
2+
 studies. 
Rhod-2 AM fluoresces in the red spectrum, making it suboptimal for iCell cardiomyocytes 
which have an mRFP tag (Chapter 2.1.3) (Takahashi et al., 1999). Furthermore, Rhod-2 AM 
it is taken up and remains within intracellular organelles, in particular mitochondria, making 
it suboptimal for the measurement of cytosolic Ca
2+ 
(Takahashi et al., 1999). Finally, Fluo-4 
AM was adopted to better facilitate comparison with the large body of published literature in 
this area which have used this indicator.  
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5.3 Results 
5.3.1 Cell alignment and sarcomere structure  
 
 
Figure 5.1. Representative immunofluorescence of iPSC-CM cultured on non-structured PDMS (left) and 
microgrooved PDMS (right), Red– Sarcomeric α-actin, Blue– DAPI, scale bar 20µm. 
 
 
Figure 5.2. Quantification of cell alignment iPSC-CM on structured and non-structured constructs. The graph on the 
left is a comparison in the variation in alignment (F-test), the graph on the right shows difference in average 
alignment (Mann-Whitney U). 
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Microgrooved PDMS substrates significantly improved iPSC-CM alignment compared to the 
non-structured substrates (p<0.0001 – Mann Whitney U, SD of non-structured 50.11º n=115, 
Structured 35.60º n=596; F=1.982, p<0.0001 – F-test). This resulted in more organized 
sarcomeric structures as seen in the aligned α-actinin striation pattern of the myofibrils 
(Figure 5.1 and Figure 5.2). 
 
5.3.2 Calcium cycling 
5.3.2.1 Effect of time in culture on the calcium cycling of induced pluripotent stem cell-
derived cardiomyocytes 
 
iCell cardiomyocytes when defrosted do not spontaneously beat until approximately day two, 
and do not form beating syncytia until day 4-5. Therefore it was unsurprising to find that in 
pilot experiments to determine if there was any effect of microgrooves on the Ca
2+
 cycling of 
iPSC-CM, structured constructs were not found to have any benefit at one week. The TTP 
was significantly less in spontaneously beating iPSC-CM cultured on microgrooved tissue 
culture constructs (p=0.0251). At this time point, however, iPSC-CM in both groups had very 
slow Ca
2+
 transients (Figure 5.3 and Figure 5.4).  
 
 
 
Figure 5.3. Representative Ca2+ transients from spontaneously beating iPSC-CM, cultured on microgrooved PDMS 
substrates (blue) or non-structured PDMS substrates (grey) for 1 week. Recordings were made with confocal 
microscopy in cells loaded with the Ca2+ indicator Rhod-2 AM. A Ca2+ transient recorded from an adult rat myocyte 
is shown for comparison (rust). 
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Figure 5.4. TTP, T50, T50, F/F0 and beating rate of iPSC-CM beating spontaneously, cultured on non-structured 
PDMS and microgrooved constructs for 1 week (Mann-Whitney U). 
 
At two weeks, in spontaneously beating iPSC-CM cultured on microgrooved tissue culture 
substrates there was a significantly reduced TTP (p=0.0124), and larger amplitude of peak 
Ca
2+
 transient (P<0.0001). There was no significant difference in spontaneous beating rate 
(Figure 5.5 and Figure 5.6). All subsequent experiments with iPSC-CM were performed two 
weeks following recovery from liquid nitrogen freezing. 
 
Figure 5.5. Representative Ca2+ transients from spontaneously beating iPSC-CM, cultured on microgrooved PDMS 
substrates (blue) or non-structured PDMS substrates (grey) for 2 weeks. Recordings were made with confocal 
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microscopy in cells loaded with the Ca2+ indicator Rhod-2 AM. A Ca2+ transient recorded from an adult rat myocyte 
is shown for comparison (rust). 
 
 
Figure 5.6. TTP, T50, T90, F/F0 and beating rate of iPSC-CM beating spontaneously, cultured on non-structured 
PDMS and microgrooved constructs for 2 weeks (Mann-Whitney U). 
 
5.3.2.2 Effect of microgrooved constructs on calcium cycling in induced pluripotent 
stem cell-derived cardiomyocytes 
 
iPSC-CM cultured on structured substrates had a shorter TTP (p=0.0002), and T50 
(p=0.0065) when stimulated at 1Hz. There was no change in the T90. At 0.5Hz there was a 
shorter TTP (p=0.0073) but no changes in T50 or T90. Similarly while iPSC-CM were 
beating spontaneously, there was a reduced TTP (p=0.0012) in structured cells but no change 
in the T50 or T90. At 1Hz (p=0.0004) and 0.5Hz (p=0.0023) the amplitude was significantly 
reduced in the iPSC-CM cultured on microgrooved PDMS substrates, however not when 
beating spontaneously. There was no significant difference in the rate of spontaneous Ca
2+
 
transients (Structured: 11.67 beats per minute +/-1.495, n=18; Non-structured: 12.43 beats 
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per minute +/-1.432, n=37; p=0.8859). Similarly the proportion of iPSC-CM with 
spontaneous Ca
2+
 transients did not differ significantly between groups (Structured: 18/37 
(48.6%); Non-structured: 37/64 (57.8%); p=0.73) (Figure 5.7)  
 
Figure 5.7. TTP, T50, T90, F/F0 of iPSC-CM cultured on non-structured PDMS and microgrooved constructs field-
stimulated at 1Hz, 0.5Hz, and beating spontaneously (Mann-Whitney U). 
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Figure 5.8. TTP, T50, T90, and F/F0 of spontaneously beating and non-spontaneously beating iPSC-CM cultured on 
structured and control substrates field-stimulated at  0.5Hz (Mann-Whitney U). 
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iPSC-CM spontaneously beating on structured tissue culture substrates had significantly 
reduced TTP, T50 and T90 when field stimulated at 0.5Hz compared with cells without 
spontaneous activity in culture, however this difference was not seen in non-structured 
constructs (Figure 5.8).  
 
5.3.2.3 Contribution of the sarcoplasmic reticulum to changes in calcium cycling in 
induced pluripotent stem cell-derived cardiomyocyte cultured on microgrooved 
tissue culture substrates 
 
In order to investigate whether differences in TTP between structured and non-structured 
cells was due to differences in SR Ca
2+
 release, iPSC-CM were spritzed with solutions 
containing  high concentrations of caffeine, as previously described (Lee et al., 2011, Itzhaki 
et al., 2011b). A “synchronous” SR Ca2+ release, analogous to the response of an adult 
cardiomyocyte (Figure 5.9 A) and consisting of a single large transient, was elicited in 
response to caffeine-containing NT in 77% of the structured iPSC-CM (Figure 5.9 C and 
Figure 5.9 E). However, with iPSC-CM cultured on non-structured constructs we observed 
multiple peaks of the caffeine-transient indicating irregular, asynchronous release from the 
SR (p<0.0001) (Figure 5.9 D) analogous to the response observed in immature 
cardiomyocytes (NRVM) (Figure 5.9 B). The experiments were repeated in Na
+
 and Ca
2+
 free 
solution to exclude extracellular Ca
2+
 cycling by preventing Ca
2+
 extrusion via the NCX, or 
L-type Ca
2+
 current- mediated Ca
2+
 induced Ca
2+
 release. Again, “synchronous” SR Ca2+ 
release was observed in 70% of structured constructs but in only 21% of non-structured 
constructs (p<0.0001) suggesting that this effect was independent of sarcolemmal fluxes 
(Figure 5.9 F). Interestingly these changes occurred despite reduced SR Ca
2+ 
content, 
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assessed by the reduced F/F0 of caffeine-induced transient (Figure 5.9 G). It is important to 
note however that, as such quantification can only be undertaken when there is synchronous 
Ca
2+
 release from the SR, this only represents a fifth of the Ca
2+
 induced transients recorded 
from non-structured cells. 
 
Figure 5.9. Representative traces showing response to the application of 50mM caffeine solution of isolated adult rat 
ventricular cells illustrating “mature caffeine response“ (A), NRVM illustrating “immature caffeine response” (B), 
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iPSC-CM cultured on structured PDMS (C),  and iPSC-CM cultured on non-structured PDMS (D). Proportion of 
experiments that elicited an organized response to caffeine when cells were superfused in NT (Fisher's exact test) (E). 
Proportion of experiments that elicited an organized response to caffeine when cells were superfused in Na+ and Ca2+ 
free solution (Fisher's exact test) (F). Amplitude of caffeine induced Ca2+ transient when cells were superfused in Na+ 
and Ca2+ free solution (Mann-Whitney U) (G). 
 
5.3.3 Action potential duration 
 
There was no significant difference in the spontaneous AP rate in either group (p=0.16) 
(Figure 5.10). Both the uncorrected (p=0.8904) and Bazett’s corrected APD (p= 0.46) were 
not significantly different, however in both groups the rate-APD relationship was not well 
described by the Bazett’s formula (Figure 5.10).  
 
Figure 5.10. Spontaneous APD measured using sharp microelectrodes. Time to peak (A), time to 90% decay (B), and 
APD corrected for spontaneous beating rate (C) (Mann-Whitney U). Panels D and E suggest that Bazett’s correction 
(curved line) does not adequately describe the relationship between APD and beating rate. 
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5.3.4 Protein localization 
 
We did not find evidence that ultrastructural properties were affected by alignment of iPSC-
CM on microgrooved PDMS substrates. For example, Cx43 did not appear to be 
preferentially expressed along the short axis of aligned cells, as in adult cardiomyocytes, and 
RyR and PLN expression did not suggest that SR organization was improved in structured 
iPSC-CM (Figure 5.11, Figure 5.12, Figure 5.13, and Figure 5.14).  
 
Notably, the cells showed only week staining for RyR suggesting a low expression of the 
receptor, which is confirmed by qPCR (Section 5.3.5). Colocalization of RyR and Cav1.2 was 
increased in the structured group (Structured: Pearson’s coefficient (r) = 0.028, n = 6 images; 
Non-structured: r =-0.183, n = 4 images; p<0.001). However, this must be interpreted with 
caution given the minimal area colocalized in both groups (0.08% of all image pixels in the 
structured group compared to 0.24% in the non-structured group).  
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Figure 5.11. Immunohistochemistry of iPSC-CM cultured on non-structured PDMS, Red- PLN, Green– Cx-43, Blue– 
DAPI, scale bar 20µm.  
 147 
 
Figure 5.12. Immunohistochemistry of iPSC-CM cultured on non-structured PDMS, Red- Cav1.2 channel, Green– 
RyR, Blue– DAPI, scale bar 20µm. 
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Figure 5.13. Immunohistochemistry of iPSC-CM cultured on structured PDMS, Red- PLN, Green– Cx43, Blue– 
DAPI, scale bar 20µm. 
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Figure 5.14. Immunohistochemistry of iPSC-CM cultured on structured PDMS, Red- Cav1.2 channel, Green– RyR, 
Blue– DAPI, scale bar 20µm. 
 
5.3.5 Gene expression 
 
Gene expression was normalized according to expression of GAPDH. The use of alternative 
house-keeping genes for normalization, such as 18s ribosomal RNA, Cyclophilin G, and β-
actin did not significantly change the results obtained (Figure 5.15). 
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Figure 5.15. Comparison of IP3R, RyR and SERCA2a expression when normalized to GAPDH, 18s ribosomal RNA, 
Cyclophilin G, and β-actin, and expressed relative to adult heart tissue in iPSC-CM cultured on structured and non-
structured PDMS, fibroblasts, adult heart and foetal heart tissue (Kruskal-Wallis test with Dunn’s Multiple 
Comparison test). 
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Gene expression of early cardiac transcription factors and genes associated with pluripotency 
was higher in iPSC-CM than in adult and foetal tissue; however, there was no difference 
between structured and non-structured constructs (Figure 5.16).  
 
Figure 5.16. Comparison of genetic markers of differentiation (GATA4, NKX2.5, and ANF) when normalized to 
GAPDH and expressed relative to adult heart tissue in iPSC-CM cultured on structured and non-structured PDMS, 
fibroblasts, adult heart and foetal heart tissue (Kruskal-Wallis test with Dunn’s Multiple Comparison test). 
 
 
Figure 5.17. Comparison of expression of genes encoding ultrastructural proteins in cardiomyocytes (β-MHC, α-
MHC, MLC2V, cTNT, Kv4.3, CAV3) when normalized to GAPDH and expressed relative to adult heart tissue in 
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iPSC-CM cultured on structured and control substrates, fibroblasts, adult heart and foetal heart tissue (Kruskal-
Wallis test with Dunn’s Multiple Comparison test). 
 
 
Figure 5.18. Comparison of expression of genes encoding proteins important for Ca2+ cycling in cardiomyocytes 
(IP3R, RyR, SERCA2a, CASQ2, CALR, JPH2, PLN, Cav3.1, Cav1.2, NCX and TRDN) when normalized to GAPDH 
and expressed relative to adult heart tissue in iPSC-CM cultured on structured and control substrate, fibroblasts, 
adult heart and foetal heart tissue (Kruskal-Wallis test with Dunn’s Multiple Comparison test). 
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The expression patterns of genes encoding structural proteins such as alpha-myosin heavy 
chain (α-MHC), beta-myosin heavy chain (β-MHC), myosin light chain 2v (MLC2V), 
cardiac troponin T (cTNT), caveolin 3 (CAV3) (Figure 5.17) and those important for Ca
2+ 
cycling (inositol trisphosphate receptor (IP3R), RyR, SERCA2a, calsequestrin 2 (CASQ2), 
calreticulin (CALR), junctophilin 2 (JPH2), PLN, T-type Ca
2+
 channel (Cav3.1), L-type Ca
2+
 
channel (Cav1.2), NCX and triadin (TRDN)) (Figure 5.18) were similar in structured and 
non-structured iPSC-CM, and equally different from adult myocardium with gene expression 
levels generally close or below foetal heart controls. There was no significant difference in 
the expression of any gene in structured and non-structured iPSC-CM except triadin 
(p=0.0250).   
 
5.4 Discussion 
 
iPSC-CM cultured on microgrooved PDMS substrates adopted structural properties such as 
cellular alignment and sarcomeric organization which resembled adult cardiomyocytes 
(Section 5.3.1). At one week there was no benefit of structured tissue culture substrates on the 
Ca
2+
 handling properties of iPSC-CM, however at two weeks some of the changes observed 
in NRVM cultured on microgrooved PDMS (Chapter 4.3.2.2) were apparent in iPSC-CM 
(Section 5.3.2.1). This is probably because at one week iPSC-CM had not fully recovered 
from liquid nitrogen freezing, and had not yet formed beating syncytia. iPSC-CM cultured on 
microgrooved PDMS substrates for two weeks had shorter TTP and T50 when stimulated at 
1Hz. When stimulated at 0.5Hz, and when spontaneously beating, structured iPSC-CM also 
had a shorter TTP (Section 5.3.2.2). The spontaneous beating rate and APD was unchanged 
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between groups (Section 5.3.3), More organized SR Ca
2+
 release was elicited in response to 
caffeine in structured iPSC-CM (5.3.2.3).  
 
Patterning of iPSC-CM using structured PDMS substrates has previously been reported in the 
literature, however the structure and function of iPSC-CM was not characterized (Paik et al., 
2012). The finding that structured tissue culture substrates promote alignment of iPSC-CM 
and improve sarcomeric organization is consistent with our experiments with NRVM 
(Chapter 4.3.2) and is supported by several NRVM studies in the literature (Bien et al., 2003, 
Kim et al., 2010b, Wang et al., 2011b, Parker et al., 2008). Alignment of myofibrillar, 
cytoskeletal and sarcomeric structures is widely reported in the literature and is consistent 
with our findings in human iPSC-CM (Pong et al., 2011, Parker et al., 2008, Wang et al., 
2011b, Kim et al., 2010b). 
 
Several studies report that aligned NRVM express more Cx43 in clusters (Bien et al., 2003) 
localized in a bipolar fashion analogous to adult cells (McDevitt et al., 2003), and have higher 
conduction velocities in the longitudinal direction (Bien et al., 2003, Kim et al., 2010b). We 
did not find a marked difference in the distribution of Cx43 (Section 5.3.4). Whilst, we did 
not investigate conduction velocity anisotropy other investigators have subsequently found 
that iPSC-CM aligned using structured tissue culture substrates do have anisotropic 
conduction velocity (Wang et al., 2013). Furthermore, syncytia fabricated from iPSC-CM 
cultured on aligned tissue culture substrates were shown to have significantly fewer re-entry 
arrhythmias than control constructs (Wang et al., 2013). Like other groups who report the 
results of NRVM (Feinberg et al., 2012) and iPSC-CM experiments (Wang et al., 2013) we 
did not find a difference between the AP morphology of structured and non-structured cells. 
Whilst higher synchronous beating rates have been reported in anisotropic NRVM cultures 
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(Wang et al., 2011b) and increased maximum capture rate in response to electrical 
stimulation in structured NRVM culture have also been described (Feinberg et al., 2012), we 
did not find any statistically significant difference in the spontaneous beating rate of the 
structured and non-structured iPSC-CM cultures.  
 
The finding that structured tissue culture substrates significantly changed the Ca
2+
 cycling 
properties of iPSC-CM, reducing the TTP could be due to changes in entry of extracellular 
Ca
2+
 (ICa, L) and trigger for CICR. Immunohistochemistry suggests that Cav1.2 and RyR were 
poorly colocalized and the slight improvement in the structured cultures is unlikely to explain 
the faster TTP. Although expression of Cav1.2 was not significantly different between 
groups, it is possible that post translational modification may result in differential expression 
of Cav1.2 at the sarcolemma and extracellular Ca
2+
 influx may explain the faster TTP. 
Similarly, changes in intracellular Ca
2+
 buffering may also account for the changes in 
Ca
2+
 cycling induced by microgrooved PDMS substrates, however this is not supported by 
the gene expression data which suggest that the genes encoding calsequestrin and calreticulin 
were not differentially expressed (Figure 5.18).  
 
The difference between the responses of iPSC-CM to caffeine suggests that the observed 
differences may also be partly due to regulation of Ca
2+
 by the SR.  Ca
2+
 release from the SR 
is predominantly mediated by the RyR in adults, although in immature cardiomyocytes the 
IP3R plays a more significant role (Janowski et al., 2010). As IP3R mediated SR Ca
2+
 release 
is less efficient that RyR CICR mediated release (Kentish et al., 1990); a difference in the 
ratio of functional RyR and IP3R receptors, or difference in the absolute number of either 
receptor may explain our findings. This is supported by the morphology of the caffeine-
induced Ca
2+
 transients (Janowski et al., 2010) (Figure 5.9). The gene expression data 
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presented here does not suggest that there was a marked difference in IP3R, RyR, or the ratio 
of IP3R to RyR between the structured and non-structured group (Figure 5.18). Several post-
translational factors, however, could explain reduced RyR function including post 
translational modification in any of the components of the quaternary structure of the RyR 
(including calsequestrin, junction, triadin and the RyR itself), failure of the RyR quaternary 
structures to assemble, phosphorylation of the RyR, or other factors including SR Ca
2+
 
content (Terracciano et al., 1995, Lanner, 2012, Lanner et al., 2010, Van Petegem, 2012). 
Increased SR Ca
2+
 content is known to increase the open probability of the RyR, therefore SR 
Ca
2+
 content could explain these findings (Shannon et al., 2005). Whilst our data suggest that 
SR Ca
2+
 content was actually higher in the non-structured group, as most of the caffeine 
induced transients in the non-structured represented non-synchronous Ca
2+
 release and 
consequently could not be quantified, this data was from an extremely small and non-
representative sub-group of the non-structured iPSC-CM and must be interpreted with 
caution.  
 
The finding that triadin was more highly expressed in non-structured cells compared to 
structured cells is interesting as triadin overexpression has been shown to block excitation-
contraction coupling in myotubes and cardiomyocytes in the absence of extracellular Ca
2+ 
(Allen, 2009). However, the marginal raise in triadin, alone, is unlikely to explain the 
differences in Ca
2+
 cycling that we observed; firstly, despite being significantly raised in 
iPSC-CM cultured on non-structured tissue culture substrates it falls well below the levels 
seen in adult cardiomyocytes. Secondly, this small change would not be expected to reduce 
caffeine-induced Ca
2+ 
transients, and might reasonably be expected to improve the efficacy of 
CICR. Finally, it is unclear from the literature what effect a small increase in triadin would 
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have in the presence of extracellular Ca
2+
, especially given the multiple isoforms, all with 
potentially different functions (Allen, 2009, Marty et al., 2009).  
 
Whilst the role of structured tissue culture substrates has not previously been studied in iPSC-
CM, their effect on Ca
2+
 cycling has been studied in NRVM (Kaji et al., 2003, Feinberg et al., 
2012, Pong et al., 2011, Bien et al., 2003, Walsh and Parks, 2002).  In contrast to our findings 
several studies report an increase in the amplitude of Ca
2+
 transients (Yin et al., 2004, Bien et 
al., 2003, Pong et al., 2011), similarly many studies report increased SR Ca
2+
 content (Yin et 
al., 2004, Bien et al., 2003). Whilst our experiments did, like several studies, show faster Ca
2+
 
transient peak, in contrast to our own data (Chapter 4.3.2.2), and several other NRVM 
studies, we did not see any effect on Ca
2+
 extrusion (Kaji et al., 2003, Feinberg et al., 2012, 
Pong et al., 2011). The implication is that whilst Ca
2+
 release mechanisms from the SR have 
become more representative of adult myocardium, Ca
2+
 uptake mechanisms have not 
undergone a similar change. This is supported by the T50 and T90 which were not generally 
longer. The T50 at 1 Hz was reduced, but this result must be seen in the context of the 
markedly different properties between sub-populations of iPSC-CM, in particular between 
spontaneously beating and non-spontaneously beating cells which on structured constructs 
have significantly longer TTP, T50 and T90 (Figure 5.7).  
 
The effect of structured tissue culture substrates on cytosolic Ca
2+ 
extrusion is evident from 
our provisional experiments with NRVM (Chapter 4.3.2), which are concordant with the 
published literature showing reduced TTP, T50 and T90 at most frequencies. This effect is 
less evident at 2Hz where the Ca
2+
 extrusion was not sufficiently developed for it to return to 
baseline between transients (Chapter 4.3.2.2). The differences between our findings in human 
iPSC-CM and experimental data on NRVM may be due to differences in the maturity of 
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neonatal and “embryonic like” cells or due to interspecies differences. A critical difference in 
the physiology of rat and human cardiomyocytes is the relative contribution to normal Ca
2+
 
cycling of SR Ca
2+
 compared to extracellular in Ca
2+
 (Bers, 2001). We could not quantify the 
effect of structured tissue culture substrates on the ICa, L in either NRVM or iPSC-CM. 
However, if we assume that the primary effect of cell alignment is to improve SR function, 
which is entirely constant with the data that we present, then the relatively modest effect of 
structured PDMS substrates on iPSC-CM compared to NRVM could be explained. Donald 
Bers in his comprehensive review of all the literature exploring the relative contribution of 
extracellular and SR Ca
2+ 
to CICR suggests a hierarchy of SR Ca
2+
 dependence in several 
types of cardiomyocytes. The literature suggests that whilst NRVM are less dependent on SR 
Ca
2+
 than adult rat ventricular cells, they are more dependent on SR Ca
2+
 than adult human 
ventricular cells, and significantly more dependent on SR Ca
2+
 than human foetal cells (Bers, 
2001). As the effect of SR Ca
2+
 in normal Ca
2+
 cycling is more modest in human foetal 
cardiomyocytes compared to NRVM, perhaps maturation of SR function in human iPSC-CM 
will have a more modest effect than equivalent maturation of SR function in NRVM. 
 
Gene expression data did not show difference between structured and non-structured cultures. 
Even on microgrooved PDMS substrates iPSC-CM continue to express a globally immature 
phenotype. This suggests that other mechanisms which were not screened here or post 
translation modifications may be involved in the effects observed. An important caveat is that 
the summation of gene expression in all cells in a dish may not be representative of the gene 
expression of individual iPSC-CM in which Ca
2+
 were measured. Perhaps more sophisticated 
single-cell gene expression techniques should be employed to address this point (Buganim et 
al., 2012). It is telling that many of the studies employing iPSC-CM as disease models which 
have successfully demonstrated differences in gene expression have used single-cell gene 
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expression assays (Lan et al., 2013), and this may reflect the heterogeneity inherent in 
immature cardiomyocytes. 
 
As we discuss in Section 4.4, it is not clear from existing evidence in the literature whether 
ultrastructural reorganization influences Ca
2+
 handling or whether changes in Ca
2+
 handling 
are independent. Several studies suggest that aligned cells generate greater force (Bien et al., 
2003, Feinberg et al., 2012), and we hypothesized that the mechanical load that cells exert on 
themselves may have a role in promoting cellular maturation. This may be supported by our 
finding that iPSC-CM beating in culture on structured tissue culture substrates had 
significantly reduced TTP, T50 and T90, but cells beating on non-structured constructs did 
not. Spontaneously beating and non-spontaneously beating iPSC-CM were aligned on 
structured constructs; however, the fact that spontaneously beating iPSC-CM on structured 
constructs had reduced TTP, T50 and T90 suggests that load may be important.  Although 
spontaneously beating cells may have different physiological properties for other reasons 
(e.g. a different sub-population with different properties), the fact that spontaneously beating 
cells on non-structured constructs were not different from non-beating cells suggests that 
anisotropic load in particular may have an important effect on Ca
2+
 cycling (Figure 5.7). This 
is supported by the rapid changes in cardiomyocyte morphology, Ca
2+
 cycling, and 
electrophysiology following birth (Zhang et al., 2013, Novak et al., 2009, Mahmoud and 
Porrello, 2012, Bers, 2001), and evidence from experimental models in immature 
cardiomyocytes in which stretch has been shown to have a direct effect on Cx43 expression, 
cell coupling, ion channel activity, and APD (Jacot et al., 2010b, Tulloch et al., 2011, Fink et 
al., 2000, Gwak et al., 2008, Brown et al., 2008).  
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Several critical experiments would have significantly improved our understanding of the 
mechanisms that underlie the changes in Ca
2+
 cycling that we observed in this chapter and in 
Chapter 4. In particular, we did not investigate if anisotropic conduction velocity was present 
in the structured constructs, as described by other groups (Wang et al., 2013). AP 
measurements were undertaken using sharp electrode measurement in current clamp mode, a 
technique which has a number of limitations including inaccurate measurements of small 
changes in voltage because of the high resistance associated with the thin pipette tip and ionic 
leak associated with membrane tearing (Waters et al., 2005). The ICa,L, a critical component 
of CICR was not measured. Also, experiments were not undertaken to investigate our 
hypothesis that anisotropic self-loading of aligned cells was the critical determinant of the 
changes we observed. These experiments were not undertaken, despite being relatively 
simple, because of the technical problems associated with performing these experiments on 
cells cultured on the PDMS tissue culture substrates.  
 
As a consequence of the thickness of the constructs we were unable to visualize the target 
cells using an inverted microscope. This meant that standard patch clamp, optical mapping 
and even serial microscopy of live cultures were technically problematic. The thick PDMS 
substrate would also insulate the cells from the underlying electrodes if field potential 
recordings were attempted with an MEA system. Whilst some of these problems could be 
overcome by adapting experimental apparatus to image the cells using an upright microscope, 
the difficulty in fully evaluating the physiology of iPSC-CM cultured on structured tissue 
culture substrates limits the utility of microgrooved PDMS substrates. 
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5.4.1 Conclusion 
 
The data presented in this chapter, to the best of our knowledge, is the first demonstration, 
and at present the only demonstration in the literature, that structured tissue culture substrates 
affect Ca
2+
 cycling and structural properties in human iPSC-CM. This is an important first 
step in promoting a cellular phenotype in iPSC-CM that is more representative of adult 
myocardium. We did not investigate whether this may increase the utility of iPSC-CM as 
disease models; however other studies subsequently published suggest that this may be the 
case (Wang et al., 2013). Further construct development may be useful to facilitate 
investigation of the incremental value of structured constructs in myocardial disease 
modelling with iPSC-CM. Construct development may also make it easier to fully interrogate 
the complex interaction between structure, function and environment in developing 
cardiomyocytes.  
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6 The Effects of Further Development of Tissue 
Culture Constructs on the Calcium Cycling 
Properties of Immature Cardiomyocytes 
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6.1 Introduction 
 
The data presented in Chapter 5.3.2 confirms that culture conditions can be used to modify 
the Ca
2+
 cycling of iPSC-CM in order to promote a phenotype which is more representative 
of adult myocardium. Despite being readily reproducible and cost-effective, our results 
suggest that the utility of microgrooved tissue culture substrates may be limited. This is 
primarily for two reasons. Firstly, despite their simplicity many commonly used techniques in 
cell physiology are difficult to apply. The thickness of the constructs makes the use of MEA 
impossible. It is also highly problematic to image the constructs using an inverted 
microscope. Whilst live cell imaging, patch clamping, confocal microscopy and optical 
mapping can be performed by adapting experimental apparatus to use an upright microscope 
this is not without problems. As most objectives are required to be immersed in the culture 
medium, serial evaluation is difficult because of difficulties in maintaining sterility. Whilst 
these problems can be overcome, a construct that could be used with an inverted microscope 
would be more versatile. The second limitation of microgrooved tissue culture substrates for 
the maturation of iPSC-CM highlighted by the data presented in Chapter 5 is the relatively 
modest effect microgrooved substrates had on the maturity of the structural and functional 
phenotype of iPSC-CM. Whilst the demonstration that the phenotype of iPSC-CM can be 
modified using structured tissue culture substrates is an important first step, several 
publications have highlighted the striking effect that constructs which facilitate 3D cell-cell 
interaction can have on the phenotype of NRVM (Boudou et al., 2012, Eschenhagen et al., 
2002, Zimmermann et al., 2000). Recently, similar techniques have been shown to be also 
applicable to iPSC-CM (Christoforou et al., 2013).  
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The limitations with the microgrooved tissue culture substrates described in Chapter 5 
therefore suggest two distinct strands of research. Firstly a 2D tissue culture substrate that is 
compatible with the tools currently used in cell physiology which would allow investigation 
of the mechanisms that link structural organization and improved function to be more readily 
investigated. In particular it is important to determine exactly why Ca
2+
 cycling is improved 
in aligned cells. A tissue culture substrate on which high-throughput techniques could be 
readily applied would also facilitate investigation of the value of structured 2D tissue culture 
techniques in drug development and toxicology screening. The second strand of research 
suggested by the limitation of PDMS microgrooved constructs highlighted in Chapter 5 is the 
development of a construct which permits 3D cell-cell interaction but which can be readily 
fabricated and examined without specialist equipment or techniques. Such a construct may 
have a more profound effect on the phenotype of cultured cells than existing 2D tissue culture 
systems (Wang et al., 2011b, Yin et al., 2004, Bien et al., 2003, Kim et al., 2010b, Kaji et al., 
2003, Pong et al., 2011) whilst still being easier to interrogate than 3D tissue culture systems 
previously described in the literature (Boudou et al., 2012, Tulloch et al., 2011, Zimmermann 
et al., 2000, Eschenhagen et al., 2002). 
 
6.1.1 Two-dimensional Parylene-C constructs  
 
We determined to fabricate a novel 2D tissue culture substrate using Parylene-C. Parylene-C 
is widely used to coat implantable medical devices such as guide-wires, intra-arterial stents, 
implantable defibrillators and pacemakers (Khan et al., 2008, Loeb et al., 1977, Fontaine et 
al., 1996). It is insoluble at room temperature, has excellent barrier properties and is pinhole-
free above 100nm. It is biologically inert, inexpensive, and easily processed (Khan et al., 
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2008, Loeb et al., 1977, Fontaine et al., 1996, Tan and Craighead, 2010). Furthermore, its 
mechanical properties mean it can be used in flexible devices, for example, implantable-
flexible chemical sensing arrays (Zoumpoulidis et al., 2009), or pressure sensors for 
measuring intraocular pressure in glaucoma patients (Chen et al., 2008). These properties 
may make Parylene-C suitable as a thin tissue culture substrate, which would facilitate live-
cell microscopy, and in which electrical and chemical sensors can readily be integrated. It is 
theoretically possible that thin Parylene-C layers could be added to existing proprietorial 
MEA dishes. The flexible properties of Parylene-C may also potentially allow the application 
of continuous or cyclical mechanical strain to cultures, which has been shown to promote 
maturation of immature myocytes in some studies (Fink et al., 2000, Tulloch et al., 2011, 
Gwak et al., 2008). Parylene-C has already been used to fabricate thin films, that can be 
peeled off tissue culture substrates after seeding or protein coating to facilitate cell and 
protein patterning applications (Tan et al., 2010, Wright et al., 2008). However, as with other 
existing technology to micropattern cells on thin tissue culture substrates, or around 
embedded electrodes this technique is technically difficult and time-consuming (Michel et al., 
2002, Fan et al., 2008).  
 
Despite the ideal chemical and biological properties of Parylene-C, a major obstacle to its 
application as a tissue culture substrate is its hydrophobic surface properties. Several 
approaches have been adopted to modify its surface properties. In particular, several groups 
have sought to exploit the poor oxidative resistance of Parylene-C (~115 °C) (Fortin and Lu, 
2001), which mean that its surface properties can be readily altered using techniques such as 
controlled oxygen plasma exposure. Oxygen plasma treatment has been previously employed 
to effectively modify the surface properties of Parylene-C, in order to facilitate its use as a 
tissue culture substrate (Chang et al., 2007, Hoshino et al., 2012), and the surface properties 
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of Parylene-C have previously been successfully modified in order to fabricate neural cell 
cultures with specific patterns (Delivopoulos et al., 2010).  
 
6.1.2 Three-dimensional biomimetic tissue engineered constructs 
 
In order to investigate whether tissue culture constructs which facilitate 3D interaction 
between immature cardiomyocytes more effectively improve Ca
2+
 cycling of immature 
cardiomyocytes we used a synthetic PCL construct and decellularized myocardial tissue. As 
discussed in Chapter 1.7.1, synthetic polymers such as PCL have the theoretical advantage 
that their physical and chemical properties can easily be modified in order to mimic 
myocardial characteristics. Unfortunately, cellular interaction with synthetic materials is 
limited, and consequently substrates usually have to be coated in ECM components to 
promote cell adhesion (Li and Guan, 2011). Electrospinning was performed to fabricate a 
construct from PCL with a high surface-area to volume ratio, which mimics the fibrous 
architecture of ECM and promotes cell adhesion (Rockwood et al., 2008, Krupnick et al., 
2002, Zong et al., 2005, Ishii et al., 2005, Papadaki et al., 2001, Xing et al., 2012, Shin et al., 
2004) (Chapter 1.7.1). There is already evidence in the literature that electrospun 3D 
synthetic constructs, coated in ECM components can support NRVM in culture (Ishii et al., 
2005, Rockwood et al., 2008), often for long periods of time, and promote greater structural 
maturation than standard culture techniques (Papadaki et al., 2001, Zong et al., 2005, Xing et 
al., 2012). There is a paucity of evidence on what effect electrospun networks have on Ca
2+
 
cycling in NRVM compared to 2D tissue cultures. Consequently, in this chapter we aim to 
test the feasibility of using electrospun fiber networks for Ca
2+
 cycling studies and to test the 
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hypothesis that NRVM cultured in these networks will have enhanced Ca
2+
 cycling properties 
compared to NRVM cultured on 2D constructs. 
 
Since NRVM were used to recellularize a decellularized adult rat heart there has been 
increasing interest in using decellularized ECM as a tissue engineering scaffold (Ott et al., 
2008). Cells have been shown to infiltrate decellularized ECM and distribute evenly 
throughout the construct (Wang et al., 2010). Cells contract spontaneously and synchronously 
(Ott et al., 2008). Reseeded constructs generate more force comparable to that of artificial 
ECM constructs seeded with NRVM (Ott et al., 2008). Significantly, a decellularized mouse 
heart has recently been recellularized with iPSC (Lu et al., 2013). For these reasons 
decellularized ECM appear to be an ideal tissue culture substrate for disease modelling. The 
use of whole organ recellularized preparations, however, is expensive and has limited utility 
as a cellular disease model. For this reason we determined to investigate the efficacy of using 
thin recellularized myocardial tissue slices for Ca
2+ 
cycling studies. We aimed to investigate 
whether culture of immature cardiomyocytes in decellularized slices has a beneficial effect on 
their Ca
2+
 cycling, testing the hypothesis that NRVM cultured in decellularized myocardial 
tissue slices will have improve Ca
2+
 cycling properties compared to NRVM culture in 2D 
cultures. 
 
6.2 Materials and methods  
 
Two Parylene-C constructs were fabricated using oxygen plasma treatment as previously 
described (Trantidou et al., 2012) (Chapter 2.2.3). In summary, both constructs were 
fabricated from glass coverslips which were coated in Parylene-C films by chemical vapour 
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deposition. An HDMS contact mask was then spin-coated on to the Parylene-C-coated 
coverslips, followed by a 1.4μm thick positive photoresist. The samples were then exposed to 
UV light to remove the exposed photoresist. Oxygen plasma was then used to achieve 
selective hydrophobic patterning, with most of the Parylene-C was protected from the 
oxidative effects of the oxygen plasma by the contact masks. The geometry of the constructs 
(parallel lines 10µm wide and 10µm apart) was chosen as previous experiments (Chapter 
4.3.2.2) and other groups (Pong et al., 2011) had shown this geometry effectively altered the 
physiological properties of immature cardiomyocytes. After plasma treatment, the remaining 
photoresist was removed. Short exposure of the 7μm thick Parylene-C films to oxygen 
plasma at 50W for 1 min altered the surface properties of the polymer without significant 
etching or altering its geometry, resulting in alternating hydrophobic and hydrophilic areas 
(H/H construct). Exposure of the 1µm thick Parylene-C constructs at 400 W for 15 min 
resulted in the exposed areas of Parylene-C being completely removed. This resulted in 
alternating glass and Parylene-C areas (G/H Construct) and a construct with similar geometry 
in the case of the 4µm Parylene-C film to the previously described PDMS construct (Chapter 
2.2.1 and Chapters 4.3.2.2). 2 million NRVM were seeded on each construct.  
 
PCL constructs were fabricated as previously described (Chapter 2.2.4) (Zong et al., 2002, 
Jeun et al., 2005). Briefly, PCL granules were dissolved in chloroform and the solution was 
injected through a fine needle under pressure onto a collecting drum rotating at 3000 rpm. 
The resulting structure was formed from fibers 300-1100nm in diameter, 100-2000nm apart. 
The solvent was left to evaporate from the fabricated constructs. They were then washed 
several times to ensure all of the solvent was removed. The constructs were then stretched 
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over a Scaffdex ‘cell crown’. 2 million NRVM were seeded onto each construct after coating 
with fibronectin.  
 
Decellularized heart slices were produced as described in Chapter 2.2.5. In summary, 350µm 
thick tissue slices were cut from ventricular tissue with a high precision vibrating microtome 
in cold solution (Camelliti et al., 2011). Slices were decellularized by placing them on a 
shaker in 1% SDS at room temperature for 24 hours then washing with PBS before being left 
on a shaker, at room temperature for 4 hours in 1% Triton (Ott et al., 2008, Godier-
Furnemont et al., 2011). These slices were then washed with PBS and frozen until required. 
Once defrosted the constructs were then stretched over a Scaffdex ‘cell crown’. 1 million 
NRVM were seeded onto each construct (Camelliti et al., 2011).  
 
NRVM on both 3D and 2D constructs were loaded with Fluo-4AM and Ca
2+
 transients were 
recorded according to the optimized protocols previously described (Chapter 2.3.3, Chapter 
4.2, and Chapter 4.3). All experiments were performed at day 4 post-seeding. 
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Figure 6.1. Bright field images, scale bar 50μm (above) and immunohistochemistry (Green - Myosin heavy chain 
antibody, Blue – DAPI, scale bar 50μm) (below) images of NRVM cultured on non-structured hydrophilic (left), H/H 
(middle) and G/H Parylene-C constructs. 
 
6.3 Results 
6.3.1 Parylene-C constructs 
6.3.1.1 Effect of Parylene-C constructs with modified hydrophobicity on neonatal rat 
ventricular myocyte structure 
 
NRVM seeded onto non-structured glass or hydrophilic areas of the constructs were aligned 
in the direction of the construct (Figure 6.1). Consequently, NRVM cultured on both the H/H 
(p<0.001) and G/H (p<0.001) constructs showed greater anisotropy than NRVM cultured on 
non-structured hydrophilic substrates (Figure 6.2). G/H constructs were more strictly aligned 
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than H/H constructs (F=1.409, p=0.0034 – F-test). Both structured constructs were more 
strictly aligned than the non-structured controls (F=2.064, p<0.0001 – F-test, H/H) (F=2.907, 
p<0.0001 – F-test, G/H). 
 
Figure 6.2. Quantification of cell alignment of NRVM cultured on Parylene-C with altered surface chemistry 
following exposure to oxygen plasma. Alignment is quantified by measuring variation of the long-axis of each nucleus 
from the mean long-axis of all the nuclei. The graph on the left is a comparison in the variation in alignment (F-test), 
the graph on the right shows difference in average alignment (Kruskal-Wallis test with Dunn’s Multiple Comparison 
test).  
 
The constructs appeared to be robust and durable. Experiments were performed within one 
week of fabrication of the constructs, however NRVM seeded 4 weeks following fabrication 
of G/H and H/H were also strictly aligned in the direction of the construct (Figure 6.3). 
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Figure 6.3. Bright field images of NRVM on Parylene-C constructs at x10 (left) and x40 magnification (right). Images 
A and B show NRVM cultured on non-structured hydrophilic Parylene-C seeded 1 week after production. Images C 
and D show structured H/H constructs seeded with NRVM 1 week after production. Images E and F show structured 
H/H constructs seeded with NRVM 4 weeks after production, suggesting that modification of the surface properties 
of Parylene-C with oxygen plasma is durable. Images G and H show structured G/H constructs seeded with NRVM 1 
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week after production. Images I and J show structured G/H constructs seeded with NRVM 4 weeks after production, 
also suggesting that modification of the surface properties of Parylene-C with oxygen plasma is durable. 
 
6.3.1.2 Effect of Parylene-C constructs with modified hydrophobicity on neonatal rat 
ventricular myocyte calcium cycling 
 
At 0.5Hz, 1Hz and 2Hz field stimulation, the F/F0 of the Ca
2+
 transients were significantly 
larger in NRVM cultured on both the G/H and the H/H constructs when compared to NRVM 
on non-structured constructs (p<0.001 in all cases) (Figure 6.4 and Figure 6.5). There was no 
statistically significant difference in transient amplitude in NRVM cultured on H/H and G/H 
constructs at any frequency. TTP was significantly shorter in NRVM cultured on H/H 
constructs when compared to those cultured on non-structured (p<0.01) and G/H constructs 
(p<0.001) at 0.5Hz. Similarly TTP was significantly shorter in NRVM cultured on HH 
constructs compared to non-structured constructs at both 1Hz (p<0.05) and 2Hz (p<0.001) 
and compared to G/H constructs at both 1Hz (p<0.001) and 2Hz (p<0.001). The T90 was 
significantly less in NRVM cultured on the G/H constructs compared to non-structured 
controls at both 0.5Hz (p<0.001), 1Hz (p<0.001) and 2Hz (p<0.001). Similarly, the T90 was 
significantly less in NRVM cultured on the H/H constructs compared to non-structured 
controls at both 0.5Hz (p<0.001), 1Hz (p<0.05) and 2Hz (p<0.001). There was no difference 
between NRVM cultured on G/H and H/H constructs in T90 at any frequency. Interestingly 
although there was no difference in T50 between the three groups at 0.5Hz and 1Hz, both 
G/H (p<0.001) and H/H (p<0.001) had shorter T50s at 2Hz. There was no difference in T50 
between the two structured constructs at any frequency (Figure 6.4 and Figure 6.5).  
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Figure 6.4. Representative Ca2+ transients for NRVM beating at 0.5Hz, cultured on H/H Parylene-C substrates 
(orange), G/H Parylene-C substrates (yellow), or non-structured Parylene-C substrates (grey), for 4 days. Recordings 
were made with confocal microscopy in cells loaded with the Ca2+ indicator Fluo-4 AM. A Ca2+ transient recorded 
from an adult rat myocyte is shown for comparison (rust). 
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Figure 6.5. Effect of Parylene-C with altered surface chemistry following exposure to oxygen plasma on TTP, T50, 
T90, and F/F0 (Kruskal-Wallis test with Dunn’s Multiple Comparison test). 
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Figure 6.6. Amplitude-frequency and decay frequency of NRVM cultured on non-structured, H/H and G/H Parylene-
C constructs (Kruskal-Wallis test with Dunn’s Multiple Comparison test).  
 
NRVM cultured on none of the three constructs showed any obvious amplitude-frequency 
relationship or decay-frequency relationship, suggesting that whilst structured cultures on 
Parylene-C with altered surface chemistry did have improved Ca
2+
 cycling properties, the 
NRVM in the structured constructs did maintain an immature phenotype (Figure 6.6). 
 
6.3.2 Three-dimensional constructs 
6.3.2.1 The structure of neonatal rat ventricular myocytes cultured on three-
dimensional polycaprolactone constructs  
 
Evaluation of the structural characteristics of NRVM cultured on 3D PCL constructs was 
problematic because of the significant auto-fluorescence of the PCL fibers and a tendency of 
the monoclonal antibodies to adhere non-specifically to the PCL fibers (Figure 6.7). Despite 
their poor quality DAPI staining of sectioned constructs suggested that cells migrated 
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throughout the full depth of the construct (Figure 6.7). SEM suggested that cells became 
aligned in the direction of the PCL fibers (Figure 6.8). 
 
Figure 6.7. Immunohistochemistry of micro-patterned NRVM. Red - Myosin Heavy Chain, Blue – DAPI, Scale Bar 
100μm. There is significant autofluorescence from the PCL fibres, consequently it is difficult to discern the cell 
bodies. 
 
 
Figure 6.8. SEM of NRVM seeded onto 3D PCL constructs, showing cardiomyocytes aligned in the direction of the 
PCL fibers. The cells have not formed a confluent monolayer. 
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6.3.2.2 The structure of neonatal rat ventricular myocytes cultured on decellularized 
myocardial slices 
 
Figure 6.9. Second harmonic imaging microscopy showing a myocardial tissue slice. Green – autofluorescence from 
cardiomyocyte sarcomeric proteins. Purple – second harmonic signal from extracellular matrix collagen.  
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Figure 6.10. Second harmonic imaging microscopy showing decellularized myocardial tissue slice. Green – 
autofluorescence from cardiomyocyte sarcomeric proteins. Purple – second harmonic signal from extracellular 
matrix collagen. 
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Figure 6.11. Immunohistochemistry Z-stack of NRVM seeded onto a decellularized myocardial slice. Red – MHC, 
Green – α-SMA, Blue – DAPI. Each slice is 1µm thick. Scale Bar 100µm. 
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SHG was performed to characterize the structure of myocardial slices before and after 
decellularization (Figure 6.9 and Figure 6.10). It is apparent that whilst decellularization 
removed cellular membranes, quite a significant amount, if not most of the myocyte 
cytoskeletal proteins remained (Figure 6.9 and Figure 6.10). It was not possible to remove 
these proteins as prolongation of the decellularization protocol resulted in complete loss of 
structural integrity in the myocardial slices making it impossible to use them as tissue culture 
substrates as they could not be sterilized, manipulated, seeded or placed on Scafdex frames to 
perform experiments using the slices. 
 
The failure of decellularization protocols was confirmed by immunohistochemistry which 
suggest that sarcomeric proteins were not removed. As a consequence, whilst NRVM were 
successfully cultured on the decellularized myocardial slices, they did not infiltrate beyond 
the surface of the myocardial slice (Figure 6.11). Immunofluorescence demonstrated no 
obvious alignment of the NRVM on the decellularized slices (Figure 6.11 and Figure 6.12). 
 
 
Figure 6.12. Immunohistochemistry of NRVM seeded onto a decellularized myocardial slice. Green – α-SMA, Blue – 
DAPI. 
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6.3.2.3 Effect of three-dimensional cultures on neonatal rat ventricular myocyte 
calcium cycling 
 
The amplitude of Ca
2+
 transients were significantly increased in NRVM cultured on 
decellularized myocardial slices compared to non-structured PDMS when field stimulated at 
0.5Hz, 1Hz and 2Hz (p<0.001 in all cases). They were also significantly larger than the 
amplitude of Ca
2+
 transients in NRVM cultured in 3D PCL constructs at 0.5Hz (p<0.001), 
1Hz (p<0.001), and 2Hz (p<0.05). Although NRVM cultured in 3D PCL constructs had 
larger amplitudes than NRVM cultured in 2D at 2Hz (p<0.001), this was not significant at 
0.5Hz and 1Hz (Figure 6.14). The TTP of NRVM cultured on decellularized myocardial 
slices were significantly reduced compared to non-structured PDMS at 0.5Hz (p<0.001), 1Hz 
(p<0.01), however not 2Hz. Similarly the TTP of NRVM cultured on decellularized 
myocardial slices were significantly reduced compared to NRVM cultured in 3D PCL 
constructs at 0.5Hz, 1Hz, and 2Hz (p<0.001 in all cases. The T50 and T90 of NRVM cultured 
on decellularized myocardial slices were significantly reduced compared to NRVM cultured 
on non-structured PDMS at all frequencies (p<0.001 in all cases). The T50 of NRVM 
cultured on decellularized myocardial slices were significantly reduced compared to NRVM 
cultured in 3D PCL constructs at 0.5Hz (p<0.05), 1Hz (p<0.01), and 2Hz (p<0.001). 
Similarly, the T90 of NRVM cultured on decellularized myocardial slices were significantly 
reduced compared to NRVM cultured in 3D PCL constructs at 2Hz (p<0.001). The T50 of 
NRVM cultured in 3D PCL constructs were significantly reduced compared to NRVM 
cultured on non-structured PDMS at all frequencies, and the T90 was significantly reduced 
when field stimulated at 0.5Hz and 1Hz (p<0.001 in all cases) (Figure 6.14 and Figure 6.15). 
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Figure 6.13. Representative Ca2+ transients from NRVM beating at 0.5Hz, cultured in a PCL fiber network (purple), 
on decellularized myocardial slices (pink), or non-structured 2D PDMS substrates (grey), for 4 days. Recordings were 
made with confocal microscopy in cells loaded with the Ca2+ indicator Fluo-4 AM. A Ca2+ transient recorded from an 
adult rat myocyte is shown for comparison (rust). 
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Figure 6.14. Effect of 3D constructs on TTP, T50, T90 and F/F0 (Kruskal-Wallis test with Dunn’s Multiple 
Comparison test). 
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NRVM cultured on non-structured PDMS and 3D PCL constructs showed no change in Ca
2+
 
transient amplitude with increasing frequency of field stimulation. Interestingly, NRVM 
cultured on decellularized slices demonstrated a positive amplitude-frequency relationship 
(p<0.001) (Figure 6.15). NRVM cultured on non-structured PDMS, PCL constructs and 
decellularized slices showed no obvious T50 decay-frequency relationship (Figure 6.15). 
   
 
Figure 6.15. Amplitude-frequency and decay frequency of NRVM cultured on 3D constructs (Kruskal-Wallis test 
with Dunn’s Multiple Comparison test). 
 
6.4 Discussion 
6.4.1 Parylene-C constructs 
 
The data presented in this chapter suggests that plasma-treated Parylene-C constructs are 
durable, influence cell alignment and modify Ca
2+
 handling. Interestingly the effect of 
structured Parylene-C constructs on the Ca
2+
 cycling properties of NRVM was more marked 
than that of the microgrooved PDMS tissue culture substrates (Chapter 4.3.2.2), with the H/H 
construct in particular having comparable Ca
2+
 cycling parameters to rat adult 
cardiomyocytes at some frequencies (Figure 6.4 and Figure 6.5). Whilst this is impressive, in 
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some respects the Ca
2+
 cycling parameters of NRVM remained immature, for example 
lacking the characteristic negative amplitude-frequency relationship which is observed in 
adult rat myocytes (Shattock and Bers, 1989) ( 
Figure 6.6).  
 
The reasons why the H/H Parylene-C constructs should more effectively modify the 
phenotype of NRVM than microgrooved tissue culture substrates is unclear. There was not a 
marked difference in cellular alignment between the constructs (compare Figure 6.2 with 
Figure 4.5). Substrate stiffness has been shown to have a marked effect on cellular phenotype 
(Engler et al., 2006, Palchesko et al., 2012, Tzvetkova-Chevolleau et al., 2008, Chou et al., 
2009, Wang et al., 2011b, Shimazaki et al., 2008), and whilst it is possible that this could 
explain differences in the effectiveness of the H/H and the microgrooved tissue culture 
substrate this is unclear. If the observed differences were because of substrate stiffness it 
would be expected that the control group cultured on the Parylene-C construct would have 
better Ca
2+
 cycling properties than the control group cultured on non-structured PDMS. 
Comparison of the Ca
2+
 cycling properties of the control constructs in both experiments do 
appear to suggest that Ca
2+ 
cycling was faster on the Parylene-C constructs (compare Figure 
6.4 and Figure 6.5, with Figure 4.12 and Figure 4.13).  However, the G/H construct which 
will have comparable stiffness to the H/H construct (and did in fact enforce stricter alignment 
on the NRVM than the H/H construct) was not markedly more effective than the 
microgrooved construct in terms of amplitude and TTP (although Ca
2+
 extrusion was 
probably faster). As the H/H construct appears to be more effective than both the 
microgrooved G/H construct and the microgrooved PDMS construct perhaps the grooved 
substrate, whilst beneficial in promoting cellular alignment, is in other respects detrimental. It 
could for example result in the cells sitting in the groves having less exposed sarcolemma, 
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and therefore a reduced ICa,L and impaired CICR. Alternatively it may inhibit coupling of 
cells in the adjacent direction to the grooves. Ultimately measurement of the ICa,L, and 
conduction velocity would be required to resolving this question, both these measurements 
are feasible using the Parylene-C constructs. 
 
The strength of the plasma-treated Parylene-C constructs that we describe is that they have 
the possibility of being generated on MEA dishes potentially making them a tool for high-
throughput toxicology screening and drug development. It would then be easy to evaluate 
whether structured tissue culture substrates have an incremental benefit for these applications 
over existing non-structured cultures used in Chapter 3 (Section 3.2 and Section 3.3). Perhaps 
more interesting is the possibility that MEA technology in conjunction with other tools of cell 
physiology such as patch clamping and optical mapping can now be applied to these 
constructs to elucidate the mechanisms by which structure modifies the function of immature 
cardiomyocytes. Not only is this important in understanding myocardial development 
prenatally and in early life, this may have a role in understanding myocardial pathological 
mechanisms and possible mechanisms implicated in recovery. The loss of structure in the 
failing myocardium is a well-documented phenomenon (Spinale et al., 2013, Goldsmith et al., 
2013), and there is evidence that adult myocytes have phenotypic plasticity (Ibrahim et al., 
2012, Mann et al., 2012). Finally, whilst some studies have been successful in recapitulating 
aspects of the molecular phenotype associated with inherited cardiomyopathies (Carvajal-
Vergara et al., 2010, Lan et al., 2013, Sun et al., 2012, Tse et al., 2013, Hick et al., 2013, 
Dick et al., 2013), many such studies have failed to demonstrate physiological changes 
associated with the molecular phenotype at a cellular level (Dick et al., 2013, Hick et al., 
2013). This has worrying implications for the application of iPSC-CM as disease models. 
Pathological mechanisms elucidated and novel therapies suggested in the absence of a 
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cellular phenotype may be irrelevant when patients eventually become symptomatic. It is 
important to note that patients in NYHA Class I failure are asymptomatic (New York Heart 
Association. Criteria Committee. and New York Heart Association., 1979) despite having a 
clear physiological phenotype (Rostagno et al., 2000). The substrate that we have developed 
theoretically represents a good balance between a construct that promotes maturity, but also 
one in which physiological mechanisms can be comprehensively interrogated. Therefore, it 
would be interesting to investigate whether differences in cell physiology could be elucidated 
in diseases such as DMD using iPSC-CM where only a molecular phenotype has previously 
been described (Dick et al., 2013).  
 
The H/H construct theoretically has the possibility to be used in stretch-induced maturation 
systems. Uniaxial stretch improves cardiomyocyte organization, increases cell length, 
increases density and length of myofilaments, increases mitochondrial density and increases 
contractile force (Fink et al., 2000, Tulloch et al., 2011). It is feasible that the addition of 
mechanical stimulation to the structural alignment seen in the H/H constructs would have an 
incremental benefit on cell maturity. Undoubtedly this would add a degree of complexity that 
would have to be justified by the incremental utility of this system. Uniaxial stretch has been 
combined with structured tissue culture substrates in order to fabricate models of mechanical 
overload (McCain et al., 2013). This study showed that cellular structure and function were 
adversely affected by cyclical stretch. They did not, however, investigate if reduced load in 
combination with structured tissue culture substrates would have a beneficial effect on 
cellular phenotype (McCain et al., 2013). 
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6.4.2 Three-dimensional constructs 
6.4.2.1 Fabrication of electrospun constructs 
 
The evaluation of the structural properties of NRVM cultured in the 3D PCL construct was 
problematic, because of the auto-fluorescence of PCL and the tendency of antibodies to 
adhere to it. Although not explicitly discussed this appears to be a problem in other studies 
describing PCL constructs in the literature based on the representative images that they report 
(Fleischer et al., 2013). Immunofluorescence, however, suggests that cells were distributed 
throughout the construct. SEM culture of the PCL constructs suggested that NRVM were 
aligned in the direction in the fibers. Despite the significant number of NRVM seeded (PCL 
constructs were seeded at double the density compared to myocardial slices, and four times 
the density of the non-structured 2D PDMS controls), the PCL constructs were not densely 
populated with NRVM to the extent that formation of a single beating syncytium would be 
unlikely (Figure 6.7 and Figure 6.8).   
 
There was significant variability in the density with which electrospun constructs were 
seeded. Whilst in some studies the seeding density was significantly greater than in our 
experiments (Xing et al., 2012), in others however it was significantly less (Zong et al., 2005, 
Fleischer et al., 2013). Despite efforts to increase the seeding density until a confluent 
syncytium was fabricated, the use of more cells of any type (including NRVM) would not be 
cost-effective. 
 
It is possible that a significant number of cells was lost through the construct, and whilst 
some constructs had reduced porosity (Zong et al., 2005), this was not the case when 
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comparing our constructs to electrospun constructs described in the literature (Xing et al., 
2012, Papadaki et al., 2001). It is interesting, however that the constructs where fewest cells 
were used had the lowest porosity (Zong et al., 2005). Further development of PCL 
constructs is probably required to ensure that fibers are smaller and closer together to 
recapitulate the structure of endogenous myocardium (Stevens and George, 2005). Whether 
this can be achieved using these fabrication techniques without critically compromising the 
mechanical properties of the substrate or fabricating a very thick construct is uncertain. 
 
6.4.2.2 Decellularized myocardial slices as scaffold. 
 
Myocardial slices were only partially decellularized. Consequently NRVM did not penetrate 
throughout the construct, but formed a beating syncytium on the surface of the myocardial 
slice. NRVM seeded onto the myocardial slices did not appear to adopt any aspects of the 
structure of the underlying myocardium (Figure 6.11 and Figure 6.12).  
 
There are several examples in the literature where tissue has been decellularized prior to re-
seeding (Lu et al., 2013), however we were not able to successfully apply this technique to 
myocardial slices. Attempts were made to optimize the protocol, but this resulted in a non-
structured gel. A critical difference between reports in the literature and the techniques that 
we adopted are that many of the studies in the literature perfused the tissue through a vascular 
arcade (Lu et al., 2013, Song and Ott, 2011). Perhaps this facilitates better delivery of 
decellularizing detergents in a homogenous fashion throughout the tissue. By contrast 
exposing myocardial slices to these agents in a shaker may result in sub-optimal delivery to 
the centre of the tissue, whilst the outside including extracellular matrix components are 
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completely degraded. Other investigators have successfully decellularized myocardial slices, 
however they are usually much thicker, and thus maintain their structural integrity despite 
being decellularized (Wang et al., 2010). 
 
6.4.2.3 Functional properties of three dimensional constructs 
 
The Ca
2+
 cycling properties of NRVM cultured on the partially decellularized slices were 
undoubtedly modified compared to the NRVM cultured on the control constructs. At most 
frequencies the TTP, T50 and T90 were faster compared to the controls and the F/F0 was 
larger. Whilst the NRVM cultured in the PCL fibers generally had shorter T50 and T90 than 
control NRVM, there was difference in the F/F0 and the TTP at 0.5Hz and 1Hz. At 2Hz 
NRVM in the PCL constructs had a significantly larger F/F0 but longer TTP (Figure 6.13 and 
Figure 6.14).  None of the constructs had a mature decay-frequency or amplitude-frequency 
relationships. 
 
NRVM cultured on decellularized slices had the Ca
2+
 handling properties most representative 
of adult myocardium. As is often the case with complex culture systems the factors 
underlying this change in phenotype are probably multi-factorial. The degree to which any of 
these constructs facilitate 3D cell-cell interaction is debatable with the small cell density in 
the PCL constructs and the NRVM essentially seeded on the surface of the myocardial slices. 
Consequently, the critical differences between the three constructs are the substrate stiffness 
and the ECM the NRVM were exposed to. Although the failure to fabricate a 3D PCL 
construct fully populated with cardiomyocytes is disappointing, it was important to 
demonstrate the feasibility and ease with which Ca
2+
 cycling studies can be performed using 
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PCL given the paucity of reports in the literature of functional characterization of 
cardiomyocytes cultured in these constructs. 
 
Substrate stiffness has been shown to alter cardiomyocyte maturation (Forte et al., 2012) 
(Jacot et al., 2010a). Culture on stiff substrates disrupts the contractile apparatus (Jacot et al., 
2010a). Cardiomyocytes cultured on softer substrates are more elongated, have a predictable 
connexin-43 distribution and increased expression of cell adhesion and ECM remodelling 
genes (Forte et al., 2012). When cardiomyocytes have been cultured on substrates mimicking 
the stiffness of the myocardium they have better aligned sarcomeres and generate more force 
(Forte et al., 2012). The design of our experiments was not really optimal to test the effect of 
substrate stiffness in a controlled fashion. This is probably most easily done using 2D 
constructs with varying stiffness (Palchesko et al., 2012), however spiral electrospun PCL 
have recently been described that could be adopted for this purpose (Fleischer et al., 2013). It 
is possible that the improved phenotype of NRVM cultured on the partially decellularized 
slices compared to PCL substrates and the flat PDMS substrates could at least in part be 
attributed to the substrate stiffness. Studies which suggest that modification of PCL substrates 
to reduce their stiffness may have a beneficial effect on cellular phenotype partially support 
this hypothesis (Fleischer et al., 2013). 
 
ECM protein signaling is known to influence the function of cultured cardiomyocytes. All the 
PCL and PDMS constructs were coated with fibronectin before seeding. The NRVM seeded 
on the PCL constructs were, however, probably not exposed to endogenous myocardial ECM 
proteins to the same extent that NRVM cultured on the myocardial slices were. Laminin and 
collagen proteins in hydrogel preparations increase cardiomyocyte cell adhesion, cell 
spreading, maturity of the contractile apparatus and SERCA expression (LaNasa and Bryant, 
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2009). An increase in ECM content of hydrogel has been shown to increase the 
differentiation of cardiomyocytes when compared to hydrogel with low ECM content or 
collagen alone (Duan et al., 2011). High ECM content also increased cardiac striations, up-
regulation of connnexin-43 expression and improved contractile function. As these studies 
suggest that many endogenous ECM proteins have a positive effect on the cellular phenotype 
of NRVM, it would be reasonable to assume that a partially decellularized native ECM may 
have a positive effect on the Ca
2+
 handling properties of cultured NRVM. Future studies will 
aim to characterize the ECM components of the partially decellularized slices, and their 
effects on cell structure and function. 
 
In contrast with the previous experiments where alignment has been the predominant factor 
in modifying the phenotype of immature cardiomyocytes, these experiments demonstrate that 
ECM proteins and substrate mechanical properties are also significant, however unlike the 
results presented in Section 6.3.1 further work is required to quantify these effects before they 
can be applied to myocardial disease modelling, and experiments need to be designed which 
will specifically investigate the mechanisms underlying the observed changes in Ca
2+
 cycling 
properties. It may even be possible to apply substrate stiffness and ECM after further 
characterization to aligned constructs in order to incrementally enhance the phenotype of 
immature cardiomyocytes.  
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7 Discussion 
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7.1 “All models are wrong, but some are useful.” 
 
The words of the great statistician George Edward Pelham Box are very resonant in every 
branch of science. His advice that, “….the practical question is how wrong do they [models] 
have to be to not be useful?” underlies the interpretation of almost every scientific 
experiment, study, or body of literature (Box and Draper, 1987).  
 
When this work was started three years ago there was significant interest in utilizing iPSC-
CM as human, patient-specific disease models. Several instances were subsequently 
published in which cellular disease phenotypes were replicated using iPSC-CM (Chapter 
1.6.1 and Chapter 1.6.2). In some studies novel disease mechanisms were elucidated and 
novel therapies suggested (Chapter 1.6.1 and Chapter 1.6.2).  The other major application that 
was suggested was the use of iPSC-CM as a high throughput drug development or toxicology 
screening tools. It is with these applications in mind that we undertook a focused comparative 
characterization of iPSC-CM with respect to hESC-CM and established disease models.  
 
Even the much focused characterization undertaken in Chapter 3 demonstrates that with 
respect to the function of K
+
 channels and pacemaker mechanisms these cells exhibit an 
immature and heterogeneous phenotype.  The immature heterogeneous phenotype of iPSC-
CM is now widely accepted in the literature. Several studies, however, have demonstrated 
that, despite this phenotype, it is feasible to use iPSC-CM as toxicology screening tools 
(Harris et al., 2013, Liang et al., 2013, Braam et al., 2013). The heterogeneous phenotype of 
iPSC-CM was controlled in one study by classifying cells according to their APD and 
performing single-cell studies (Liang et al., 2013), other studies have controlled for this 
heterogeneity by using a highly purified population of commercially differentiated cells 
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(Harris et al., 2013). Despite their immature phenotype, however, iPSC-CM have already 
arguably yielded insights into the mechanisms underlying hypertrophic cardiomyopathy (Lan 
et al., 2013), and have been used to suggest novel therapy for cardiac arrhythmias (Matsa et 
al., 2011).   
 
Does then in vitro modelling with iPSC-CM pass the “Box” test? Are iPSC-CM a useful tool 
despite the limitations that make them unrepresentative of adult myocardium in many 
respects? The answer is a cautious and qualified yes; iPSC-CM are a useful addition to the 
toolbox of scientific techniques that can be used to investigate the mechanisms underlying 
cardiovascular disease and therapies. Their immature, heterogeneous phenotype means that in 
many instances they are not representative of adult myocardium. However, as the multitude 
of experimental studies which show their feasibility as disease models or toxicology 
screening tools demonstrate these problems can be overcome. As a consequence of the 
limitations of in vitro iPSC-CM modelling, experimental results need to be triangulated with 
data from other cellular and animal models.  In this respect however, iPSC-CM are no 
different from many of the most widely used tools in cardiovascular research, such as 
transgenic rodent models which also need to be triangulated with human or large-animal data.  
 
7.2 Structured Tissue Culture Constructs 
 
Whilst iPSC-CM are unquestionably useful tools in cardiovascular research there is still 
scope to further improve their utility. In several instances only a limited cellular phenotype or 
none at all has been elucidated using iPSC-CM derived from patients with inherited 
cardiomyopathies (Hick et al., 2013, Dick et al., 2013). The single-cell genetic (Lan et al., 
2013) and electrophysiological assays (Liang et al., 2013) used to control for the 
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heterogeneous immature phenotype of iPSC-CM are arguably time consuming and poorly 
suited for high-throughput screening. Furthermore, there may also be some circumstances 
when iPSC-CM cannot be used to model myocardial disease because of differences between 
the structure of iPSC-CM cultures and adult myocardium (Wang et al., 2013). 
 
These limitations with iPSC-CM, which stem from their immature heterogeneous phenotype, 
became evident to us during the experiments that we describe in Chapter 3. Consequently, we 
embarked on experiments to modify the phenotype of iPSC-CM. After validation of the 
methodology required to align immature cardiomyocytes in Chapter 4, we demonstrated in 
Chapter 5 that the phenotype of iPSC-CM could be modified using structured PDMS tissue 
culture substrates. In particular the speed of Ca
2+
 cycling was modulated by cellular 
alignment. Experiments to characterize the mechanisms underlying these changes suggest 
that the modulation of SR function may be an important consequence of structured tissue 
culture.  The finding that the cellular phenotype of iPSC-CM was modulated using structured 
culture was a novel finding in the literature (Rao et al., 2012). Other investigators have 
subsequently shown that different aspects of the cellular phenotype are also be modulated in 
structured iPSC-CM cultures (Wang et al., 2013).   
 
Interestingly, we also found that the response of NRVM and iPSC-CM to structured culture 
differed. The different response of NRVM and iPSC-CM to culture on structured tissue 
culture substrates highlights firstly, the necessity for a human myocardial cellular model. 
Secondly, it represents a note of caution in how the large body of literature on tissue 
engineering using NRVM should be interpreted.  There are a paucity of studies in the 
literature which directly compare iPSC-CM and NRVM for tissue engineering applications, 
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and the different response of NRVM and iPSC-CM Ca
2+
 cycling to structured culture  is to 
our knowledge a novel finding in the literature (Rao et al., 2012).   
 
7.3 Development of Tissue Engineering Constructs and Suggestions for 
Further Work 
 
A limitation of PDMS tissue culture substrates was the difficulty of investigating the cellular 
phenotype of cultured iPSC-CM to the extent that the mechanisms causing changes in Ca
2+
 
cycling in iPSC-CM could not be interrogated to our satisfaction using the techniques 
available to us. This was the catalyst to develop a novel Parylene-C construct that could be 
fabricated on commercially available MEA dishes or glass coverslips suitable for optical 
mapping and cell electrophysiology using an inverted microscope. It was also hoped that such 
Parylene-C constructs would be suitable for experiments in which uniaxial stretch could be 
combined with cell-alignment.    
 
We were also interested to develop a construct that would be suitable for optical mapping and 
MEA analysis that would also facilitate 3D cell-cell interaction. Consequently, in addition to 
electrospun 3D PCL constructs, two novel tissue engineering constructs were characterized in 
Chapter 6. The data presented in Chapter 6 demonstrates that Parylene-C tissue culture 
substrate successfully aligned immature myocytes and effectively modulated their Ca
2+ 
cycling properties. Neither of the 3D constructs were suitable for assessment of whether 3D 
cell interaction had an effect on function. This was because the NRVM cultured in the PCL 
constructs did not form a syncytium and we were unable fully decellularize the tissue slices, 
and consequently the NRVM were cultured as a monolayer on the surface.  
 202 
 
An obvious next step would be to use the novel Parylene-C constructs described in Chapter 6 
with both NRVM and iPSC-CM to explore both the mechanisms underlying modulation of 
cellular phenotype caused by cell alignment, and the mechanisms underlying differences in 
the response of iPSC-CM and NRVM to structured tissue culture.  
 
It has recently been shown that structured iPSC-CM cultures possibly have a role in 
modelling re-entry arrhythmias (Wang et al., 2013). A critical next step, however, will be to 
demonstrate that tissue engineering approaches, such as the ones we describe in Chapters 4-6, 
have a wider role in myocardial in vitro modelling. In particular it would be interesting to 
investigate if structured culture results in the demonstration of a cellular phenotype in 
pathological iPSC-CM cell lines in which no clear cellular phenotype has previously been 
demonstrated (Hick et al., 2013, Dick et al., 2013). It would also be interesting to investigate 
if structured culture improves the utility of multi-cellular toxicology screening assays. 
 
It is not clear whether the 3D constructs that we attempted to optimize in Chapter 6 will ever 
realize their theoretical potential. They are not currently suitable for fabrication without 
specialist skills and knowledge. It is important that tissue engineering systems continue to be 
developed and optimized which promote the degree to which iPSC-CM are representative of 
adult myocardium, whilst also allowing the cellular function of cultured cells to be readily 
interrogated. Ultimately the techniques for fabrication of 3D constructs that we describe in 
Chapter 6 may not be the most effective way to achieve this and it is possible that they may 
be superseded by more sophisticated multi-modal tissue engineering approaches that combine 
electrical, mechanical and structural cues with integrated mechanisms for electromechanical 
interrogation (Rao et al., 2013, Boudou et al., 2012). 
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Finally, it can be anticipated that experimental results from in vitro disease modelling using 
iPSC-CM will be increasingly applied to clinical problems. As tissue engineering approaches 
become increasingly sophisticated, and more widely applied to disease modelling, it is 
important to establish fabrication standards to ensure robust and reproducible experimental 
results (Nawroth and Parker, 2013). It may also be useful, in the context of the rapid 
proliferation of tissue engineering approaches for industry, bio-medical and engineering 
stakeholders to discuss consensus guidance on critical cellular assays that tissue engineering 
approaches must facilitate.    
 
7.4 Conclusions 
 
In this thesis we highlight the limitations of iPSC-CM and hESC-CM as in vitro disease 
models. This work suggests that existing efforts to modify the phenotype of NRVM by 
systematic modification of culture conditions using tissue engineering approaches are likely 
to be relevant to in vitro modelling with iPSC-CM. This work also suggests that the effect 
that these techniques will have on iPSC-CM may differ subtly from NRVM experimental 
results. An important next step will be to demonstrate that these techniques improve the 
efficacy of iPSC-CM for myocardial disease modelling. Finally, tissue engineering 
techniques must continue to be developed that increase the degree to which iPSC-CM are 
representative of adult myocardium, whilst also allowing the cellular phenotype to be readily 
interrogated. 
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Appendices 
Appendix A - Fabrication of structured silicone culture substrates 
 
Structured flexible microgrooved silicone culture substrates were fabricated using PDMS, a 
biologically inert non-toxic silicon-based organic polymer (McDonald and Whitesides, 
2002). PDMS is used extensively in contact lenses, medical devices, cosmetics, foods, and is 
often used as scaffold material for tissue engineering as its mechanical properties can be 
manipulated to resemble physiological values of human tissue. This is important as substrate 
elasticity has been shown to affect cellular functions such as adhesion, proliferation, 
migration and gene expression (Brown et al., 2005, Gray et al., 2003, Forte et al., 2012).  
 
Micro-grooved PDMS scaffolds were produced using standard photolithography rules, as 
previously described (Figure A.1) (Isenberg et al., 2008). Briefly, these were generated by 
spinning SU-8, an epoxy-based negative photoresist polymer onto monocrystalline silicon 
wafers. The photoresist was then exposed to ultraviolet (UV) light (365nm) through a 
patterned high-resolution transparency glass mask containing areas with parallel grooves. 
They were then developed using 100% ethyl lactate. The result was SU-8 moulds with 22 
patterned circular areas 14mm in diameter, with parallel lines etched into them. The SU-8 
moulds contained four different patterned areas. Two patterned areas consisted of grooves 
20µm apart, 20µm wide and either 3.75µm or 4.5µm deep. Similarly, two patterned areas 
were fabricated with grooves 10µm apart, 10µm wide and either 3.75µm or 4.5µm deep. 
PDMS was prepared by mixing a pre-polymer and a curing agent (Sylgard 184 Kit, Dow 
Corning), and then a degassing process was applied to remove any gas bubbles. PDMS was 
casted onto the SU-8 mould. PDMS was then cured at 70°C for 1 hour before each PDMS 
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construct was carefully cut from the master mould. The individual circular patterned areas on 
the constructs were then removed using a 3/4 inch carpentry punch to fit into the bottom of a 
12-well plate and a 9/16 inch carpentry punch to fit into the bottom of a 24-well plate. The 
larger constructs (3/4 inch) were more suitable for electrophysiological applications as the 
unpatterned area around the structured area reduced the volume of the bath, and consequently 
also reduced the volume of solution required to superfuse the constructed, facilitating faster 
changes of solution, and more accurate regulation of experimental temperature. The smaller 
constructs (9/16 inch) were used for imaging and molecular biological applications as they 
required fewer cells to be seeded and there was no unstructured area surrounding the 
structured area, thus preventing confounding of gene and protein expression studies by 
pooling cells from structured and unstructured areas. Unstructured PDMS tissue culture 
substrates were constructed by simply inverting the structured PDMS culture substrates 
fabricated as previously described. This ensured that the structured and unstructured 
constructs had the same stiffness. The constructs were then sterilized by immersion in 70% 
ethanol and then exposure to UV light overnight. The following day the constructs were 
rinsed three times with sterile water, coated with 50μg/ml human-plasma fibronectin (Sigma-
Aldrich) and then left for at least four hours prior to plating of the cells. Excess fibronectin 
was removed immediately prior to plating of the cells. To ensure similar plating densities, 2/3 
million NRVM were seeded into each well in the 12-well plate and 1/3 million i-cell 
cardiomyocytes were seeded in each well in the 12-well plate as i-cell cardiomyocytes had 
greater plating efficiency and contained a far greater proportion of cardiomyocytes (over 95% 
Purity). Similarly 1/3 million NRVM were seeded into each well in the 24-well plate and 1/6 
million i-cell cardiomyocytes were seeded in each well in the 24 well-pate. 
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Figure A.1. Schematic diagram, not drawn to scale illustrating the fabrication of microgrooved PDMS constructs 
(With thanks to Umar Chaudhry for assistance in producing this figure) 
 
Photolithography and PDMS molding was performed by Miss Tatiana Trantidou and Dr 
Themistoklis Prodromakis at the Centre for Bio-Inspired Technology, Imperial College 
London. 
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Appendix B - Fabrication of Parylene-C constructs 
 
Parylene-C is the trade name for a group of poly(chloro-para-xylylene) polymers formed by 
chemical vapour deposition (Tan and Craighead, 2010). Parylene-C in particular is widely 
used as a coating for printed circuit boards and medical devices such as guide-wires, intra-
arterial stents, implantable defibrillators and pacemakers (Khan et al., 2008, Loeb et al., 1977, 
Fontaine et al., 1996). It is insoluble at room temperature, has excellent barrier properties and 
is pinhole-free above 100nm, is biologically inert, inexpensive, and easily processed (Khan et 
al., 2008, Loeb et al., 1977, Fontaine et al., 1996, Tan and Craighead, 2010). Furthermore, its 
mechanical properties mean it can be used in flexible devices, for example, implantable-
flexible chemical sensing arrays (Zoumpoulidis et al., 2009) or pressure sensors for 
measuring intraocular pressure in glaucoma patients (Chen et al., 2008). These properties 
may make Parylene-C suitable as a thin tissue culture substrate, which would facilitate live-
cell microscopy, and in which electrical and chemical sensors can readily be integrated. The 
flexible properties of Parylene-C may also potentially allow the application of continuous or 
cyclical mechanical strain to cultures which has also been shown to facilitate promote cell 
maturation in some studies (Fink et al., 2000, Tulloch et al., 2011, Gwak et al., 2008).   
 
Despite the ideal chemical and biological properties of Parylene-C, a major obstacle to its 
application as a tissue culture substrate is its hydrophobic surface properties. Several 
approaches have been adopted to modify its surface properties. In particular, several groups 
have sought to exploit the poor oxidative resistance of Parylene-C (~115 °C) (Fortin and Lu, 
2001), which mean that its properties can be readily altered by oxygen plasma fabrication 
 208 
techniques. Oxygen plasma treatment has been previously employed to effectively modify the 
surface properties of Parylene-C, in order to facilitate its use as a tissue culture substrate 
(Chang et al., 2007, Hoshino et al., 2012), and the surface properties of Parylene-C have 
previously been successfully modified in order to fabricate neural cell cultures with specific 
patterns (Delivopoulos et al., 2010). 
 
Two Parylene-C constructs were fabricated using oxygen plasma treatment using techniques 
previously described (Trantidou et al., 2012). In both cases glass coverslips 25mm in 
diameter were thoroughly degreased in acetone, isopropanol and deionized water, and 
dehydrated for 60s at 90ºC. They were then coated in Parylene-C films by chemical vapour 
deposition, using a commercially available coater (PDS2010, Specialty Coating Systems) by 
vaporizing (150ºC) and then pyrolising Parylene-C dimer (690ºC). Three runs were carried 
out, facilitating different thicknesses of 1µm and 7µm. The film thickness was determined 
through calibration samples where Parylene-C was selectively removed to create a step that 
was measured by a Veeco Dektak Stylus profiler (Figure B.1).  
 
Parylene-C is ordinarily hydrophobic, and cells and tissues do not readily adhere to it; 
however, we sought to modify the surface properties using oxygen plasma (Tan and 
Craighead, 2010) (Figure B.1). A contact mask was fabricated using hexamethyldisilazane 
(HMDS) (Sigma-Aldrich) which was spin-coated on the Parylene-C-coated coverslips, 
succeeded by a 1.4μm thick positive photoresist (AZ5214, Clariant SE). The samples were 
then soft baked on a hotplate at 90ºC for 60s, exposed to UV light for 60s, and developed in 
AZ400K (Clariant SE) Developer and H2O (1:4) to remove the exposed photoresist. The 
Parylene-C constructs were then treated with oxygen plasma to achieve selective 
hydrophobic patterning, with most of the Parylene-C protected from the oxidative effects of 
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the oxygen plasma by the contact masks. An ultra-high purity plasma etcher (Nano UHP) was 
used at a working pressure of 0.8mbar. Before exposure to oxygen plasma, samples were 
prebaked on a hotplate at 110ºC for 60s to harden the protective photoresist mask. Several 
different patterns of exposed areas were tried; however, we focused on parallel lines 10µm 
wide and 10µm apart as previous experiments (See Chapter 4) and other investigators 
(Boudou et al., 2012) had shown this geometry effectively altered the physiological 
properties of immature cardiomyocytes (Figure B.1).  
 
 
Figure B.1. Schematic diagram, not drawn to scale, illustrating the fabrication of Parylene-C constructs 
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Figure B.2. Microscopic image of Parylene-C surface exposed to water which has been modified following oxygen 
plasma exposure resulting in hydrophobic areas on which water bubbles have formed, and hydrophilic areas which 
are free of water (With thanks to Themis Prodromakis, Department of Bio-inspired Design). 
 
After plasma treatment, the remaining photoresist was removed by immersing the constructs 
into acetone, isopropanol and deionized water. Short exposure of the 7μm thick Parylene-C 
films to oxygen plasma at 50W for 1min altered the surface properties of the Parylene-C 
without significant etching or altering its geometry, resulting in alternating hydrophobic and 
hydrophilic areas which will subsequently be referred to as the Hydrophobic-Hydrophilic 
(H/H) construct. Exposure of the 1µm thick Parylene-C constructs at 400W for 15min 
resulted in the exposed areas of Parylene-C being completely removed. This resulted in 
alternating glass and Parylene-C areas and a construct with similar geometry in the case of 
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the 4µm Parylene-C film to the previously described PDMS construct (see Section 2.2.1). 
This construct will subsequently be referred to as the Glass- Parylene-C (G/H) construct. 
Unstructured glass and Parylene-C coated areas were used as controls (Figure B.2). 
 
 
      
 
Figure B.3. Scale Bar 20μm, GFP tagged fibronectin in green, dashed line indicates cross-section shown above. A) 
Hydrophilic glass (10μm) - hydrophobic Parylene-C (10μm), Groves depth ~1.1μm, Treated with plasma at 400W for 
16min. B) Hydrophilic Parylene-C (10μm) - hydrophobic Parylene-C (10μm), Groves depth ~0.08μm, Treated with 
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plasma at 400W for 1min. C) Hydrophilic Parylene-C (10μm) - hydrophobic Parylene-C (10μm), Groves depth 
<0.01μm, Treated with plasma at 50W for 1min. D) Hydrophilic Parylene-C (10μm) - hydrophobic Parylene-C 
(10μm), Groves depth ~0.08μm, Treated with plasma at 400W for 1min, 8 weeks previously.    
 
To assess the stability of oxygen plasma fabricated Parylene-C constructs we seeded them at 
1 and 4 weeks after fabrication. Parylene-C has poor UV stability and yellows with regular 
exposure to sunlight (Fortin and Lu, 2001), consequently the constructs were not sterilized as 
previously described with UV light (Section 2.2.1). Prior to seeding these constructs were 
sterilized by emersion in 100% ethanol. The ethanol was left for at least 1 hour and then 
removed. The constructs were then washed with sterile phosphate buffered solution (PBS). 
They were then coated in 5μg/ml fibronectin (Sigma-Aldrich) and stored in an incubator 
(37ºC, 5%) until evaporated. Immunohistochemistry suggests that the geometry of the 
Parylene-C constructs did not exactly replicate the geometry of the contact photoresist, with 
the hydrophilic areas being slightly less than 10µm (Figure B.3). 2x10
6
 cells were seeded on 
each construct. All seeded constructs were then incubated. Complete medium was changed 
every other day. All experiments were performed at day 4 post-seeding. 
 
Oxygen plasma-treated structured Parylene-C constructs were fabricated by Tatiana 
Trantidou with the assistance of Themistoklis Prodromakis at the Centre for Bio-Inspired 
Technology, Imperial College London. 
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Appendix C - Fabrication of three-dimensional polycaprolactone constructs 
 
PCL is biodegradable polyester. It is degraded by hydrolysis of its ester linkages in 
physiological conditions without changing the pH or releasing toxins into surrounding 
tissues. Consequently, it has been approved by the Food and Drug Administration for use in 
suture material, adhesion barriers and drug delivery devices (Zong et al., 2005, Labet and 
Thielemans, 2009). 
 
Figure C.1. Schematic diagram, not drawn to scale illustrating the fabrication of 3D PCL constructs  
 
A detailed description of the fabrication of PCL tissue culture scaffolds has previously been 
published (Zong et al., 2002, Jeun et al., 2005). Briefly however, PCL granules (PCL MW 
40000, Solvay) were dissolved in chloroform at a concentration 0.1mg/ml. Chloroform and 
the solution was injected through a fine needle (diameter 0.56mm) under pressure (6.5bars) 
onto a collecting drum rotating at 3000rpm. The distance between the pump and the rotating 
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drum was 30cm (Figure C.1). The resulting structure was formed from fibers 300-1100nm in 
diameter, 100-2000nm apart, with greater than 95% porosity. The solvent was left to 
evaporate from the fabricated constructs. They were then washed several times to ensure all 
the solvent was removed. The constructs were then stretched over a Scaffdex ‘cell crown’ 
(Scaffdex) and stored in 70% ethanol until required. Prior to seeding they were washed with 
sterile PBS several times, placed under ultraviolet light for 8 hours and then inserted into a 
24-well plate (Figure C.2). 1 million NRVM were seeded onto each construct.  
 
 
Figure C.2. Scanning electron microscopy images of 3D PCL constructs (A and B). The Scaffdex cell crown used to 
hold the PCL construct to facilitate tissue culture and Ca2+ cycling measurements (C). 
 
Three Dimensional Polycaprolactone (PCL) constructs were fabricated by Jermone Sohier, at 
the Harefield Heart Science Centre Tissue Engineering Group, Imperial College London.  
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